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The recognition and eradication of cancer cells by the immune system is reliant on dendritic 
cells (DCs). DCs are professional antigen-presenting cells (APCs) that are integral for the 
initiation of an adaptive immune response targeted to eliminate cancer cells. DCs are capable 
of cross-presentation, a necessary function for priming of cytotoxic T lymphocyte (CTL) 
responses. Specialised DC subsets are reported to be superior at cross-presenting and have 
been implicated as crucial cells for CTL responses against tumour progression. However, 
DCs are often inactive in the presence of immune-suppressive tumours and require 
stimulation to become activated.  
Immunotherapy can be utilised to provide stimulatory-factors that drive the activation of DCs 
and subsequent initiation of effective anti-tumour responses. The immunotherapies 
investigated in this thesis were poly I:C, a toll-like receptor (TLR) 3 ligand; and combination 
of the danger signal monosodium urate crystals (MSU) and a Mycobacterium (M.smegmatis) that 
provides pathogen-associated molecular patterns (PAMPs). Peritumoural treatments with 
immunotherapies were successful at slowing tumour growth and prolonging survival of mice 
bearing 4T1 murine mammary tumours and B16 melanoma tumours. 
To investigate the role of cross-presenting DCs in the efficacy of immunotherapies, a mouse 
model was used whereby specialist cross-presenting DCs can be deleted. CD8α+ and CD103+ 
cross-presenting DCs express the C-type lectin domain family 9 member A (Clec9A) and 
through administration of diphtheria toxin (DT) in Clec9A-DTR mice, successful depletion of 
CD8α+ and CD103+ DCs is achieved. MSU+M.smegmatis immunotherapy was dependent on 
Clec9A+ DCs for efficacy. Conversely, poly I:C immunotherapy remained successful in the 
absence of these cells, suggesting an effective T cell response can be induced in mice lacking 
specialist cross-presenting DCs. 
The antigen-specific T cell responses generated with poly I:C were investigated in basic 
leucine zipper ATF-like transcription factor 3 (BATF3) knockout (KO) mice, which are 
deficient in CD103+ DCs. In the absence of Batf3-dependent DCs, treatment with poly I:C 
immunotherapy still induced proliferation of antigen-specific CTLs that were capable of 
producing IFNγ; however, their ability to kill target cells was impaired.  
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To identify DCs involved in the anti-tumour response initiated by poly I:C immunotherapy, 
DC subsets were examined for the ability to acquire and present antigen. CD8α+, CD103+, 
triple negative (TN), CD11b+ and monocyte-derived DCs (moDCs) were able to capture cell-
associated tumour antigen. Furthermore, these DC subsets were able to acquire soluble 
ovalbumin (OVA), with CD11b+ DCs demonstrating the greatest uptake. Interestingly, 
moDCs were unable to induce antigen-specific T cell proliferation ex vivo, whereas the 
CD11b+ and CD11b- DCs were capable of stimulating T cell expansion. 
There is considerable interest in combining chemotherapy with immunotherapy, as 
chemotherapeutic agents are capable of inducing immunogenic cell death. Treatment of 4T1 
tumours with doxorbucin successfully reduced tumour growth; however, combination of 
MSU+M.smegmatis immunotherapy with doxorubicin provided no additional benefit to single 
treatments. Conversely, combination of poly I:C immunotherapy with doxorubicin enhanced 
anti-tumour responses compared to either monotherapy. 
In summary, the findings from this thesis show that MSU+M.smegmatis immunotherapy 
requires CD8α+ and CD103+ DCs for efficacy, whereas poly I:C immunotherapy remains 
successful in their absence. This finding also emphasises the ability of multiple DC subsets to 
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  1 General Introduction 2 
1.1 Cancer - the growing global affliction 
Cancer is one of the world’s leading causes of death, accounting for 8.2 million deaths in 2012 
(1). It is not a modern-day disease, having been reported since the time of the ancient 
Egyptians. However, it was the famous Greek physician, Hippocrates, that first coined the 
word ‘cancer’. Treatments have varied throughout history, with surgery as the first 
intervention to remove tumour mass. Surgery remains an effective strategy when appropriate; 
however, the size and location often deem this unfeasible. Additionally, cancer cells readily 
metastasise to other sites and thus escape removal. More recently today, cancers are treated 
according to location and grade, with a multitude of interventions, including radiation and 
chemotherapy. These therapies induce unspecific DNA damage and often a portion of 
tumour cells will remain following treatment, which become resistant to such therapies. 
Research into harnessing the body’s own immune system to fight cancer has become 
prominent in the last 30 years and has opened up the age of cancer immunotherapies. The 
aims of this thesis are to explore the involvement of the immune system in specific 
immunotherapies used to treat cancer, investigated through murine models. 
 
1.2 The immune system 
The immune system is a collection of receptors, chemical messengers, cells and organs, which 
work together to distinguish foreign from self. It must defend the body from all manner of 
infections, whilst maintaining stability and control of healthy tissue. The immune system is 
classically categorised into the innate and the adaptive arms, which work to target and 
eliminate pathogens. 
The innate immune system senses the environment using a collection of receptors that can 
recognise conserved regions of pathogens, such as pathogen-associated molecular patterns 
(PAMPs) or danger-associated molecular patterns (DAMPs), which are released from sites of 
injury. Phagocytic cells such as macrophages, dendritic cells and neutrophils use these 
receptors to initiate rapid responses, killing directly or producing cytokines and chemokines 
that work to eradicate the foreign material. While effective at generating an immediate 
response, no immunological memory is generated. Conversely, the adaptive immune response 
involves antigen-specific targeting and produces immunological memory, which can be called 
upon in the event of re-exposure. Antigen recognition occurs through unique cell surface 
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receptors, enabling a large repertoire of lymphocytes that recognise a wide variety of antigens. 
Upon antigen encounter via the T cell receptor (TCR), effector lymphoid cells are generated 
that have toxic, but short-lived functions. In addition, memory cells are generated that 
remain, ready to respond rapidly should the same antigen be encountered again. 
 
1.3 Dendritic cells 
1.3.1 Dendritic cell development  
Dendritic cells (DCs) were first discovered by Steinman and colleagues in the 1970’s and were 
named according to the morphology observed (2). Similar to other leucocytes, DCs are 
derived from haematopoietic stem cells that give rise to a common myeloid progenitor (CMP), 
thus distinguishing them from T, B and natural killer (NK) cells, which originate from a 
common lymphoid progenitor (CLP) (3). From the CMP, there are divergent developmental 
pathways resulting in three distinct DC lineages. A common DC progenitor (CDP) in the 
bone marrow (BM) will give rise to conventional DCs (cDCs) and plasmacytoid DCs (pDCs). 
Differentiation of cDCs occurs either in the peripheral lymphoid organs (lymphoid-resident 
DCs) or tissues (migratory DCs), whereas pDCs develop in the BM (4). Another subset of DCs 
that are derived from monocytes, but share function and cell surface markers with DCs, are 
the monocyte-derived DCs (moDCs) (Figure 1.1). Within these broad DC populations there 
are many subtypes, which are defined based on surface markers and will be discussed in 1.3.4. 
DCs involved in anti-tumour immune responses will be described in further detail in 1.3.7. 
 
1.3.2 Dendritic cell activation  
DCs act as sentinels of the immune system, constantly scanning the environment and being 
exposed to antigens in peripheral tissues. There are inconsistencies in the literature 
surrounding the terminology describing DCs in different activation states. In this thesis, DCs 
that are sampling but not presenting antigen will be referred to as immature. DCs that have 
upregulated MHC and costimulatory molecules and gained the capacity to migrate, will be 
called mature. Mature DCs are further divided into tolerogenic DCs, which induce tolerance; 
or, activated DCs that stimulate naïve T cells.  






Figure 1.1: Dendritic cell lineage. Dendritic cells are derived from a common myeloid 
progenitor (CMP). Classical DCs are derived from a common dendritic cell progenitor (CDP) 
that generates both pDCs and cDCs. Monocytes have a distinct development, separate from 
cDCs but can give rise to moDCs. Figure adapted from Reizis (4). 
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Immature DCs have low levels of expression of MHC II and costimulatory molecules and are 
efficient at antigenic sampling. They employ multiple mechanisms to capture antigen, such as 
receptor-mediated endocytosis through receptors like DEC205 (5,6). They can also sample 
antigens through phagocytosis and pinocytosis (7). In order to migrate to the draining lymph 
node (dLN) to present antigen, immature DCs must undergo maturation (8). Maturation 
involves upregulation of costimulatory molecules such as CD40, CD80 and CD86 and 
upregulation of MHC II coincides with down regulation of receptors involved in antigen 
recognition, such as DEC205 (5). In addition, homing receptors like CCR7 are upregulated 
on the DC and help trafficking to the dLN (9).  
In steady-state conditions, some DCs will take up self-antigen and undergo spontaneous up-
regulation of MHC II, costimulatory molecules and homing receptors to aid migration to the 
dLNs (9). Presentation of cognate antigen to T cells induces peripheral tolerance through 
anergy, deletion, or production of regulatory T cells (Tregs) (10-12). These mature, but 
tolerogenic DCs, have intermediate expression of MHC II and produce the immune 
regulatory cytokine interleukin-ten (IL-10) (13,14). 
DCs detect PAMPs and DAMPs through pattern recognition receptors (PRRs), which detect 
invading micro-organisms or “danger” signals and contribute to DC activation. Activated 
DCs display the highest levels of surface MHC II to maximise antigen presentation to naïve T 
cells (13). They also secrete high levels of interleukin-twelve (IL-12), tumour necrosis factor 
alpha (TNF) and other pro-inflammatory cytokines that contribute to T cell priming and 
differentiation (11,15).  
The activation state of a DC is important for determining whether antigen presentation to a T 
cell will result in tolerance or immunity. The expression of costimulatory molecules, the 
cytokines secreted and the degree of stimulation will all contribute to the type of effector or 
memory cell induced (16). 
 
1.3.3 Recognition of PAMPs and DAMPs 
The expression of PRRs on DCs allows them to detect PAMPs from foreign microbial 
components. Upon binding of a PAMP to its corresponding receptor, such as a toll-like 
receptor (TLR), the DC will become activated and the appropriate immune response against 
the pathogen begins (17). Acting as the bridge between innate and adaptive immunity, DCs 
activated from PAMP recognition that have taken up antigen, will present antigen to induce 
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an antigen-specific T lymphocyte response (9). Activated DCs also up-regulate co-stimulatory 
molecules such as CD80/86, which are required for efficient T cell activation (17,18). The 
distinct differences between the PRRs on DC subsets, allow for a repertoire of DCs that are 
able to recognise and respond to a variety of pathogens (19). 
In addition to PAMPs, DCs can also sense danger signals and DAMPs, which are often 
cellular components that have been released from dying cells. Recognition of DAMPS, such 
as high mobility group box 1 (HMGB1) and adenosine-triphosphate (ATP), can lead to local 
inflammation and recruitment of immune cells, contributing to appropriate immune 
responses (20,21). Immunogenic cell death can occur when the release of DAMPs from dead 
cells is recognised by immune cell populations, causing activation. Phagocytes can engulf cells 
dying via apoptosis through the recognition of molecules expressed on the cell surface (22,23). 
Chemotherapy has also been implicated in inducing immunogenic cell death and there is 
evidence to suggest that the activation of DCs through immunogenic cell death, and the 
subsequent initiation of anti-tumour immune responses, contribute to the success of 
chemotherapy in patients (24). 
Recognition of PAMPs and DAMPs will also stimulate the production of cytokines necessary 
to shape the T cell response and differentiation, further contributing to the appropriate 
immune response targeted to the specific pathogen first recognised. There are a range of 
receptors involved in recognition of PAMPs and DAMPs, which will be described in 1.6. 
Ligands for these receptors are described as adjuvants, as they can activate and enhance 
immune responses to antigens. The use of adjuvants to stimulate anti-tumour responses will be 
discussed further in 1.7.1. 
 
1.3.4 Antigen presentation by DCs 
Antigens need to be processed and presented via MHC molecules before they can be 
recognised and stimulate T and B cell activation. This is true for all peptide antigens from 
“self” antigens in thymic selection, to pathogen and tumour-derived antigens. T cells only 
recognise antigen in the context of MHC molecules and require additional activation through 
costimulatory molecules and cytokine signals, to differentiate into effector cells for the 
appropriate response to progress.  
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1.3.4.1 Antigen presentation pathways 
DCs are efficient at taking up peptide antigen, either by phagocytosis or endocytosis, and 
must then process the antigen to be presented on MHC molecules. There are two classical 
pathways, the MHC I pathway, which activates CD8+ T cells; and the MHC II pathway that 
presents peptide to CD4+ T cells. There are additional pathways, namely cross-presentation, 
where exogenous antigen can be presented via MHC I, and cross-dressing, whereby whole 
peptide-MHC complexes can be acquired from other cells ( 
Figure 1.2). 
Antigens presented by the MHC class I pathway are derived from the cytosol and processed 
by the proteasome. The proteasome degrades proteins into smaller peptides of 8-12 amino 
acid length, which are then released back into the cytosol. Translocation from the cytosol into 
the endoplasmic reticulum (ER) is assisted by the molecule “transporter associated with 
antigen processing” (TAP). Once in the ER, the peptides can be loaded onto MHC I 
molecules. Multiple proteins are involved in forming a loading complex, which are required 
for successful peptide loading (25,26). Binding of the peptide causes disassociation of the 
loading complex and the complete peptide-MHC I complex is then transported to the cell 
surface via the Golgi apparatus, allowing CD8+ T cell recognition. All cells express MHC I 
and can utilise this pathway, enabling infected cells to present antigens to the immune system. 
Antigens presented by the MHC class II pathway are usually from extracellular proteins, and 
as such, these proteins first have to be internalised. Phagocytosed or endocytosed proteins are 
degraded in the endosome and processed to lengths of 12-24 amino acids. The MHC II 
molecule is produced in the ER and stabilised by the invariant chain, which also acts to 
facilitate the transport of MHC II to the Golgi apparatus, where peptides from the endosome 
are present (27). The invariant chain is degraded by proteases, leaving a small fragment called 
CLIP, which protects the binding groove until it is removed to allow the binding of peptides. 
The peptide-MHC II complexes are then transported to the cell surface, allowing recognition 
by CD4+ T cells (28,29). 
The third well-recognised pathway is cross-presentation, where exogenous antigens can be 
presented on MHC I molecules to induce CD8+ T cell responses. This cross-over of pathways 
is necessary to allow appropriate immune responses to tumours and viruses that do not 
directly infect APCs. The exact mechanisms involved, including where the peptide processing 
occurs, is still debated. Some studies show that endocytosed proteins are transported out of the 
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endosome into the cytoplasm to be processed by the proteasome, with the resulting peptides 
translocated into the ER via TAP, and loaded onto MHC I molecules (30). Others suggest 
fusion of the phagosome to the ER, where TAP can transport proteins out of the ER into the 
cytosol for degradation before transport back into the same phagosome-ER complex for 
MHC I loading (31). The CD8α+ LN resident and the CD103+ migratory DCs are 
characterised as specialised cross-presenting DCs, as discussed in 1.3. 
Recently, another pathway has been coined “cross-dressing”, whereby peptide-MHC I 
complexes are transferred from cell to cell (32,33). There are multiple mechanisms through 
which this can occur. Patches of membrane that contain MHC complexes can be transferred, 
a process called trogocytosis. This can occur rapidly and requires cell to cell contact (34). 
Another mechanism is endosome mediated transfer, which is typically slower and can occur 
without direct contact (35). DCs can either 1) capture the exosome material, internalise it and 
reload peptides onto endogenous MHC I; or, 2) secrete MHC I-containing exosomes directly 
(34). One study found that an MHC II vaccine was mediated through DCs that could “cross-
dress” and activate CD4+ T cells for a tumour-specific response (33). Furthermore, it has been 
revealed that CD8α+ and CD103+ DCs were required for effective cross-dressing following 
vaccination, and CD8+ T cell responses initiated were as strong as those induced exclusively 
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Figure 1.2: Antigen-processing and presentation pathways for MHC class I and 
II molecules: A) MHC I molecules present peptides derived from endogenous proteins that 
are degraded in the proteasome and transported via TAP into the ER for MHC I loading. B) 
MHC II molecules present endocytosed exogenous proteins. Binding is prevented by the 
invariant chain (Ii), which is then degraded to CLIP. Once CLIP is removed, antigen-MHC II 
complexes are transported to the cell surface. C) Cross-presentation occurs when exogenous 
antigen is diverted to the conventional MHC I pathway. Adapted from Heath and Carbone 
(37). 
 
1.3.4.2 Costimulatory molecules 
Costimulation is an important part of antigen presentation, to prevent T cell tolerance and to 
appropriately activate effector T cells. CD80 and CD86 are costimulatory molecules, which 
are upregulated on mature APCs (38). They bind to the receptor molecule CD28 on T cells, 
an interaction that promotes T cell proliferation (39). CD80 and CD86 can also bind to 
cytotoxic T lymphocyte associated antigen-4 (CTLA-4), which acts to regulate T cell 
activation. Engagement of CTLA-4 expressed on the T cell surface results in an inhibitory 
signal, causing blocking of TCR signalling and ultimately, preventing survival of the T cell 
(40,41). PD-1 is another molecule expressed by T cells, which acts to down regulate immune 
responses by preventing T cell activation. The two known ligands of PD-1 are PD-L1 and PD-
L2. PD-L1 is constitutively expressed on multiple immune populations, whereas PD-L2 is 
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inducibly expressed (42). Binding of PD-1 to ligands causes a decrease in T cell activity and 
therefore limits damage to the tissue in response to an infection or a tumour. PD-1 is 
upregulated on exhausted T cells generated during chronic infection, and is also a mechanism 
tumour cells use to evade immune-mediated killing (43,44).  
Another costimulatory molecule expressed on DCs is CD40, which binds to the ligand 
CD40L expressed on T cells. This interaction causes further activation of the DCs and 
increases IL-12 production (45). CD40:CD40L interactions are also important for licensing, 
which describes where the contact of CD40L on CD4+ T cells with CD40 expressing DCs 
provides help for the generation of CD8+ T cells, through increased antigen-presentation and 
costimulation (46-48). 
 
1.3.5 Dendritic cell subsets 
Murine lymph node cDCs are broadly separated into lymphoid-resident and migratory. 
Lymphoid-resident cDCs have lower MHC II  and higher CD11c expression than migratory 
DCs (49). The lymphoid-resident can be separated by CD8α expression. Other important 
markers for discrimination are CD4, CD11b, DEC-205 and the chemokine receptor XCR1 
(Table 1.1). There is an inverse relationship between CD11b and CD8α expression levels, 
with CD11b+ low populations having high CD8α+ expression and vice versa (50,51). 
Expression of DEC-205 is positively correlated with that of CD8α+ and is not seen on CD8α- 
DCs. CD8α+ DCs are known to be specialised at cross-presentation and express a number of 
cell surface markers that contribute to antigen uptake, such as DEC-205 and the C-type lectin 
domain family 9 member A Clec9A (DNGR-1) (52-55). DEC-205 and Clec9A are endocytic 
receptors, contributing to the capture and processing of antigen for MHC presentation. 
Moreover, DEC-205 recognises ligands exposed during apoptosis and necrosis (54). Clec9A 
has also been shown to recognise ligands released from necrotic cells, and can promote 
production of inflammatory cytokines such as TNF (53,56). Both CD8α- and CD8α+ DCs rely 
on the growth factor Fms-like tyrosine kinase (Flt3) for development and are strongly reduced 
in Flt3-/- mice (57,58) and the transcription factor RelB is important for the development of 
CD11b+ CD8α-  splenic DCs (59). 
The first migratory DCs described, the Langerhans cells (LC), were found in the skin (60). 
They were originally identified by expression of the C-type lectin receptor langerin, however 
other dermal DCs were subsequently found to also be langerin+ (61,62). LC sample antigen 
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within the epidermis and once activated will migrate to the skin dLN. The other two subsets 
of migratory DCs are broadly split into CD11b+ and CD103+ (60). A recent population of 
DCs was discovered in the dermis, termed the “triple-negative” (TN) DCs as they are 
CD103loCD11bloCD326lo (63,64). The development of TN DCs is dependent on interferon 
regulatory factor 4 (IRF4) and Flt3 ligand. Upon maturation, TN DCs migrate into the skin 
dLN. This population has been linked to Th2 responses (64), however they are yet to be 
investigated in Th1 responses. 
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E2-2, Irf8 Irf4, PU.1 
(Sfpi1) 
Growth factors Csf-1 Flt3 Flt3 Flt3 Flt3  Csf-1,  
M-Csf 
 
Table 1.1: Summary of dendritic cell subsets. The known cell surface proteins and 
TLR receptors expressed by DC subsets, as well as the transcription factors and growth 
factors involved in differentiation are summarised. BATF3, basic leucine zipper ATF-like 
transcription factor 3; BST2, bone marrow stromal antigen 2; CLEC9A, C-type lectin 
domain family 9 member A; CSF-1, colony-stimulating factor one; E2-2, HLH family 
member E-protein; FLT3, FMS-related tyrosine kinase 3; ID2, helix-loop-helix (HLH) 
transcription factor family member inhibitor of DNA binding protein 2; IRF, interferon 
regulatory factor; M-CSF, macrophage colony-stimulating factor; RELB, NFκB transcription 
factor; SICLEC-H, sialic acid-binding immunoglobulin-like lectin H; SFPI1, Spi-1 proto-
oncogene; TLR, toll-like receptor; ZBTB, zinc finger transcription factor BTB.*strain 
dependent.(49,57-59,65-72).  
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CD103+ DCs share markers with the CD8α+ cDCs, such as Clec9A, DEC-205 and XCR1, 
and as such are well characterised specialist cross-presenting DCs (73,74). CD103+ DCs are 
dependent on the basic leucine zipper transcription factor ATF-like 3 (BATF3) for 
development and it was previously understood that CD8α+ DCs were also dependent on 
BATF3 for generation (75,76). However, studies have shown that CD8α+ DCs can be present 
in Batf3-/- mice not only during infection, but also at steady-state and there are also strain-
dependent differences (77-79). CD11b+ DCs are important for CD4+ T cell activation, as they 
present antigen via MHC II (80,81). Studies have also found that CD11b+ DCs are important 
in tolerance since they produce retinoic acid and convert CD4+ T cells into Tregs (82,83). 
However, CD11b+ DCs can also produce pro-inflammatory chemokines (84) and are needed 
for Th2 responses against the allergen house dust mite (HDM) (85). 
Murine pDCs are characterised as B220+, BST2+, CD11clow and SiglecH+ and are the major 
producers of type I interferons (IFNs) (86,87). They express TLR7 and TLR9 that aid in the 
recognition of viral RNA and DNA, inducing IFN production (88), which inhibits virus 
replication and stimulates NK cells. However, studies have also proposed they play a role in 
tolerance, since pDCs that capture antigen and migrate to the thymus can induce deletion of 
thymocytes (89).  
In inflammatory settings, monocytes are recruited from the blood to inflamed tissue, where 
they acquire expression of MHC II and CD11c, thus differentiating into inflammatory 
moDCs. However, under steady-state conditions, blood monocytes can also extravasate into 
the mucosa and skin to give rise to moDCs with a short half-life (90,91). Therefore, it is likely 
that moDCs represent the same Ly6Chi monocytes in alternative contexts (92). 
Inflammatory monocytes are dependent on colony-stimulating factor one (CSF-1) for 
development and are able to continuously exit the bone marrow to enter the circulation, a 
process that is largely mediated by C-C chemokine receptor type 2 (CCR2) (93-95). MoDCs 
that develop during infections can produce copious amounts of TNF and inducible nitric 
oxide synthase (iNOS). For this reason, these moDCs are sometimes referred to as TNF and 
iNOS-producing DCs (TipDCs) (96,97). They were first described in bacterial infections with 
Listeria monocytogenes, where monocytes arriving at the site of infection differentiate into 
TipDCs, which are critical for host defense, as Ccr2-/- mice are no longer able to clear the 
bacteria (98). However, most studies investigating moDCs in tumours have focused either on 
the activation state of tumour-infiltrating DCs or did not investigate particular DC subsets 
(99,100). Several studies show that after recognition of pathogens via TLR signalling during 
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infection, Th1-type cytokines, especially interferon-gamma (IFNγ) and IL-12, can favour 
development of inflammatory DCs (97,101,102). While recognition of TLRs is important to 
initiate the inflammation that drives the development of moDCs (96,103), the level of 
inflammation may be critical. If there is only a low, chronic level of inflammation present, 
such as in many cancers, monocytes can develop into suppressive monocytic myeloid-derived 
suppressor cells (moMDSC) (104). In patients with hepatocellular carcinoma, activated 
monocytes were shown to express programmed cell death 1 (PD-1), induce T cell anergy and 
were associated with poor survival (105).  
 
1.3.6 Comparison of DC subsets between mice and humans 
Early work highlighted similarities between human and murine DCs; however, the absence of 
shared expression markers hampered the translation. In mice, cDCs are grouped into 
migratory DCs and lymphoid resident DCs, which are distinct from pDCs. MoDCs are also 
present in steady-state, but increase in response to inflammation (90,96). In humans, 
peripheral blood DCs are split into three main subsets: two cDC populations separated by 
CD1c (BDCA-1) and CD141 (BDCA-3) expression, and pDCs. In addition, humans have 
tissue-derived migratory CD14+ DCs that resemble the DCs derived from monocytes 
described in mice; however, differentiation from monocytes is yet to be proven in humans 
(106). 
Many human DC subsets have been linked to murine populations by shared expression of 
markers, and perhaps more importantly function (Figure 1.3). The human CD141+ DCs are 
related to the murine CD8α+ DCs and connectivity map analysis (CMAP) has shown that the 
CD141hi skin DCs have a transcriptional prolife that links them to both murine CD103+ and 
CD8α+ DCs (107,108). Human CD141+ DCs also express Clec9A and XCR1 shared with 
murine CD8α+ DCs, which is important for associating the populations since human DCs 
lack CD8 expression.   





Figure 1.3: DC classification in humans and mice. Human myeloid DCs are 
equivalent to murine cDCs. The CD141+ DCs in human blood are thought to be equivalent 
to murine CD103+/CD8α+ DCs in their ability to cross-present antigen. Shared markers for 
this DC population include Clec9A, XCR1 and TLR3. Most human organs contain a 
proportion of migratory CD1c+ myeloid DCs and monocyte-derived DCs expressing CD14 
and CD209. Human lymphoid tissue also contains resident CD1a+ DCs and CD14+ 
monocyte-derived DCs. DCs found in the blood in mice are less well described, however 
pDCs are present. BST2, bone marrow stromal antigen 2 (also known as PDCA1); CLEC9A, 
C-type lectin domain family 9 member A; CX3CR1, CX3C-chemokine receptor 1; FLT3, 
FMS-related tyrosine kinase 3; iNOS, inducible nitric oxide synthase; M-CSFR, macrophage 
colony-stimulating factor receptor; SICLEC-H, sialic acid-binding immunoglobulin-like lectin 
H; TIP, TNF and iNOS producing; TNF, tumour necrosis factor; TLR, toll-like receptor. 
Figure adapted from Collin (106).  
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Unsurprisingly, the CD141hi DCs are migratory and have been found to be superior at cross-
presentation (108-111). However, murine CD103+ and CD8α+ DCs are recognised main 
producers of IL-12, whereas human IL-12 is not limited to one subset (107,112). The CD1c+ 
DCs are the largest DC population found in human blood, and are related to the murine 
CD11b+ population (113). Nevertheless, they have been found to cross-prime CD8+ T cells 
and produce IL-12 (114), functions  that would normally be associated with the murine 
CD103+ and CD8α+ DCs. These findings highlight the differences that still exist between 
human and murine subset classification, despite correlating phenotypes. 
Human pDCs were discovered before the murine courterpart, and share a similar large, 
round morphology, as well as ability to produce large amounts of IFNα/β (113,115). They 
also share expression of TLR 7 and TLR9 with murine pDCs, allowing recognition of CpG 
oligonucleiotides. They differ in their ability to produce IL-12, with murine pDCs able to 
produce high levels of IL-12 once activated; however, human pDCs are limited in this 
function (116,117). Human LC are classified by langerin expression, similar to murine LC, 
but also express CD1a, which has the capacity to present lipid antigens to T cells (115,118). In 
humans, LC are responsible for the proliferation of Tregs that reside in the epidermis, and 
limit their activation during inflammation (119). 
During inflammation, Ly6Chi monocytes are recruited from the blood into the inflamed 
tissue and develop into moDCs, which have been identified in both mice (96) and humans 
(120). A subset of human monocytes, defined through the expression of CD14 and CD16, can 
develop higher MHC II expression following TLR activation, and corresponds to the 
CX3CR1+Ly6C+CD11b+ murine moDCs (121). There is shared expression of DC-SIGN 
(CD209) between species, as well as the ability to produce TNF and iNOS, exhibiting 
powerful antimicrobial effector functions (90,122,123). 
It is important to note that the majority of information available for human DCs has come 
from populations found in the blood, or those generated in culture. Consequently, some of the 
known discrepancies are reflective of a difference between blood versus lymphoid-resident 
DCs, and in vitro-generated compared to freshly isolated DCs (115). Therefore, further 
understanding of the differences and similarities of the murine and human DCs is required. 
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1.3.7 DCs involved in anti-tumour responses 
1.3.7.1 Tumour-infiltrating DCs 
DCs play a major role in cancer immune surveillance as tumour-infiltrating DCs (TIDCs) will 
migrate to the local lymph node and will present tumour antigens to stimulate naïve tumour-
specific T cells, initiating anti-tumour immune responses. However, there is also evidence to 
suggest that cross-presentation of tumour antigen can occur within the tumour itself, with 
naïve T lymphocytes infiltrating tumours and being primed on site (124,125). These findings 
suggest that TIDCs may prime T cells locally, in addition to driving responses in the lymphoid 
tissues. 
There are a number of DC subsets that are associated with infiltration into tumours. CD103+, 
CD11b+ and pDCs are found in tumours, with CD103+ and CD11b+ represented in low 
numbers in both murine and human tumours (126-129). The CD103+ DCs share cell-surface 
markers with the CD8α+ cDCs, such as Clec9A, DEC-205 and XCR1, and as such are well-
characterised specialist cross-presenting DCs (68,73,74). Although the CD103+ DCs are a rare 
population in tumours compared to the abundance of other myeloid cells (130), they are 
important for the presentation of tumour antigens to CD8+ T cells to induce cytotoxic T 
lymphocytes (CTLs) (75,76). Another study revealed the importance of tumour-associated 
CD103+ DCs, as they were the main producers of IL-12p40, indicating that they could be a 
source of IL-12 (131). However, IL-12p40 is produced in excess of IL-12p35, therefore it is 
not definitive. A more recent paper showed that CD103+ DCs and human CD141+ DCs 
found in tumours, were critical for trafficking of tumour antigen to LNs (132). CD11b+ DCs 
are also found in tumours; however, they are mainly associated with melanoma, as 
CD11b+CD207- DCs form the largest proportion of the dermal DCs (133). CD11b+ DCs are 
predominantly involved in CD4+ T cell activation and consequently, have a minor role in 
anti-tumour responses compared to the CD8+ T cell-activating DC subsets (134). 
Type I IFN plays a crucial role in DC accumulation within tumours. One study showed that 
type I IFN signalling on CD8α+ DCs was required for innate immune recognition of tumour 
growth, leading to accumulation of CD8α+ DCs in the tumour, which in turn promoted 
CD8+ T cell activation (135). Another study found that mice lacking IFNα/β receptor 1 
(IFNAR1) signalling in DCs could not reject high immunogenic tumours and CD8α+ DCs in 
particular had defects in antigen cross-presentation (136). Infiltration of DCs into primary 
tumours has been associated with prolonged survival in patients with a range of cancers, such 
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as head and neck carcinoma, lung cancer and melanoma (137). Using intra-vital imaging in a 
murine breast cancer model, a study observed that T cell:DC clusters were interacting for 
prolonged periods of time, as well as transient single T cell:DC interactions (138). Another 
study in melanoma observed DCs in contact with CTLs in lesions that were regressing (139). 
These results suggest that activated DCs within a tumour can promote effective CTL 
responses. However, not all DCs are equal, as infiltration of pDCs within tumours of patients 
with ovarian or breast cancer is correlated with poor prognosis (126,140).  
As mentioned above, the activation of the DCs is also important for driving the desired 
response, as TIDCs are not always sufficiently activated to drive tumour-specific T cell 
responses, often inducing anergy and immune tolerance (127). Treatment of tumours with 
immune-stimulatory, inflammation-promoting agents can activate DCs and induce the 
differentiation of moDCs that contribute to effective anti-tumour responses (100,141,142). 
The concentration of the agent may be a critical factor as high doses of lipopolysaccharides 
(LPS) fail to promote moDC generation (141) but systemic stimulation with an intermediate 
dose of LPS or bacteria can induce differentiation of fully functional moDC from monocytes. 
(143).  
 
1.3.7.2 DCs involved in uptake and presentation of tumour-antigen  
All DC subsets have the ability to acquire antigen and there are multiple mechanisms DCs 
employ to take up antigen, namely through receptor-mediated endocytosis, pinocytosis and 
phagocytosis (5-7). However, the ability to process and present antigen differs among subsets. 
The CD8α+ DCs express a number of cell surface markers that contribute to antigen uptake, 
such as DEC-205 and Clec9A (DNGR-1) (52-55). DEC-205 and Clec9A are endocytic 
receptors, contributing to the capture and processing of antigen for MHC presentation. 
Moreover, DEC-205 recognises ligands exposed during apoptosis and necrosis (54). Clec9A 
has also been shown to recognise filamentous actin released from necrotic cells, and can 
promote production of inflammatory cytokines such as TNF (53,56). The human equivalent, 
the CD141+ DCs, have also been found to cross-present necrotic cell antigen (111). DEC-205 
and Clec9A are also expressed on CD103+ DCs, the migratory DC associated with superior 
cross-presentation (68,108). 
Multiple DC subsets can take up soluble and cell-associated antigen in vivo; however, it is still 
unclear whether particular subsets favour uptake of certain antigens. Studies have shown that 
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CD8α+ DCs alone presented cell-associated antigen to prime T cells (144), but others found 
that both the CD8α+ and CD8- DCs were capable of this function (145,146). CD103+ DCs 
were found to take up soluble and cell-associated antigen at much higher amounts than the 
migratory CD11bhi DCs (73,129). Although CD8α+/CD103+ DCs are still referred to as the 
superior cross-presenting DCs, it is now accepted that other DC subsets can cross-present 
antigen, suggesting that multiple factors influence antigen uptake, such as the mode of 
delivery, type of antigen and the activation signals for the DC (147,148). There is evidence 
suggesting that CD11b+ DCs can cross-present antigen, showing enhanced antigen-specific T 
cell responses (149). Others found that CD11b+ DCs were responsible for capturing antigen in 
skin allografts and priming host-graft reactive CD8+ T cells (150).  
MoDCs can also cross-present soluble and cell-associated antigen in vitro and in vivo, with one 
study finding moDCs superior at cross-presentation to both CD8+ and CD4+ T cells (143). 
Yet others found moDCs to be less efficient than cDCs for antigen presentation to CD4+ T 
cells (151). A recent study showed that anthracycline chemotherapy stimulated 
Ly6ChiCD11c+ cells at the tumour site that were required for anti-tumour activity as they 
were capable of activating T cells (100). Hence, there is evidence to suggest moDCs are 
involved in anti-tumour responses; however, further research is required. Plasmacytoid DCs 
(pDCs) are also able to present antigen, however they are touted as inferior cross-presenters 
compared to cDCs. They not only express lower amounts of MHC II and costimulatory 
molecules, but they are also less efficient at antigen capture, processing and loading (152,153). 
Despite these limitations, pDCs have been shown to be involved in the generation of antigen-
specific CTLs (87). The addition of TLR-stimulation enabled pDCs to present antigen and 
cross-prime T cells in a viral context (154), but has also been observed in mammary and 
melanoma tumour models (155,156).  
The observation of preferential subsets taking up and cross-presenting antigen is dependent 
on a number of factors including, but not limited to; the environmental stimulus, the antigen 
and the activation status of the DC (157). However, the mechanisms that drive DC responses 
to different antigens and how specific DC activation influences the ability to cross-present, 
remain unclear. Moreover, most of what is known for human DCs is obtained from in vitro 
studies and may not accurately represent functionality in vivo (147). Therefore, different DC 
subsets may be implicated in diverse inflammatory conditions and further studies are critical 
for increased understanding in this area. 
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1.3.8 Activation of adaptive and innate immune responses 
DCs are well-characterised as professional antigen presenting cells (APCs), as they are 
extremely efficient and will stimulate T cell responses, even with low numbers (158). Other 
APC populations exist, such as macrophages and B cells. Nonetheless, DCs are considered the 
most effective at antigen presentation (159). APCs are critical for inducing anti-tumour 
immune T cell responses, which are required to reject tumours as mice lacking T cells have 
increased tumour susceptibility to MCA-induced tumours (160). The recognition of PAMPs 
and DAMPs will drive distinct DC cytokine profiles that will in turn drive particular T cell 
responses (17,161,162). In the absence of stimulatory signals, DCs with antigen can still 
migrate to the dLN and through presentation to antigen-specific T cells, induce peripheral 
tolerance (11,163). However, activated DCs that have migrated to the dLN will present 
antigen in the context of costimulatory molecules, and induce T cell activation and 
differentiation into effector cells (9,162). The priming and differentiation of different T cell 
subsets will be described further in 1.4. 
Migratory DCs are constantly encountering antigen in the periphery and during activation 
are exposed to pathogen-derived PAMPs. However, LN-resident DCs do not necessarily get 
the same exposure to these signals. Despite this, the CD8α+ DCs are still famous for their 
ability to cross-present and induce CD8+ CTL activation (52,164). One hypothesis to explain 
this, is that migratory DCs are able to deliver both antigen and PAMPs to the LN resident 
DCs (165,166). Studies have shown that migratory DCs that have taken up antigen can 
transfer antigen to other DC subsets to present (166-168); however, the transfer of information 
relayed from PAMPs is still unknown. Another hypothesis is that migratory DCs activate 
CD4+ T cells that can then interact with the LN-resident DCs, causing activation of CD8+ 
CTLs (169,170).The CD4+ T cells would interact with migratory DCs and then relay the 
information about the pathogen to the LN-resident DCs to achieve the appropriate licensing. 
After trafficking to the dLN, migratory DCs can also present antigens and induce CTL 
activation (73,129).  
In addition to the priming of effector T cells, DCs can also activate innate cell populations. 
DCs can enhance NK cell cytotoxicity and IFNγ production, which was shown to control 
mesothelioma growth in mice (171). Activated DCs can also cause recruitment of NK cells to 
LNs in the presence of IFNγ (172) and DC:NK interactions have been implicated in the 
control of tumour regression in humans (173). NK cells also contribute to DC stimulation, by 
inducing further activation and increased IL-12 production of the DCs (174,175).  
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1.4 T cell activation and effector subsets  
T lymphocytes originate from haematopoietic stem cells in the bone marrow that seed the 
thymus, where they undergo development. Selection in the thymus determines CD4+ or 
CD8+ expression and only T cells that recognise MHC molecules are permitted to enter the 
lymphoid network. T cells yet to encounter antigen are termed naïve and recirculate in the 
lymphatics and peripheral tissues. When a TCR binds with sufficient affinity, the T cell will 
form a stable interface with the cell they are recognising, termed an immune synapse. Cell-
surface receptors, including the TCR and CD28, will be enriched in distinct areas of the 
interface, whereas larger cell-surface molecules not contributing to sigalling will be moved to 
distal areas (176). All of this rearrangement contributes to the stabilisation of the MHC:TCR 
interaction, the first of three signals required for T cell activation (177). MHC-peptide-TCR 
ligation alone (signal 1) is insufficient to generate effector T cells, which require costimulatory 
molecule engagement (signal 2) through binding of CD28 on the T cell, to CD80/86 
expressed on the APC. The third signal required is cytokine mediated, with the production of 
cytokines responsible for directing CD4+ T cell differentiation into one of a number of subsets, 
or to achieve CD8+ T cell activation (178,179). 
Once activated, CD8+ T cells become CTLs, which are licensed to directly kill cells 
expressing the antigen they recognised via MHC I (176). The mechanisms through which 
CTLs operate to kill tumour cells will be discussed further in 1.5.1. CD4+ T cells are also 
known as T helper (Th) cells and can differentiate into a number of subsets, each with 
distinctive functions (180). Th1 and Th2 cells are defined by the production of IFNγ and IL-
4/IL13, respectively. Th1 cells can also produce TNF, IL-2 and granulocyte macrophage-
colony stimulating factor (GM-CSF). They are associated with inflammatory conditions, 
important for bacterial infections and are also involved in anti-tumour responses (181,182). 
Th2 effector cells are involved in immune responses that are associated with pathogens such 
as helminths, as well as allergic disease (183-185). CD4+ T cells can also differentiate into 
induced Tregs, which exert immunosuppressive functions and will be discussed in 1.5.3.2. 
Th17 cells produce IL-17 and are important in antifungal responses and have been linked to 
the autoimmune disease multiple sclerosis (186). However, Th17 cells have been shown to 
have both pro-tumourigenic and anti-tumourgenic activity (187). Th22 cells produce IL-22 
and are involved in the maintenance of mucosal wound healing (188). Th9 cells are involved 
in airway inflammation (189) and finally T follicular helper cells (Tfh), which are important 
for B cell antibody class switching (190).  
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It is important to note that CD4+ T cells can develop into effector cells themselves, although 
in a limited capacity compared to CD8+ T cells (181,191-193). However, the main role of 
CD4+ T helper cells in anti-tumour responses is to maintain tumour-specific CD8+ T cells, 
through the production of IL-2, which is an important survival and growth factor for CTLs 
(194,195). CD4+ T cells can also produce IL-21, which is important for sustaining a CD8+ T 
cell response in chronic viral infections (196) as well as anti-tumour responses. IL-21 enhances 
sustained clonal expansion of CD8+ T cells (197) and it has been found that IL-21R-/- mice 
have impaired antigen-specific CD8+ T cell responses (198). IL-21 has also been shown to 
work synergistically with IL-15 to promote regression of B16 tumours (198). 
Due to the opposing immune responses, the Th1/Th2 paradigm is often referred to as a way 
of describing the cytokines and immune responses induced from a particular stimulus. Anti-
tumour responses have long been associated with a Th1 response, as TNF and IFNγ are 
required for effective tumour cell killing (181,199). However, this reductionist approach does 
not accurately portray the complexity associated with anti-tumour immune responses. For 
instance, eosinophils that are associated with allergic responses (200), are also important for 
promoting tuour rejection through remodelling of the tumour microenvironment (201). 
 
1.5 Immune surveillance of tumours 
The immune system is capable of generating anti-tumour responses to eliminate tumours. 
However, evidence reveals that tumours can remain and progress, which indicates that anti-
tumour responses can either be 1) unable to be initiated or, 2) insufficient. 
Cancer immune surveillance was first predicted in the early 1900’s, and describes the concept 
that the immune system can detect cancer cells in early transformation and remove them 
before the onset of a detectable tumour (202). However, it only gained further traction in the 
1970’s with the discovery of mouse tumour-specific antigens. This finally allowed the 
hypothesis of the “theory of cancer immune surveillance” from Burnet and Thomas to be 
recognised (203,204). The function of the immune system is such that detection and 
elimination of tumour cells can, and does occur. It is well documented that mice lacking key 
immune populations are more susceptible to both spontaneously arising and inducible 
tumours. Recombination-activating gene 2 (RAG2)-deficient mice lacking T, B and natural 
killer T (NKT) cells and nonobsese diabetic/severe combined immunodeficiency 
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(NOD/SCID) mice lacking T and B cells, have increased tumour growth compared to 
immune-sufficient mice.  
There is also evidence in humans that immune involvement helps to control the development 
of cancer. A discovery made by William Coley found that patients with spontaneous tumour 
regression also had concurrent bacterial infections (205). Further investigation into 
spontaneous regression discovered that antigens expressed on tumour cells could be 
recognised by the immune system to prime targeted responses, as seen in the spontaneous 
regression of melanoma in patients, which involved a large expansion in T cells around the 
tumour site (206). Patients with compromised immune systems, such as acquired immuno-
deficiency syndrome (AIDS) patients, have higher incidences of particular cancers (207), 
suggesting that a healthy immune system has the capacity to stop the growth of cancerous 
cells. This is further confirmed in patients that are treated with immune-suppressive drugs 
following organ transplants, which increases their risk of developing melanoma and non-
melanoma skin cancer (208,209). 
Early work found that (IFNγ) was a key molecule required for tumour protection. Endogenous 
IFNγ was required to protect the host against implanted tumours (160,210), with other studies 
in IFNγ receptor deficient and Ifnγ-/- mice showing increased rates of spontaneous and 
chemically induced tumours (211,212). Other effector molecules such as TNF-related 
apoptosis-inducing ligand (TRAIL) are also involved. Mice treated with neutralising 
antibodies and TRAIL-knock-out mice (KOs) have both shown higher incidences of 
fibrosarcomas compared to wild-type (WT) mice (213,214). 
Investigation into the tumours that had developed in immune compromised mice, revealed 
that they were more immunogenic when compared to tumours in immune-competent hosts 
(215,216). The idea that the immune system not only contributes to the prevention of tumour 
development, but also shapes tumours was developed into the cancer immune-editing 
hypothesis. The dynamic interplay was proposed to have three phases: elimination, 
equilibrium and escape (217). 
 
1.5.1 Elimination  
Although tumour cells arise from healthy cells, the transformation process involves mutations, 
which can result in altered or neoantigens being expressed. These altered antigens allow 
  1 General Introduction 24 
recognition by adaptive immune cells in order to activate effector cells, which are then primed 
to target and eliminate the tumour. 
Many different tumour-associated antigens (TAAs) have been discovered over the last decade. 
Tumour cells can over-express differentiation antigens in specific tissues, such as the well-
characterised melanocyte differentiation antigens (Melan-A/MART-1, gp100, TRP-2) 
(218,219). Other antigens that are expressed on tumour cells are those that are normally 
restricted to male germ cells, such as the cancer/testis antigens MAGE and NY-ESO-1 
(220,221). As tumour cells modify and convert from normal to abnormal, the genetic 
mutations can cause cells to express tumour-specific neoantigens (TSAs), such as mutated 
forms of p53 and CDK4 (220,222). Tumours can also over-express antigens that are found on 
healthy tissues at much lower levels, such as the breast cancer antigen HER-2/neu (223).  
In addition, tumour cells can also express a myriad of other surface molecules that can 
contribute to detection by the immune system. Tumour cells have differentially expressed 
MHC class I chain-related proteins A and B (MICA/B), which function as ligands for 
receptors found on NK and γδ T cells (217,224). Heat-shock proteins (HSPs) on tumour cells 
have also been linked to immunogenicity, with human γδ T cells requiring them to respond to 
Burkitt’s lymphoma (225). Murine melanoma tumours with increased expression of HSP70 
have enhanced immunogenicity, leading to increased killing (226). Downregulation of 
molecules can also contribute to enhanced recognition. Tumour cells can downregulate the 
expression of MHC I molecules, which aids NK cell recognition and leads to elimination 
(227).  
Following recognition of tumour cells, a number of immune cells, such as macrophages, NK 
and T cells, are involved in direct tumour cell killing. Studies have shown direct CTL killing 
of tumour cells derived from TILs in melanoma patients (228,229) and with the growth in 
imaging technologies, real-time imaging of CTL, and NK-induced tumour cell killing in 
murine tumours has been observed (230,231). 
CTLs are critical to anti-tumour immune responses and are able to induce target cells to 
undergo apoptosis through different mechanisms. One mechanism used is the release of 
cytotoxic granules that contain the proteins perforin and granzymes. Perforin was one of the 
earliest molecules discovered and it works to form pores in cell membranes. This allows entry 
of other granzymes into the target cell, ultimately leading to cell death (232). Granzymes are 
serine proteases that induce apoptosis through activation of caspases. It was found that the 
CD8+ T cells in Perforin-KO mice had defects in the ability to induce membrane damage, 
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and the mice were more susceptible to tumours (212,233). A second mechanism of inducing 
apoptosis involves the activation of death receptors, triggering the extrinsic apoptotic 
pathway. One of the most well-known receptors is FAS, which can be expressed on tumour 
cells. CTLs and NK cells can express FAS-ligand (FAS-L) and through FAS:FAS-L 
interactions including the adaptor protein FAS-associated death domain protein (FADD), 
apoptosis is achieved (234,235). Other death receptors, such as DR4 and DR5, bind the 
appropriate cytotoxic ligand, TRAIL1/2 to induce apoptosis (236). 
The cytotoxic molecules perforin and grazyme, are dependent on cell contact for release. 
However, CTLs can also produce a number of cytokines that have cytotoxic function. As 
mentioned earlier, IFNγ is a critical effector molecule, with Ifnγ-/- mice developing tumours 
more frequently (212). IFNγ  is also involved with upregulation of MHC I and MHC II on 
tumour cells, making them susceptible to killing (237). TNF is another key molecule secreted 
by NK and T cells. Upon binding to the TNF receptors, caspase-mediated apoptosis is 
induced (238).  
Macrophages were first shown to have direct tumouricidal effects ex vivo, from mice 
immunised with lymphoma cells or the Mycobacterium bacillus Calmette-Guerin (BCG) vaccine 
(239). However, there are multiple macrophage populations in vivo that range from M1-type 
classical macrophages to M2-like, alternatively-activated macrophages, and the dynamic 
assortment between (240). M1 macrophages are known for high levels of expression of IL-12 
and low IL-10, thus promoting a Th1 anti-tumour immune response. Myeloid cells can also 
contribute to tumour cell killing by the production of TNF, as well as chemicals such as nitric 
oxide (NO). Activated M1 macrophages are known to produce high levels of NO, since they 
increase expression of iNOS upon activation (241,242). NO has many mechanisms, including 
causing oxidative DNA damage and disruption to mitochondrial processes (241,243). iNOS is 
similarly implicated in tumour killing, with iNOS-KO mice having increased numbers of 
spontaneous intestinal tumours (244).Through direct phagocytosis, release of cytotoxic 
chemokines, or NO/iNOS, macrophages are able to eliminate tumour cells (245,246). 
Conversely, M2-like macrophages produce high levels of IL-10, low levels of IL-12 and 
promote tumour progression (247,248), which will be discussed further in 1.5.3.2. 
NK cells are also involved in anti-tumour immune responses and were first demonstrated in 
studies showing that NK-deficient mice could not reject tumour metastases (249). The natural 
cytotoxicity receptors (NCRs) and NKG2D receptor expressed on NK cells have both been 
implicated in the lysis of tumours (250,251) and these cells have the ability to release 
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cytoplasmic granules containing perforin and granzymes, which lead to tumour cell death 
(252). As mentioned previously, tumours can also express surface markers, such as MICA/B, 
which render them susceptible to NK-mediated killing (224,253). 
 
1.5.2 Equilibrium 
Equilibrium is the next phase observed if there are tumour cells that remain from elimination. 
The host and surviving tumour cells enter into equilibrium whereby the immune system exerts 
selection pressure that is enough to prevent tumour growth, but allow the persistence of 
survival (217). Equilbirum has the potential to last the lifetime of the host, with tumour cells 
remaining in a similar state to dormancy (254). Evidence for equilibrium is found in mice 
treated with low dose MCA that harbored tumour cells but had no visible tumours. 
Antibodies inhibiting T cells and IFNγ caused outgrowth of the tumours and further 
investigation revealed that IL-12, IFNγ and adaptive T cells were required to maintain 
equilibrium (255). Often this phase will result in eventual immunoediting of the tumour cells, 
which can result in new populations with reduced immunogenicity, leading to escape.  
It is important to note that there may not be a linear progression through the phases. A 
tumour cell in equilibrium may remain under immune control, eventually entering 
elimination, or escape from immune pressure, highlighting the dynamic process of 
immunoediting (253).  
 
1.5.3 Escape 
Escape is the final phase, where tumour cells that have survived equilibrium and developed 
mechanisms to favour immune evasion can proceed to grow unrestrained and cancer 
progresses. Acquisition of mutations and changes in chromosomal structure in the tumour cell 
can be advantageous, increasing proliferation and causing amplified growth that outcompetes 
the speed of the host’s ability to kill.  
The loss of more immunogenic antigens is a well-described mechanism that tumour cells 
utilise to escape immune detection (256). Due to genetic instability there can also be a 
generation of defects in death-receptor signalling, further contributing to immune evasion and 
increasing resistance to cell death (257). Tumours can lose or show altered MHC expression, 
which also contributes to evasion of recognition. In addition, defects in MHC as well as other 
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components of the antigen presentation pathway, such as TAP and LMP2/7, interfere with 
antigen loading (258). IFNγ insensitivity contributes to this capacity, with some human 
adenocarcinoma cell lines showing unresponsiveness to IFNγ, leading to a failure to 
upregulate MHC I pathway activity (211). 
T cell exhaustion also contributes to tumour immune escape. T cells in a dysfunctional state 
express inhibitory receptors and have poor effector functions (259). It was initially observed 
during chronic infection where T cells failed to proliferate and secrete cytokines in response to 
antigen (260). There is now ample evidence implicating the PD-1/PD-L1 pathway in cancer 
(261-263), with blockade aiding in successful T cell responses (264). 
Central to immune escape, is the generation of an immunosuppressive tumour 
microenvironment. Tumour cells can also adopt immunosuppressive mechanisms to inhibit 
immune cell activation, which will be discussed in more detail below.  
 
1.5.3.1 Tumour-mediated immune suppression 
In addition to downregulation of surface marker expression, tumours can secrete numerous 
factors that contribute to immune suppression. Prostaglandin E2 (PGE2), a pro-inflammatory 
mediator that also stimulates the production of IL-10, can act to inhibit DC maturation and 
promote MDSC recruitment to the tumour (265). Vascular endothelial growth factor (VEGF) 
is another cytokine produced by tumour cells and works to inhibit DC differentiation and 
maturation. In patients with ovarian cancer, increased VEGF was correlated with decreased 
T cell infiltration into the tumour and reduced overall survival (266). 
Tumours can also express the tryptophan catabolising enzyme indoleamine 2,3-dioxygenase 
(IDO) that not only limits the amount of tryptophan available to T cells, but accumulates 
tryptophan catabolites, which are inhibitory to T and NK cell proliferation (267). Other 
cytokines affecting T cell proliferation are transforming growth factor beta (TGF-β) and IL-
10, which can both be secreted by tumours. TGF-β has been implicated in tumour invasion 
and metastasis, as well as affecting CD8+ differentiation into CTLs (268,269). TGF-β is also 
important for Th17 and Treg differentiation (180) and therefore can be used as a mechanism 
by tumours to promote the development of immunosuppressive cells. IL-10 is well-known as 
immune regulatory, and has been shown to favour tumour growth by promoting cell 
proliferation and angiogenesis (270). Secretion of both TGF-β and IL-10 by tumour cells 
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contributes to the immune suppressive environment since they generate tumour-associated 
macrophages (TAMs) that are skewed to an M2 phenotype (271). 
 
1.5.3.2 Cells involved in immune suppression 
Regulatory T cells (Tregs) 
Tregs are a population of CD4+ T cells that are involved in the maintenance of peripheral 
tolerance by suppressing the activation of self-reactive T cells (272). First described using 
CD25 expression as a surface marker, the transcription factor forkhead box P3 (FOXP3) is 
now widely used to characterise Tregs (273). Classical Tregs are thymus-derived 
CD4+CD25+FOXP3+, however induced expression of FOXP3 can drive CD4+ T cells to 
develop into Tregs in the periphery (273) Tumour-derived cytokines such as TGF-β and IL-
10 have been implicated in the conversion of CD4+ T cells to Tregs to exploit their ability to 
inhibit immune responses (274). Moreover, tumours can actively recruit Tregs via CCL22 
production by macrophages (275). 
Increased Treg infiltration into tumours has been correlated with poor prognosis in multiple 
cancers (275,276). Depletion of Tregs in vivo was successful at causing regression of numerous 
murine tumours (277) and αCD25 treatment during human ovarian and breast cancer was 
successful at achieving a clinical response showing a reduction in tumours and no appearance 
of new lesions. However it is clear that not all cancers are responsive to this line of treatment 
(274). 
Tregs can inhibit anti-tumour responses in multiple ways. They are producers of suppressive 
cytokines such as TGF-β and IL-10 that inhibit T cell responses, as well as expressing 
inhibitory ligands, such as CTLA-4, which binds to CD80/CD86 on dendritic cells and 
reduces the availability of co-stimulatory molecules for other T cells (278). Tregs can interfere 
with DC:effector T cell interactions by causing downregulation of activation markers on DCs 
(279,280). Tregs also compete for and sequester the cytokines required for effector T cells, 
such as IL-2, thereby inhibiting T cell survival (281). There is also evidence in tumour-bearing 
mice, that Tregs can directly kill DCs found in tumour dLNs, impairing antigen-specific 
CD8+ T cell responses (282). 
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Anergic T cells 
T cell anergy describes a hyporesponsive state that occurs when naïve T cells have either low 
costimulation or high coinhibitory stimulation, often coupled with low IL-2 production (283). 
This tolerance often serves as protection from autoimmunity; however, the tumour 
microenvironment is capable of driving T cell anergy to escape death. Tumour-induced 
anergy has been observed in both murine and human cancers (284-287) and production of 
molecules like PGE2, IL-10 and TGF-β from tumour cells can inhibit DC maturation, 
contributing to T cell anergy (265,288). Indeed, DCs within the tumour and tumour dLN can 
induce T cell anergy, leading to tolerance instead of cytolytic anti-tumour acitivty (163,289). It 
is suggested that this tolerogenic response by DCs is due to insufficient activation (128), 
supported by evidence that blocking of IL-10 and administration of immunostimulatory 
agents were capable of activating DCs, leading to effective anti-tumour T cell responses 
(290,291). T cells recognising antigen without costimulation will fail to sufficiently activate the 
cell, which can occur directly from tumour cells that express MHC I but do not express 
costimulatory molecules, rendering unresponsive T cells during tumour progression (292,293). 
 
Macrophages 
TAMs can have multifaceted functions, but are often characterised as macrophages that are 
polarised to an M2-like phenotype within the tumour microenvironment (294,295). They 
show upregulated production of IL-10, TGF-β and VEGF, but fail to produce pro-
inflammatory cytokines such as IL-1β, IL-6, TNF and IL-12 (294). Furthermore, they deplete 
L-arginine from the immediate environment, which hinders T cell activation and proliferation 
(296). In addition to their immune-suppressive effects, TAMs can promote tumour 
progression and angiogenesis by producing pro-angiogenic enzymes and growth factors (297).  
The release of these tissue-remodelling enzymes such as matrix-metallo-proteinases and 
osteonectin from TAMs can also favour metastasis (298,299). Macrophages found at the 
metastatic site, sometimes called metastasis-associated macrophages (MAMs), can migrate 
with cancer cells and help facilitate cancer cell extravasation (300). CCL2 is a chemokine 
produced by MDSCs that is associated with recruitment of macrophages and promotion of 
tumour growth (301). An autocrine CCL2:CCR2 CCL3:CCR1 loop in MAMs amplifies 
MAM-cancer cell interactions, thus increasing extravasation, cell retention and metastasis 
(302). Depending on the type of tumour, TAMs can account for up to 50% of the total 
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tumour mass (303) and a high level of infiltration with TAMs has been linked to poor 
prognosis in several types of cancer including breast, prostate and bladder cancer (304).  
Myeloid derived suppressor cells (MDSCs) 
MDSCs consist of two populations: monocytic MDSCs (moMDSCs) that are CD11b+Ly6G-
Ly6Chi and granulocytic CD11b+Ly6G+Ly6Clow MDSCs (PMN-MDSCs) (305,306). 
MoMDSCs and PMN-MDSCs have been described as equally suppressive in vitro (305). 
However, others have found that moMDSCs are more suppressive than PMN-MDSCs in vitro 
(307,308) and that tumour progression is not affected by a loss of PMN-MDSCs, suggesting 
that moMDSCs are the principal suppressive subset in vivo. MoMDSCs are usually only 
phenotypically defined as CD11b+Ly6ChiLy6G- cells; therefore, it is not yet clear whether 
they actually represent a form of differentiation from Ly6Chi monocytes or whether their 
suppressive capacity is merely a functional state that may easily be altered by exposure to new 
signals. 
MDSC populations sorted ex vivo are potent suppressers of T cell proliferation in vitro. Using 
selective inhibitors, it was found that sorted moMDSCs preferentially suppress via iNOS 
production, whereas PMN-MDSCs suppress through reactive oxygen species (ROS), 
including NO. (305,307,309). NO can inhibit T cell proliferation by blocking IL-2 signalling 
and inducing apoptosis (310-312). NO can also impair antigen presentation by DCs through 
MHC II inhibition (313). Furthermore, MDSCs can inhibit T cell activation and proliferation 
through the depletion of the essential amino-acids L-arginine and L-cysteine from the tumour 
environment (314,315). They also disrupt T cell migration by releasing ADAM 1, which down 
regulates CD62L, a homing receptor (316) and they can inhibit CD4+ T cell responses via the 
PD-1-PD-L1 axis (317). In addition to their suppressive effects on effector T cells, MDSCs can 
also make immuno-suppressive cytokines including IL-10 and TGF-β (318,319).  
 
1.6 Adjuvants and recognition through PRRs 
Adjuvants that act to stimulate an immune response, will often bind to PRRs to cause DC 
activation. The concept of adjuvants has been around since the 1920s, when it was observed 
that horses with abscesses around sites of injected diphtheria toxin had higher specific 
antibody titres (320). In the 1930s, one of the most well-known adjuvants was made using an 
oil and water emulsion containing Mycobacteria, called complete Freund’s adjuvant (CFA). A 
less toxic version without the Mycobacteria, incomplete Freund’s adjuvant (IFA), has been used 
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in human vaccines (321). Alum was also discovered around the 1930s as a potent adjuvant 
made of aluminium compounds, and is still used today (322). Adjuvants used in vaccines to 
cause an immune response are artificial immune-stimulators, as opposed to natural adjuvants 
that are present in the host. 
DCs, and other innate immune cells, recognise pathogens and adjuvants through PRRs that 
bind PAMPs, leading to cellular activation. DAMPs can also be sensed by innate immune cells 
to induce activation. DCs express a range of receptors that can sense these signals including 
TLRs, nucleotide-binding oligomerization domain (NOD)–like receptors (NLRs) and retinoic 
acid-inducible gene (RIG) 1-like receptors (RLRs), which will be discussed below.  
 
1.6.1 Toll-like receptors (TLRs) 
TLRs are integral membrane glycoproteins, with leucine rich extracellular domains and a 
signalling domain homologous to that of IL-1R (71). There are an estimated 10-15 members 
of the TLR family in mammals, and they are subcategorised into those that recognise lipids 
(TLR1, 2, 4, 6, 11 and 12) and those that recognise nucleic acids (TLR3, 7, 8 and 9) (323). 
The first set of TLRs are expressed intra- or extracellularly, whereas the second group are 
expressed in intracellular compartments only (71). The variety ensures recognition of a large 
array of pathogens. Particular DC subsets can have higher expression of specific TLRs 
compared to others. TLR7 and 9 is expressed by pDCs, whereas cDCs do not express TLR9, 
but express other TLRs (324,325). For example, TLR3 is preferentially expressed by CD8α+ 
and CD103+ DCs, whereas pDCs express TLR9 and cDCs do not (75,326). 
Activation of TLRs causes signalling cascades that result in the production of inflammatory 
cytokines. TLR2 interacts with TLR1 and TLR6 to recognise lipoproteins from Gram 
positive bacteria, whereas TLR4 recognises LPS from Gram negative bacteria (327-329). 
TLR2 has been implicated in DC dysfunction, with tumour-derived extra-cellular matrix 
proteoglycan, versican, binding TLR2 and reprogramming DCs to produce IL-6 and IL-10 
(330). However, TLR2 has also been shown to increase CD8+ T cell effector activity (331). 
There is evidence to suggest this is due to tumour specific differences, but further verification 
is required (332,333). TLR5 binds flagellin from motile bacteria and TLR11 recognises 
Toxoplasma gondii and Escherichia coli by binding profilin (334,335). Viruses are typically 
recognised by the intracellular receptors. TLR3 senses double-stranded RNA, while TLR7 
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and TLR8 bind to single-stranded RNA (336,337). TLR9 recognises unmethylated CpG 
motifs in DNA, found in bacterial and viral genomes (338,339).  
TLR3 signalling involves TIR-domain-containing adapter-inducing interferon-β (TRIF), 
indirectly activating IRF3, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB), activator protein-1 (AP-1) and production of type I interferons (IFNs) (340), whereas all 
other TLRs recruit the adaptor protein myeloid differentiation primary response protein 88 
(MyD88) (71). TLRs can also recognise bacteria, such as Mycobacterium, which can bind to 
TLR2, TLR4, and TLR9 (341,342). A particular Mycobacterium, M.smegmatis binds to TLR2 
and TLR9 through CpG motifs (71,343) and has been shown to differentiate human 
monocytes into activated moDCs in vitro (344).  
The discovery of the ligands for TLRs introduced the production of synthetic TLR ligands, 
that are now commercially available, including Pam3Cys, polyriboinosinic-polyribocytiylic 
acid (poly I:C), monophospholyl lipid A (MPL) and CpG motifs (336,339,345,346). Some of 
these ligands have been used in the treatment of skin cancer and leukemia (347,348). There is 
also evidence to suggest that DCs can recognise more than one DAMP or PAMP and that the 
pathways activated by the different ligands can cause a synergistic effect, with amplified T cell 
activation (349). Another study showed synergy between TLR3/TLR4 and endosomal TLR8, 
which resulted in increased production of IL-12 by DCs (350).  
 
1.6.2 Nucleotide-binding oligomerization domain (NOD)–like 
receptors (NLRs) 
Another family of receptors involved in the recognition of bacterial components are NLRs, 
which contain C-terminal leucine-rich repeat (LRR) domains that are involved in ligand 
sensing. NLRs make up part of the inflammasome that is involved in cleavage of pro-caspase 
1 into the active form caspase-1, which results in IL-1β, IL-18 and IL-33 (351). The most 
characterised inflammasome is NLRP3, which is activated by a range of adjuvants such as 
alum, ATP and monosodium urate crystals (MSU) (351-353). The NLRP3 inflammasome has 
been highlighted as an important link between the innate and adaptive immune response 
against dying tumour cells. Tumour-derived ATP acts on DCs and triggers the formation of 
the NLRP3 inflammasome that secretes IL-1β. IL-1β is required for effective anti-tumour 
responses, as the priming of IFNγ producing CD8+ T cells fails in Nlrp3-/- mice and is only 
resolved with the addition of endogenous IL-1β (354). 
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Two well-known NLRs, NOD1 and NOD2, are not involved in the formation of 
inflammasomes, but are important for the recognition of peptidoglycans on bacteria. NOD1 
only recognises peptidoglycans from gram-negative bacteria, whereas NOD2 can recognise 
from both gram-negative and gram-positive, through muramyl dipeptide (MDP) (342). Both 
operate to evoke signalling cascades involving mitogen-activated protein kinase (MAPK) and 
NF-κB pathways, leading to production of pro-inflammatory cytokines and chemokines. 
NOD1 and NOD2 are involved in DC activation and have both been shown to significantly 
enhance the DC-mediated cross-priming of CD8+ T cells (355), although others have shown 
that NOD1/2 can be inhibitory to DC cross-presentation (356). These results highlight the 
lack of understanding in the molecular pathways regulated by NLRs and it is likely that there 
is cross-over between the intrinsic pathways activated in DCs through NLRs and TLRs (357). 
It is not yet known whether DC subsets respond differentially to NLRs and further knowledge 
may help in the manipulation of desired adaptive immune responses. 
 
1.6.3 Retinoic acid-inducible gene (RIG) 1-like receptors (RLRs) 
As well as TLRs, viral RNA can be recognised by RLRs, which include RIG-I and melanoma 
differentiation associated factor 5 (MDA-5). RIG-I recognises 5’-triphosphate RNA from viral 
single- or double-stranded RNA and RIG-I activation is important for virus-induced 
production of type I IFN (358,359). Poly I:C is a well-known TLR3 ligand that can also 
activate RIG-I or MDA-5. The shorter form of poly I:C is preferentially recognised by RIG-I, 
and the longer form by MDA-5 (360-362). Mda5-/- mice have impaired antiviral responses to 
encephalomyocarditis virus (EMCV), with impaired production of type I IFN from DCs and 
macrophages. Importantly, when poly I:C was administered in vivo, these mice had impaired 
IFNα and IFNβ production, showing that MDA-5 is important for type I IFN responses to 
poly I:C (363). Type I IFN responses are imperative for poly I:C as blockade of IFNα/β 
inhibits the poly I:C induced CD8+ T cell activation (364). 
RNA sensing through RLRs as well as TLRs, all lead to the production of type I IFNs and 
other pro-inflammatory cytokines, such as TNF and IL-6 (365,366), which contribute to the 
generation of adaptive immune responses. Recognition of PAMPs and DAMPs is crucial to 
initiating immune responses and is thought to work in synchrony to activate PRRs, inducing 
the release of pro-inflammatory cytokines (367,368). DAMPs can be released as a part of 
immunogenic cell death, which will be discussed further in 1.8.1.2. Uric acid is a known 
DAMP released from dying cells and is recgonised by monocytes, causing inflammatory 
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cytokine production (369,370). It can stimulate DC activation, contributing to tumour 
rejection in a murine model of thymoma (371). Uric acid can also be administered as an 
adjuvant in the form of MSU (352). 
 
1.7 Tumour immunotherapy 
Although the use of immunotherapy to treat cancer is considered a relatively new approach, 
the concept has been around since the late 19th century. William Coley discovered that 
patients with high fevers from bacterial infections showed increased rates of spontaneous 
tumour regression. Using this knowledge he developed the first immunotherapy, a mixture of 
pyrogenic bacteria now known as Coley’s toxin (205). Treatment via various routes and 
regimes had impressive results of progression-free survival (372). A strong focus of 
immunotherapy since then has come from a better understanding of how the innate immune 
system interacts with the adaptive system, and the discovery of TAAs, involving specific T cell 
recognition and assault (373,374). Stimulation of T cell responses was a main focus of 
immunotherapies, until further understanding of the negative regulation of T cells was 
extended. The current movement of “checkpoint blockade” immunotherapy is underway and 
focuses on removing T cell suppression (375,376).  
The goal of immunotherapy is to stimulate the immune system of the host, either enhancing 
an existing response or creating an appropriate novel one. In theory, generation of an effective 
anti-tumour immune response should result in complete eradication of tumour cells. 
However, this often isn’t the case due to tumour suppressive function, as described in 1.5.3.1. 
Nonetheless, there are multiple tactics that can be employed to induce an anti-tumour 
response. As such, there is comprehensive collection of anti-cancer immunotherapies 
including tumour-targeting and immunomodulatory monoclonal antibodies; DC-, peptide- 
and DNA-based anticancer vaccines; oncolytic viruses; PRR agonists; immunostimulatory 
cytokines; immunogenic cell death inducers; inhibitors of immunosuppressive metabolism; 
and adoptive cell transfer (377). Described below are the immunotherapies that are relevant to 
the scope of this thesis. I have also included immunotherapies that highlight the history and 
development of immunotherapeutic strategies, as well the newest immunotherapies being used 
in the clinic that are gaining public attention. 
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1.7.1 Adjuvant immunotherapy 
Adjuvant immunotherapy aims to stimulate anti-tumour immunity by introducing molecules 
that will bind PRRs on APCs. BCG was first used in the 1970s for the treatment of bladder 
cancer (378) and is still used in the clinic today (379). Despite the continued use of this 
treatment, relatively little is known about the mechanisms through which it works (380). One 
study found in a murine bladder cancer model that a single BCG treatment caused priming of 
IFNγ-producing T cells in the dLN, but multiple treatments were necessary for T cell 
infiltration into the bladder itself (381).  
DNA from bacteria, such as M.smegmatis, contains CpG oligodeoxynucleotides (CpG ODN) 
that act as ligands for TLR9 (339,382). TLR9 activation has been shown to stimulate 
differentiation and proliferation of NK cells, T cells and monocytes, and the response 
generated is characterised by Th1-related cytokines such as TNF, IFNγ and IL-12 (339,383). 
CpG has also been shown to enhance the production of CTLs targeting tumour antigens 
(384,385). A phase I trial in non-Hodgkin’s lymphoma patients found synthetic CpG ODN 
increased NK cell numbers and effector functions. Although, this only occurred in a small 
number of patients and the response was modest (386). Anti-tumour activity after CpG ODN 
treatment has also been found in melanoma, lymphoma and renal cell carcinoma (385,387-
389); however, the limited responses mean it is not currently used as a first-line therapy. 
Imiquimod is another adjuvant that is used in the clinic, as a TLR7 ligand. It is used to treat 
warts and other skin lesions, including basal cell carcinoma and induces a Th1 immune 
response, with the release of pro-inflammatory cytokines, such as IL-12 and TNF from 
macrophages (390,391). In addition to the release of Th1-type cytokines, imiquimod inhibits 
the expression of IL-4 and IL-5 (392). In a murine model of spontaneous mammary tumours, 
addition of imiquimod with a DNA vaccine reduced tumour incidence three times more than 
the DNA vaccine alone, associated with an increase in CTL activity (393). 
Poly I:C is another TLR therapy that has been used in the clinic. Poly I:C induces type I IFN 
production from DCs and generates a systemic IFN response that mimics the early effects of 
viral stimulation (394,395). When administered intravenously to patients with solid tumours or 
acute leukemia, poly I:C had increased serum IFN, measured by inhibition of viral activity; 
however, the tumour response was varied (347). One patient with leukemia had complete 
remission, but many continued with progressive tumour growth, suggesting poly I:C was not 
effective at slowing tumour growth overall. However, it is known that human serum contains 
nucleases that can cause rapid hydrolysis of poly I:C, which may impact on the efficacy (347). 
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Two phase I clinical trials investigated poly I:C therapy, one in metastatic carcinoma patients 
and the other with a range of solid tumours. Both these studies found that poly I:C treatment 
induced mild to severe toxicities that ultimately limited any therapeutic potential (396,397).  
 
1.7.2 Cytokine immunotherapy 
Cytokines can be used to modulate immune responses and have shown effective responses in 
patients (398). These immunotherapies are used to modulate immune cells or activate specific 
receptors on immune populations, and are therefore often used early in intervention with the 
aim to initiate an effective anti-tumour response (399). 
The cytokine IL-2 was FDA approved in 1998 (400) due to the success of therapy in 
metastatic melanoma patients, of which >10% of patients had partial or complete regression 
(398,401). High dose treatment with IL-2 has shown long-term responses in a small group of 
patients (400,402). However, there is toxicity associated with higher doses of IL-2, and only a 
small fraction of patients will respond to therapy (403). Administration of IL-2 either before, 
or combined with the transfer of CTLs, increases the survival and leads to improved anti-
tumour efficacy in patients with metastatic melanoma (404,405). 
IL-12 has also been used to enhance anti-tumour responses, and was administered in 
combination with trastuzumab in a phase I clinical trial. Patients with increased pro-
inflammatory cytokines exhibited clinical benefit (406). A further clinical trial investigating IL-
12 in combination with paclitaxel and trastuzumab suggested that IL-12 enhanced the anti-
tumour effects of trastuzumab, and was able to exert immunostimulatory effects in the 
presence of a potentially immunosuppressive chemothereapy (407). However, severe fatigue 
was a side effect that correlated with the combination of trastuzumab and IL-12, since it was 
not encountered with IL-12 alone (407). Therefore, further studies are needed to assess the 
efficacy of IL-12, especially in combination with other immunotherapies.  
 
1.7.3 Cell-based immunotherapy 
Since CTLs play a significant role in effective anti-tumour responses, one tactic to amplify the 
response is to adoptively-transfer antigen-specific T cells (405,408,409). The first use of 
adoptively-transferred tumour-infiltrating T cells was successful at causing regression of 
melanoma in humans (405). It also pioneered the use of IL-2 as a pre-treatment to increase T 
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cell survival. Conditioning of the host by removal of suppressive populations such as Tregs, as 
well as populations that act as cytokine sinks, can also improve the anti-tumour response 
induced by transferred cells (410,411).  
Another cell-based immunotherapy is the adoptive transfer of genetically modified T cells. 
Chimeric Antigen Receptor (CAR)-T cells are genetically modified to express a T cell 
receptor specific to a tumour antigen, paired with the loss of αβ TCR expression (412). A 
region of the modified receptor is linked to an intracellular domain via CD28. This alteration 
allows for the recognition of antigen without MHC presentation, and therefore bypasses the 
need for processed peptide. Instead, recognition of whole protein can occur (413). Success has 
been limited for solid tumours, with most significant outcomes in hematologic cancers (414).  
DCs that have been loaded with antigen and activated ex vivo can also be used as 
immunotherapy when administered as a vaccine. Hematopoietic cells isolated from the blood 
of a cancer patient are directed to DC differentiation by the use of cytokines such as GM-CSF 
and IL-4 (415,416). DCs generated in vitro with GM-CSF are thought to resemble 
inflammatory moDCs in vivo (11,417). Dendritic cell vaccination in murine tumour models can 
induce protective anti-tumour immunity, using either soluble protein or MHC class-I-
restricted peptides from tumour antigen (418,419). However, the model systems used are 
artificial, with genes encoding foreign proteins being introduced into tumours to serve as 
model tumour antigens, making them more immunogenic than most human cancers (416). 
There has also been success with vaccines engineered by fusing tumour cells to DCs, or 
pulsing DCs with RNA from tumours (420,421). Clinical trials using DC vaccination have 
been successful at inducing tumour-specific CTLs, with some non-Hodgkin’s lymphoma 
patients going into complete remission for >3 years (422). Patients with renal cell carcinoma 
or breast cancer have also been reported to respond well to a DC vaccine in a phase I/II 
clinical trial, with low toxicity and good antigen-specific T cell responses (423). 
Another approach for DC loading is to use irradiated tumour cell vaccines. Irradiation of the 
tumour cells prevents growth while preserving tumour-specific antigens and bypassing the 
need to identify neoepitopes (424,425). However, as resected tumour tissue was originally 
derived from healthy tissue, there will be a mixture of self-tissue and transformed tissue. 
Therefore, there is a possibility that a vaccine may drive a response against healthy tissue as 
well as tumour tissue (426). 
Expansion of DCs ex vivo is a labour intensive and costly exercise. New approaches have 
attempted to avoid DC culture altogether and target DCs directly in vivo. HSPs have been 
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investigated (427) and have been used in the treatment of glioblastoma multiforme (GBM) 
(428), as well as melanoma and colon-carcinoma (429,430). 
 
1.7.4 Antibody-based immunotherapy 
In addition to cellular therapy, monoclonal antibodies can be utilised to target surface 
molecules or factors that contribute to tumour growth and progression. Antibody-based 
immunotherapy can be divided into therapies that bind directly to tumour cells to induce cell 
death, and those that stimulate adaptive immune responses. Within the adaptive response 
there are different phases, with molecules such as CTLA-4 involved in the priming of T cells 
with APCs, and molecules such as PD-1 that are upregulated following activation in late 
effector stages (375). 
Trastuzumab is a common antibody-based immunotherapy used in the clinic, which targets 
the overexpressed oncogene HER-2/neu and induces antibody-dependent cell-mediated 
cytotoxicity (ADCC) (431). Anti-CD20 antibody Rituximab is another immunotherapy that 
induces ADCC and has been used in B cell non-Hodgkin lymphoma patients (432), as well as 
other autoimmune diseases (433,434). Alemtuzumab is used to treat chronic lymphocytic 
leukemia and works through binding CD52 (435). Antibody targets for CD47 have been 
designed and are now in multiple clinical trials (436). CD47 is expressed on cancer cells as a 
“don’t eat me” signal and binds to signal regulatory protein alpha (SIRPα) on phagocytic cells 
to inhibit phagocytosis (437). It was originally thought to impact macrophage phagocytosis 
but, studies have found that the therapeutic effects of CD47 blockade, which include tumour 
regression and enhanced IFNγ production, were dependent on CD8+ T cells, as well as DCs 
(438). 
The most promising antibody-based immunotherapies to date have been the “checkpoint 
blockade” therapies, in reference to the molecules involved in immune regulation that are 
targeted by the antibody treatments. CTLA-4 was first proposed as a costimulatory molecule 
(439); however, further studies revealed it as a negative regulator of T cell activation (440). 
CTLA-4 binds to CD80/86 with a higher affinity than CD28, outcompeting CD28 and 
causing an inhibitory signal to the T cell. Krummel and Allison were the first to devise CTLA-
4 blockade as a means of enhancing T cell activation, which was demonstrated in mice 
showing an enhanced response to vaccines (441). Positive results in clinical trials for 
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melanoma lead to FDA approval for ipilimumab (monoclonal αCTLA-4 antibody) (442), 
which is now used for a range of cancers including prostate and lung cancer (443,444). 
PD-1 is another molecule that is targeted by a monoclonal therapy. It is expressed on a range 
of cells and has two ligands, PD-L1 and PD-L2. PD-L2 is expressed on activated APCs and 
binding of PD-L2 to PD-1 causes a reduction in T cell proliferation and IFNγ (445). PD-1 
regulates the T cell response in the tissues to prevent damage in response to either an infection 
or malignancy. Several tumour cell lines upregulate PD-L1 in response to IFNγ to inhibit T 
cell responses (446,447). Therefore, targeting PD-1:PD-L1 binding is an attractive mechanism 
to prevent reduced T cell activation. Pembrolizumab is an αPD-1 monoclonal antibody that 
has been FDA approved. Nivolumab is another, which showed increased progression free 
survival when compared to ipilimumab (264). The current opinion on checkpoint blockades is 
that they produce robust and durable results, with some patients surviving >10 years. 
However, only 20% of patients actually respond, therefore leaving a number of patients who 
receive no benefit from this therapy (264). 
 
1.7.5 Local tumour-immunotherapy to recruit and activate DCs 
DCs are critical to the initiation of anti-tumour responses and have been found to infiltrate 
both murine and human tumours (126,127). However, infiltrating DCs do not necessarily 
correlate to improved tumour rejection. It is the state of activation of the DCs, as well as the 
type, that is crucial. Indeed, it is only the infiltration of activated DCs that have been 
correlated with better prognosis in melanoma (448) and breast cancer patients (449). Failure 
to activate DCs can lead to T cell anergy and tolerance (450). Therefore, the activation of 
tumour infiltrating DCs is imperative to achieve a sufficient anti-tumour response.  
The use of adjuvants is one strategy that has been devised to activate DCs. Often 
administered locally around the tumour, adjuvant immunotherapy has been shown to activate 
DCs and achieve efficient T cell responses (290,451). Modification of the local expression of 
chemokines can alter the composition of cells in the tumour, which can then be targeted with 
stimulatory agents to drive effective anti-tumour responses. One study found that tumour cells 
modified to express the human β chemokine, LEC, were rejected through increased DC and 
T cell recruitment, suggested to promote DC:T cell interactions (452). Another found the 
chemokine MIP-1α inhibited the growth of pulmonary metastases through recruitment of 
CD8+ T cells (453). Once recruited, immune cells can be further activated or expanded with 
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the use of other immune stimulatory molecules. Vicari et al., were able to transform defective 
TIDCs through the addition of CpG, in combination with αIL-10R antibody. The 
combination treatment was able to enhance the TAA-specific immune response, triggering 
DCs to produce IL-12 (290). Another study first recruited tumoural DCs with the chemokine 
MIP-3α, followed by CpG immunotherapy to activate the newly recruited DCs, which led to 
complete tumour regression in a murine colon carcinoma model (451). Treatment with local 
immune-stimulatory agents is not only important for the recruitment an activation of DCs, 
but also for the extravasation of monocytes and the differentiation into moDCs, which have 
been shown to contribute to effective anti-tumour responses (141,142). 
Recent work has been able to distinguish particular DC subsets involved in uptake of tumour 
antigen, and presentation to initiate a tumour-specific CD8+ T cell response. One study was 
able to show that despite being a rare population found in tumours, both human and murine, 
the CD103+ DCs are required for the accumulation and activation of intratumoural CD8+ T 
cells (130). In addition to this finding, Salmon et al., found that CD103+ DCs were responsible 
for transporting antigen to the tumour dLN and priming CD8+ T cells in murine melanoma 
models. Furthermore, immunotherapy of  systemic Flt3L and intratumoural poly I:C was able 
to expand and activate the CD103+ DCs, which enhanced responses to PD-L1 blockade 
(129). Taken together, these studies show targeting of specific tumour-infiltrating DCs with 
immunotherapy can enhance anti-tumour responses. 
Local tumour immunotherapy is also important to reduce the immune suppression driven by 
tumour cells. Tumours are able to recruit DCs and render them tolerogenic, with factors like 
IL-10, TGFβ and VEGF secreted (265,266). These factors can cause DCs to become more 
regulatory than stimulatory, producing factors such as IDO, which reduce T cell proliferation 
and activation (454). IDO inhibitors, Treg depletion and neutralizing antibodies against 
CTLA-4 and PD-L1, are all immunotherapies that can be used to subvert tolerising 
conditions (277,278,426,455,456). Modification of the tumour microenvironment through 
alteration of inhibitory molecules, as well as cytokines present, can lead to enhanced responses 
to immune stimulatory agents (454,457). 
These studies provide evidence that use of local immunotherapy can successfully modify the 
regulatory tumour microenvironment and activate tumour-infiltrating DCs to achieve 
effective anti-tumour responses. Further investigation into the specific receptors on integral 
DC populations will advance efficacy of treatments. Improved methods of direct 
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intratumoural immunotherapy are also required, to enable the translation of the 
intratumoural delivery methods used in murine models to clinical application. 
 
1.8 Chemotherapy 
Radiotherapy and chemotherapy still remain among the first treatments offered for a range of 
cancers, and are often used in combination as chemotherapy can target metastatic cells 
outside those in the area of radiation (458,459). Despite widespread use, the success of either 
therapy for solid tumours remains limited. Chemotherapy causes non-specific damage, 
targeting tumour cells and healthy cells alike. The resulting toxicity is severe and limits the 
efficacy in patients. There are now many studies showing that chemotherapy can transform 
an environment to become more receptive to immunotherapy. Consequently, successive or 
combination treatment with chemotherapy and immunotherapy can be more effective than 
monotherapy. There are many different forms of chemotherapy, however only the class used 
in this thesis is described below. 
 
1.8.1 Anthracyclines 
Anthracyclines are a class of drugs that were initially derived from the fungus Streptomyces 
peucetius and were found to have anti-tumour properties during studies conducted in the 1960s 
(460). Daunorubicin and doxorubicin occur naturally and are the most common 
anthracyclines, which only differ by a single hydroxyl group (461). Idarubicin, epirubicin and 
valrubicin are all derivatives of either daunorubicin or doxorubicin (462,463). Anthracyclines 
are rapidly cleared from the plasma through liver metabolism, and the tissues with the highest 
accumulations of the drugs are the liver, bone marrow and the heart (464). Despite only one 
chemical modification between daunorubicin and doxorubicin, their anti-tumour activity is 
rather different. Doxorubicin is often used for breast cancer, solid tumours, soft tissue 
sarcomas and lymphomas, whereas daunorubicin is used for acute lymphoblastic and 
myeloblastic leukemias (465). Doxorubicin is the most widely used and will be discussed in 
more detail in 1.8.2.  
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1.8.1.1 Mechanisms of action 
The first mechanism described for anthracyclines was intercalation of DNA (466). It has been 
found that binding of the chemical into linker regions in DNA causes conformational changes, 
and subsequent chromatin unfolding and aggregation (467). Anthracyclines are cationic and 
lipophilic, allowing for free movement at normal intracellular pH (468). This property permits 
entry into cells through diffusion where the molecules bind to the proteasome, which can 
translocate through the nuclear pore into the nucleolus. Due to a higher affinity for nuclear 
DNA, anthracyclines are able to detach from the proteasome and bind to the DNA (469,470). 
Another mechanism is the interaction of anthracyclines with the DNA-associated enzymes, 
topoisomerase I and II. Topoisomerases are involved in relaxing the supercoiled double helix 
during DNA replication and RNA transcription. The binding of anthracyclines to the 
enzymes stabilise the transient state, causing double-stranded breaks (465). The inhibition 
halts DNA repair, leading to arrest in the G1/G2 phase of the cell cycle and therefore, cell 
death (471,472). Anthracyclines are also capable of producing free radicals, since 
anthracycline-iron complexes produce hydroxyl ions, a type of ROS (473). The production of 
ROS observed has been at low concentrations, but even small amounts of ROS can 
contribute to apoptotic cell death and therefore contribute to the cytotoxic effect of 
anthracyclines (474). 
 
1.8.1.2 Immunological effects 
Not only does chemotherapy induce cytotoxic effects, it exerts immunological effects as it 
influences and impacts the immune response to cancer. Experiments using immunodeficient 
nu/nu mice revealed that multiple mouse cancers will not respond to chemotherapy when 
implanted into immunodeficient hosts (475-477). Further evidence to show that anthracyclines 
are dependent on the immune system came from blockade experiments, which found that 
blockade of IFNγ and IL-1β caused loss of efficacy (354,476,478). 
Chemotherapy-induced tumour cell death can occur via apoptosis, and many studies have 
shown that apoptotic cell death can be immunogenic, through a number of mediators. It was 
initially thought that necrosis alone, and not apoptosis, was associated with immunogenic cell 
death (479). However, since innate immunity has been shown to be activated in association 
with apoptosis, it is now regarded as a form of immunogenic cell death. Yet, not all forms of 
apoptosis are equal. Apoptosis during tissue turnover should not induce an immunogenic 
1 General Introduction 43 
response, and can even be tolerogenic (202). Indeed, tumour cell death in the absence of 
inflammation can act similarly and cause immune ignorance (286,480). Immunogenic 
apoptosis occurs when phagocytes engulf apoptotic cells in the presence of a danger signal, 
such as calreticulin (23). Immunogenic apoptosis causes the translocation of intracellular 
calreticulin to the cell surface, which provides a signal to the immune system to phagocytose 
the cell (22,481).  
The release of antigens from dead and dying cells also provides sources of DAMPs for APC 
activation and induction of Th1 responses (482). HMGB1 can be released from dying cells in 
late-stage apoptosis and will bind to TLR4 on APCs to induce antigen presentation (20). 
Interestingly, neither HMGB1 nor calreticulin will drive complete DC activation; therefore, 
other immunostimulatory molecules must be present (483). ATP release is also commonly 
associated with chemotherapy-induced immunogenic cell death and binds to purinergic 
receptors on DCs to cause inflammasome activation, allowing for the maturation and 
secretion of IL-1β (484). It was found that anthracycline-induced immunogenic cell death 
released ATP and caused subsequent accumulation of moDCs differentiated from Ly6Chi 
monocytic precursors (100). These Ly6Chi moDCs were the most efficient population in 
taking up tumour antigen and presenting it to cognate T cells. Moreover, transfer of these 
cells protected recipient mice from tumour challenge and ablation of these cells lead to a 
complete loss of the chemotherapeutic effect in multiple tumour models (100). As mentioned 
previously, APCs require the presence of pro-inflammatory cytokines and costimulation to 
achieve appropriate activation. Therefore, the availability of antigen does not necessarily lead 
to an effective anti-tumour response (482).  
Chemotherapy can also enhance tumour immunogenicity and increase the susceptibility of 
tumour cells to CTL-mediated killing with immunotherapy (485,486). One mechanism is 
through chemotherapy-induced upregulation of MHC class I expression, which increases 
susceptibility to CTL killing (487). Chemotherapy also makes tumour cells more permeable to 
granzyme B as it causes upregulation of the mannose-6-phosphate receptor (MPR) on tumour 
cells, which mediates entry of granzyme B into the cell (488). It has also been shown that pre-
treatment of tumour cells with chemotherapy can enhance an anti-tumour immune response. 
One study demonstrated that low noncytotoxic doses of doxorubicin and paclitaxel on tumour 
cells enhanced the cytotoxic response from CTLs, compared to un-treated tumour cells (489). 
Doxorubicin can also eliminate suppressive cells, thereby releasing inhibition from anti-
tumour immune responses. Doxorubicin has been shown to eliminate MDSCs, leading to an 
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enhanced response to adoptive T cell transfer in a model of breast cancer (490). A phase II 
clinical trial that included doxorubicin in the treatment régime, found that patients with lower 
levels of circulating MDSCs prior to the last treatment, had a higher probability of achieving 
complete response (491). Other chemotherapies, such as cyclophosphamide, are efficient at 
eliminating Tregs (492,493); however, doxorubicin mainly impacts MDSCs (494). 
Despite success at initiating immunogenic anti-tumour responses, chemotherapy can also 
induce immunosuppressive responses. Treatment of GBM cells with doxorubicin caused them 
to become more immunosuppressive, inhibiting T cell proliferation in vitro (495). Studies have 
shown that supernatant from doxorubicin treated cells can contain factors that contribute to 
immune suppression (496). PGE2 has been implicated in chemotherapy-induced immune 
suppression (497), and studies have found that doxorubicin-resistant GBM cell lines produced 
higher concentrations of PGE2, which contributed to T cell immune suppression (495). PGE2 
can also contribute to the expansion of MDSCs that produce immunosuppressive factors and 
inhibit anti-tumour responses (498). The impact of chemotherapy on MDSCs differs between 
classes. Gemcitabine has been reported to selectively deplete MDSCs (499), whereas a 
cyclophosphamide/doxorubicin regimen caused an increase in MDSCs (317,500).  
Chemotherapy can also enhance the infiltration of myeloid cells, including TAMs. Infiltration 
into the tumour exposes them to an hypoxic environment and other stimulants, which can 
cause production of pro-angiogenic factors, such as VEGF (501). Therefore, chemotherapy 
induced TAMs can contribute to tumour progression by aiding re-vascularisation (502,503). 
Studies have shown that blockade of myeloid populations such as monocytes, or TAMs, will 
enhance a chemotherapeutic response (504,505). However, different chemotherapies will 
induce distinct myeloid responses that can either enhance or antagonise the activity of the 
drug, which is also likely to be tumour-type dependent (506). Chemotherapy can also ablate 
T-cell function and blunt anti-tumour responses (507), since cyclophosphamide has been 
found to inhibit CD8+ T cell activation and CD4+ anti-tumour T cells (508).  
 
1.8.1.3 Chemotherapy resistance 
A major limitation to the usefulness of chemotherapeutic agents, is the emergence of drug 
resistance (509). One mechanism that cancer cells employ to resist chemotherapy is by 
increasing the expression of efflux pumps on their cell surface (510,511). These pumps actively 
transport molecules across intra- or extracellular membranes. The ATP-binding cassette, sub-
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family G (WHITE), member 2 (Abcg2) and ATP-binding cassette, sub-family C 
(CFTR/MRP), member 1 (Abcc1) are both part of the family of ATP-binding cassette (ABC) 
transporters (511,512). Abcg2 is also known as the mitoxantrone resistance gene (MXR) and 
due to specificities in the structure, it has been associated with resistance to anthracyclines 
(513). Abcc1 encodes for multidrug resistance-associated protein 1 (MDRP1, also known as P-
gp), which is involved in multi-drug resistance due to the ability of the transporters to actively 
remove toxic molecules from the cell (513,514). Overexpression of MDRP1 has been 
associated with resistance to paclitaxel and anthracyclines, including doxorubicin (515,516). 
Additionally, MDRP1 is highly expressed in patients with secondary leukemia compared to 
primary, suggesting that exposure to chemotherapy can drive increased resistance (517). 
Resistance to one chemotherapy can often confer resistance to others that are similar in 
structure and mode of action, in a phenomenon known as multiple drug resistance (MDR) 
(511,518). MDR can limit treatment options, therefore strategies to engage or evade ABC 
transporters is one approach being used to mediate resistance (518). 
Another well studied pathway involved in chemotherapy resistance is the Raf/MEK/ERK 
kinase cascade, that is overexpressed in >70% of cases of acute myeloid leukemia (519). 
Tumour cells can exploit the pathway to prevent apoptosis, since many of the proteins 
involved in apoptosis are controlled by the Raf/MEK/ERK pathway (520). Increased Raf 
activation has been associated with doxorubicin resistance, as it was found that activated 
MEK increased the resistance of hematopoietic cells to doxorubicin ~10-fold (519). Small 
molecule inhibitors have been developed to target proteins in this pathway, with decreased 




One of the most commonly used anthracyclines is doxorubicin, also known as Adriamycin. It 
is used for a range of different cancers, inducing non-Hodgkin’s lymphomas, breast cancer 
and sarcomas (461). When administered intravenously, the kinetics follow a triphasic pattern 
of plasma clearance, which gives a rapid peak, a decline and then a slow elimination phase 
(471,523). The distribution half-life is 3-5 minutes, highlighting the rapid uptake of the drug. 
However, the terminal half-life is 24-36 hours, meaning it takes far longer to be eliminated 
from the tissue than it does to be taken up (524). It has been estimated that in humans, 
approximately 50% of doxorubicin is eliminated without changes to its structure, while the 
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remainder is processed (525). There are three major metabolic pathways: hydroxylation, 
semiquinone formation or deoxyaglycone formation. The pathway used will determine 
whether the metabolites will either augment or suppress the anti-tumour properties (526-528). 
In attempts to improve non-specific toxicity issues, various formulations of doxorubicin have 
been developed. Pegylated liposomes tolerate enhanced retention in the blood, as well as 
allowing doxorubicin to remain undetected by the phagocyte system. Pegylated liposomes can 
be formulated in such a way that leakage is minimised, and the small size allows for 
extravasation of the drug into tumour blood vessels (529,530). Nanoparticles have also been 
used as a carrier for doxorubicin delivery. One study used nanoparticles to deliver 
doxorubicin to osteosarcoma cells, which improved drug efficacy compared to free 
doxorubicin (531). 
Doxorubicin, like other anthracyclines, will intercalate DNA and interfere with topoisomerase 
I and II to cause cell death (471,472); however, doxorubicin also has multiple molecular 
targets that produce cytotoxic effects (471). Studies have shown that doxorubicin can trigger 
autophagy. Activation of nuclear enzyme, poly ADP-ribose polymerase-1 (PARP-1), is a 
critical step in determining autophagy. PARP-1 depletes NAD+ and ATP, leading to energy 
failure that causes cell death (532). PARP-1-induced death shows characteristics of both 
autophagy and necrosis. Doxorubicin can also induce apoptosis through activation of the 
AMP-activated protein kinase pathway (533). 
Associated with cytotoxic effects to individual tumour cells, are the additional toxic effects to 
the host, with the most problematic being cardiotoxicity. It is the toxicity that limits the 
usefulness of doxorubicin, with cardiomyopathy presenting as congestive heart failure 
(461,534). One study found that toxicity was mediated through TLR4 in vitro and in vivo. 
Doxorubicin treatment increased TLR4 expression on macrophages, augmenting the 
sensitivity of these cells to endotoxin, which resulted in increased systemic inflammation (535).  
 
1.8.3 Combining chemotherapy and immunotherapy 
Chemotherapy has previously been regarded as antagonistic to immunotherapy, as immune 
cell populations can be killed. However, there is growing evidence that chemotherapy can 
enhance responses to immunotherapy. Chemotherapy can be effective at making the tumour 
microenvironment sensitive to immunotherapies, including vaccines (536). In a two-target 
approach, chemotherapy is useful for de-bulking tumour mass, while immunotherapy can 
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target disseminating tumour cells (537). Resistance to chemotherapy is also a common 
problem with single modality treatment; therefore, combination of chemotherapy and 
immunotherapy attempts to exploit additive or synergistic effects of both without the 
disadvantages (482).  
As mentioned previously, immunogenic cell death plays an important role in the efficacy of 
anti-tumour drugs (538). A study in the 1960’s found that efficacy of chemotheraputic agents 
was completely lost in the absence of lymphocytes, after thymectomy or irradiation (539). The 
efficacy of combination therapy is dependent on the class of chemotherapy used, as certain 
mechanisms of cell death are more immunogenic than others. Paclitaxel, a common 
microtubule destabilising chemotherapy, was used in combination with a vaccine. However, it 
was less effective at inducing an antigen-specific CD8+ T cell response than doxorubicin, 
suggesting that mitotic disruption is less immunogenic than doxorubicin-induced cell death 
(540). Indeed, only some cytotoxic agents harbour the ability to induce immunogenic cell 
death, whilst other DNA-damaging agents such as mitomycin C and etoposide cannot, as 
measured by translocation of calreticulin (22). Sublethal doses of irradiation given to a range 
of human cancer cell lines was also effective at increasing calreticulin expression, which lead 
to increased sensitivity to CTL-mediated killing (541). 
Chemotherapy can also aid immunotherapy responses by direct effects on T cells. A 
longitudinal study in patients with thoracic malignancies found that T cells were heavily 
ablated one week after treatment with chemotherapy, but as the T cell pool recovered there 
was increased CD8+ T cell proliferation, and a greater ratio of CD8+ T cells to Tregs (542). 
Other studies have found that chemotherapy increased CD8+ cell proliferation and IFNγ 
production in models of leukemia, melanoma, mammary adenocarcinoma and fibrosarcoma 
(543,544). Therefore, chemotherapy may provide a favorable environment for the 
development of anti-tumour immunity, by providing a fresh T cell pool, a lower number of 
Tregs and even activated CD8+ T cells (542,543). Chemotherapy has also been shown to 
induce bystander activation of memory CD4+ and CD8+ T cells (545) as well as increasing 
infiltration of T cells into fibrosarcomas (546). 
Conversely, administering immunotherapy before chemotherapeutic treatment may also 
provide additional benefits to chemotherapy alone. Patients with GBM who have been treated 
previously with tumour lysate-pulsed DC vaccination, responded to chemotherapies better 
than those who had not had prior vaccination. These patients also had increased survival 
compared to those who received monotherapy of DC vaccination or chemotherapy alone 
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(547). This advantage was related to an increase in CD8+ T cells in the vaccine pre-treated 
group; thus, suggesting that enhanced CD8+ T cells are beneficial for the efficacy of 
chemotherapy. Similar results were obtained in prostate cancer trials, with patients that had 
prior cancer vaccines responding better to successive chemotherapy (548). Another study used 
non-specifically activated CD4+ T cells as a chemosensitiser and saw enhanced 
chemotherapy-induced cytotoxic effects in vitro and in vivo, in human xenograft tumour models 
(549). IFNγ production played a major role in this enhancement, but did not fully account for 
the improved response. Type 1 IFNs have also been implicated in sensitising tumour cells to 
chemotherapy by causing down regulation of a DNA repair protein (550). Taken together, 
these results provide evidence to suggest that immunotherapy given prior to chemotherapy 
can enhance anti-tumour responses. 
With the knowledge that doxorubicin was effective at inducing immunogenic cell death 
(22,475,551), there have been a number of attempts at using this drug in combination with 
vaccines or antibody-based immunotherapies. 
Treatment with doxorubicin in combination with αPD-1 and αCTLA-4 was successful at 
reducing tumour size in a lung cancer and fibrosarcoma model. Interestingly, combination 
therapy with checkpoint blockades and cisplatin was unsuccessful, further highlighting the 
importance of specific mechanisms of chemotherapy-induced death (552). Nevertheless, not 
all chemotherapy and immunotherapy combinations require anthracycline-induced cell 
death. Cyclophosphamide and paclitaxel chemotherapy when given prior to a HER-2/neu-
expressing whole-cell vaccine, enhanced the vaccine response to delay tumour growth in neu 
transgenic mice, which spontaneously develop mammary adenocarcinomas. In contrast, 
doxorubicin provided no additional benefit (553). A study undertaken in patients with 
metastatic breast cancer found that doxorubicin in combination with cyclophosphamide was 
successful at enhancing a response to a HER-2+ GM-CSF-secreting breast tumour vaccine 
(554).  
Doxorubicin has also shown success in combination with an αFAS monoclonal antibody, 
which is complemented by the fact that doxorubicin can cause an upregulation in the 
transcription of FAS-L (555). Synergistic cytotoxic effects were found against bladder 
carcinoma cells (556) and renal carcinoma cell lines (557). Combination of IL-2 and 
doxorubicin was successful at delaying tumour growth in a murine breast cancer model, and 
was curative for 40% of the mice (558). When tested in a lymphoma model, combination was 
also curative; however, monotherapies were unsuccessful. It was hypothesised that 
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doxorubicin treatment modulates the environment and stimulates an initial response that 
requires IL-2 to be maintained (558). 
Through increased knowledge of chemotherapy-induced cell death and the danger signals 
released, it is clear that chemotherapy can have immunostimulatory effects and work in 
synchronisation with immunotherapy. This understanding has implications for therapeutic 
strategies and will drive better treatments for cancer patients.  
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1.9 Aims 
DCs play a crucial role in the initiation and maintenance of immune responses in tumour 
immunity. However, often they can lack appropriate stimulation to induce a sufficient 
response. Therefore, adjuvants can be used as immunotherapy to activate DCs and produce a 
robust anti-tumour response. The known TLR3 ligand, poly I:C, and danger signal MSU in 
combination with bacterial PAMPs from whole M.smegmatis, have been shown to be effective 
at producing anti-tumour responses in a melanoma model (141). Specialised cross-presenting 
DCs are superior at presenting tumour antigens to stimulate effector T cells, and they have 
been implicated as crucial cells for appropriate CTL responses against tumours. The 
hypothesis of this thesis was that poly I:C and MSU+M.smegmatis immunotherapies required 
cross-presenting DCs to produce effective anti-tumour responses against a mammary cancer 
model. Given the interplay between chemotherapy and immunotherapy, it was also 
investigated whether tumours with prior exposure to doxorubicin treatment would remain 
sensitive to immunotherapy. 
The specific aims of this thesis were: 
• To assess whether doxorubicin-resistant tumours were sensitive to immunotherapy 
• To determine which immune cell populations are involved in the efficacy of 
immunotherapy in a mammary tumour model 
• To assess whether cross-presenting DCs are required for successful immunotherapy 
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Table 2.1: Labware 
Product Supplier/Distributor 
Axygen Micro Tubes 0.6 & 1.7 mL Axygen Scientific Inc., Union City, CA, USA 
Axygen sterile pipet tips 1000, 200and 10 µL Axygen Scientific Inc., Union City, CA, USA 
BD 1 mL Tuberculin syringes & BD 10 mL 
syringes 
BD BioSciences, Bedford, MA, USA 
BD Falcon™ polystyrene sterile conical 
tubes: Blue Max 0 mL & Blue Max Jr. 15 
mL 
BD BioSciences, Bedford, MA, USA 
BD Falcon™ polystyrene sterile 5 mL round 
bottom tubes 
BD BioSciences, Bedford, MA, USA 
BD Falcon™ polystyrene sterile tissue 
culture dishes 100 x 20 mm 
BD BioSciences, Bedford, MA, USA 
BD Falcon™ polystyrene sterile tissue 
culture plates: 6, 12, 24 & 96- well plates & 
Microtest™ U-bottom 96-well plates 
BD BioSciences, Bedford, MA, USA 
BD Falcon™ polystyrene sterile tissue 
culture flasks: 25, 75 & 175 cm2  
BD BioSciences, Bedford, MA, USA 
BD Falcon™ polystyrene sterile serological 
pipettes: 5, 10 & 25 mL 
BD BioSciences, Bedford, MA, USA 
BD Falcon™ nylon cell strainers: 40 & 70 
µM 
BD BioSciences, Bedford, MA, USA 
Bio-Plexâ Multiplex Immunoassay system Bio-Rad Laboratories, Hercules, CA, USA 
PrecisionGlide™ needles: 18, 20, 25 &27.5 
gauge (G) 
BD BioSciences, Bedford, MA, USA 
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Product Supplier/Distributor 
Ultra-Fine™ needle insulin syringes (29 G): 
0.3, 0.5 & 1 mL 
BD BioSciences, Bedford, MA, USA 
Cover Slips 22x22 mm, No. 1 thickness Biolab, Ltd., Auckland, NZ 
Cryo's™ sterile cryotubes 2 mL Greiner Bio-One, Frickenhausen, Germany 
Feeding needle (stainless steel, 20 G x 38mm) Instech Laboratories Inc, Plymouth Meeting, 
PA, USA. 
MACS® autoMACS Separation Columns Miltenyi Biotech GmbH Germany 
Microtubes 0.5, 1.7 and 2 mL Axygen Inc., Union City, CA, USA 
Millipore™ MX-Plates Millipore Corp., Billercia, MA, USA 
µltra AMP 96-well PCR Plates Millipore Corp., Billercia, MA, USA 
Nylon Gauze: 70 µM NZ Filter Specialists Ltd., Auckland, NZ 
Optical Adhesive Covers for Real-time PCR Applied Biosystems, Foster City, CA, USA 
PCR 0.2 mL thin wall tubes: 8 strips & caps Axygen Scientific Inc., Union City, CA, USA 
Petri dishes: 90 mm diameter Labserv, Auckland, New Zealand 
Sterile Carbon Steel Surgical Blades: #10 & 
#22 
Swann-Morton® Limited, Sheffield, England 
Superfrost® Plus microscope slides Biolab, Ltd., Auckland, NZ 
Titertube™ Microtubules 0.5 mL Bio-Rad Laboratories, Hercules, CA, USA 
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Product Supplier/Distributor 
Transfer pipettes: 1mL Samco Scientific, Mexico 
 
2.1.2 Reagents and buffers 
2-Mercaptoethanol (2-ME) 
2-ME was purchased from Sigma (St. Louis, MO, USA), as a 55 mM solution in PBS and 
stored at 4°C. 
 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT)  
MTT powder was purchased from Sigma-Aldrich, MO, USA. MTT was dissolved in HBSS 
at a concentration of 2.5 mg/mL and 20 µL was added per well in a 96-well plate. Dissolved 
solution was stored at 4°C and used within 3 months. 
 
5(6)-Carboxyfluorescein Diacetate Succinimidyl Ester (CFDA-SE); 5-(and-6)-
Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) 
CFDA-SE; CFSE (hereby referred to as CFSE) was purchased from Molecular Probes (San 
Diego, CA, USA) and suspended at 10 mM in dimethyl sulfoxide (DMSO). Single use aliquots 
were stored at −20°C. 
 
6-thio guanine  
6-thio guanine powder was purchased from Sigma (St. Louis, MO, USA) and stored at room 




Acetone was purchased from Merck (Darmstadt, Germany) and stored at room temperature 
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Alsever’s solution 
Dextrose, sodium chloride and sodium citrate (all from BDH Laboratory Supplies, Poole, 
England) were dissolved in ddH2O to give final concentrations of 20.5 mg/mL dextrose, 
4.2 mg/mL sodium chloride and 8.0 mg/mL sodium citrate. The pH was adjusted to 6.1 with 
1 M citric acid (BDH Laboratory Supplies, Poole, England) and the solution stored at room 
temperature until used. 
 
Ammonium Chloride Tris (ACT) Lysis Buffer 
ACT buffer containing 0.144 M NH4Cl and 0.017 M HCl was prepared by mixing 9 parts 
0.16 M NH4Cl, pH 7.4 (Sigma, St. Louis, Missouri, USA) and 1 part 0.17 M Tris-HCl, 
pH 7.65 (Merck, Darmstadt, Germany) directly before use. 
 
Assay Buffer 
Assay Buffer for Multiplex detection of cytokines was prepared by adding 0.1% BSA, 0.05% 
Tween 20, 0.005% NaN3 and 2.5 mM EDTA to CaCl2 and MgCl2-free PBS. Assay buffer 
was stored at 4°C. 
 
Bovine Serum Albumin (BSA) 
BSA with low endotoxin levels (Endotoxin: ≤ 1 EU/mg, Bioburden: ≤ 100 cfu/g) was 
purchased from ICPbio Ltd. (Henderson, Auckland, NZ) in powder form and stored at 4°C. 
BSA was dissolved in PBS to make Assay Buffer. 
 
Brefeldin A 
Brefeldin A was purchased from eBioscience (San Diego, CA, USA) at 1000x concentration 
and stored at 4°C. To block cytokine secretion in cell culture, Brefeldin A was diluted to a 1x 
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DEPC-Treated Water 
RNase-free, DNase-free, pyrogen-free, filtered DEPC treated water was purchased from 
Ambion Inc, (Austin, Texas, USA). 
 
Dimethly formamide (DMF) 
DMF was purchased from Thermo Fisher Scientific (Auckland, NZ). 
 
Dimethly sulfoxide (DMSO) 




DNase I was purchased as a lyophilised powder from Roche (Mannheim, Germany), dissolved 
at 10 mg/mL in IMDM and stored at −20°C until used. 
 
Doxorubicin Ebewe 
Doxorubicin Ebewe was purchased from EBEWE Pharma (NSW, Australia) through 
Wellington Hospital, NZ and was stored at 4°C until used. 
 
Dulbecco’s modified Eagle medium 
DMEM supplemented with 4.5 g/L D-glucose, 3.7 g/L Sodium Bicarbonate, 1 mM Sodium 
Pyruvate and 584 mg/L L-Glutamine was purchased from GIBCO (Invitrogen, Auckland, 
NZ) and stored at 4°C until used. 
 
Complete Dulbecco’s modified eagle medium (cDMEM) 
DMEM was supplemented with 1% Penicillin- Streptomycin (GIBCO, Invitrogen, Auckland, 
NZ), 2 mM Glutamax and 20% FBS. Medium was stored at 4°C for a maximum of two 
months. 
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Ethanol 
Molecular grade ethanol (100%) was purchased from Carlo Erba Reagents (Milan, Italy) and 
stored at room temperature until used. 
 
Ethylendiaminetetraacetic Acid (EDTA) 
EDTA was purchased from Sigma (St. Louis, Missouri, USA) in powder form, dissolved in 
dH2O at a concentration of 0.5 M and stored at room temperature. 
 
Fluorescence-activated cell sorting (FACs) Buffer 
EDTA, NaN3 (both from Sigma, St. Louis, MO, USA) and FBS (GIBCO, Invitrogen, 
Auckland, NZ) were added to PBS at final concentration of 10 mM EDTA, 0.01% NaN3 and 
2% FBS. FACs buffer was stored at 4°C. 
 
Foetal Bovine Serum (FBS) 
Mycoplasma and virus screened and performance tested FBS (Endotoxin level: ≤10 EU/mL. 
Hemoglobin level: ≤30 mg/dL) was purchased from GIBCO (Invitrogen, Auckland, NZ) and 
stored in 25 mL aliquots at −20°C. After thawing, aliquots were stored at 4°C for a maximum 
of three weeks. 
 
Geneticin® (G418) 
The antibiotic Geneticin was purchased from GIBCO (Invitrogen, Auckland, NZ) in liquid 
form and stored in aliquots at −20°C. In use aliquots were stored at 4°C. 
 
Glutamax 
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GW2580 
GW2580 was purchased from LC Laboratories (Boston, MA, USA) in a solution of 0.5% 
methylcellulose and 0.1% Tween 80. GW2580 was stored at 4°C and diluted in dH2O to 
desired concentration immediately before use. 
 
Hank’s buffered Salt Solution (HBSS) 
HBSS was purchased from GIBCO (Invitrogen, Auckland, NZ) and stored at 4°C. 
 
Intracellular cytokine detection kit 
The BD Cytofix/Cytoperm kit was purchased from BD Pharmingen (San Diego, California, 
USA). The kit buffers 1x Cytofix/Cytoperm buffer and 10x Perm/Wash buffer were stored at 
4°C. 10x Perm/Wash buffer was diluted to 1x with ddH2O directly prior to use. 
 
Iscove’s Modified Dulbecco’s Medium (IMDM) 
IMDM supplemented with GlutaMax, 25 mM HEPES buffer and 3.024 mg/L sodium 
bicarbonate was purchased from GIBCO (Invitrogen, Auckland, NZ) and stored at 4°C until 
used. 
 
Complete Iscove’s Modfied Dulbecco’s Medium (cIMDM) 
IMDM was supplemented with 1% Penicillin-Streptomycin (GIBCO, Invitrogen, Auckland, 
NZ), 55 μM 2-ME and 5% FBS. Medium was stored at 4°C for a maximum of two months. 
 
Isopropanol 
Analytical grade isopropanol was purchased from Scharlau Chemie (Barcelona, Spain) and 
stored at room temperature until used. 
 
Liberase TL 
Libersase TL was purchased as a lyophilised powder from Roche (Mannheim, Germany), 
dissolved in IMDM at a concentration of 1 mg/mL and stored in single use aliquots at –20°C. 
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Lipopolysaccharides (LPS) 
LPS from Escherichia coli, serotype 0111:B4, was purchased as a lyophilised powder from 
Sigma (Sit. Louis, MO, USA), dissolved in IMDM at a stock concentration of 1 mg/mL and 
stored at 4°C until used. 
 
Magnetic Separation (MACS) Beads 
Anti-CD8α, anti-CD4 and DC enrichment MACS Dynabeads® were purchased from 
Thermo Fisher Scientific (Auckland, NZ) and stored at 4°C until used. 
 
Methanol 
Analytical grade methanol was purchased from Scharlau Chemie (Barcelona, Spain) and 
stored at room temperature until used. 
 
Monosodium Urate Crystals (MSU) 
MSU was prepared from uric acid as previously described (559). Briefly, 250 mg uric acid was 
dissolved in 50 mL boiling dH2O (MiliQ) and subsequently left on the bench to cool to 50°C. 
The solution was filtered through a 0.2 μM filter and reboiled. Crystal formation was induced 
by addition of 1 mL 5 M NaCl. 7 days later, MSU crystals were washed with ethanol and 
acetone and dried. MSU crystals were 12 μm to 25 μm in size with needle-like appearance, as 
determined by light microscopy. Endotoxin content was assessed by LAL test and found to be 
0.288 EU/mg MSU. 
 
Penicillin-Streptomycin 
Penicillin-Streptomycin (10,000 U/mL and 10,000 µg/mL, respectively) was purchased in 
liquid form from GIBCO (Invitrogen, Auckland, NZ) and stored as single use aliquots at 




  2 Materials and Methods 60 
Phosphate buffered Saline (PBS) 
CaCl2 and MgCl2-free PBS was purchased from GIBCO (Invitrogen, Auckland, NZ) and 
stored at room temperature. In use PBS was stored at 4°C. 
 
PLX3397 
PLX3397 was kindly provided by Professor Peter Shepherd from the University of Auckland 
(Auckland, NZ) and the powdered drug was stored at 4°C. PLX3397 was administered in a 
formulated diet of 45 mg/kg in custom SF14-156 irradiated @25kGy feed from Specialty 
Feeds (WA, Australia). 
 
Polymerase Chain Reaction (PCR) Reagents 
2x Taqman expression master mix and Taqman primers were all purchased from Applied 
Biosystems (Foster City, California, USA). The master mix was stored at 4°C and primer 
aliquots were stored at −20°C. 
 
Polyinosinic-Polycytidylic Acid (Poly I:C) 
Low molecular weight poly I:C (0.2-11kbp) was purchased as lyophilised powder from 
InvivoGen (San Diego, California, USA) and dissolved in endotoxin-free physiological water 
(containing 1.5% NaCl) provided by the supplier at a stock concentration of 20 mg/mL. Stock 
aliquots were stored at −20°C and in use aliquots were stored at 4°C for a maximum of 4 
weeks. 
 
Reverse Transcription Kit 
The reverse transcription SuperScript Viloä kit was purchased from Invitrogen (Auckland, 
NZ) and stored at −20°C. 
 
RNA Extraction Kit 
The NucleoSpinâ RNA kit for extraction of RNA from medium-sized tissue samples was 
purchased from Macherey-Nagel GmbH & Co. KG (Düren, Germany). The DNase powder 
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was stored at 4°C. DNase was dissolved in IMDM at 10 mg/mL and aliquots of DNase 
solution were stored at −20°C. The remaining components were stored at room temperature 
as specific by the manufacturer. 
 
RPMI Medium 1640 (RPMI) 
RPMI supplemented with 2 g/L D-glucose, 2 g/L Sodium Bicarbonate, 1 nM Sodium 
Pyruvate and 300 mg/L L-Glutamine was purchased from GIBCO (Invitrogen, Auckland, 
NZ) and stored at 4°C until used. 
 
Complete RPMI Medium 1640 (cRPMI) 
RPMI was supplemented with 1% Penicillin-Streptomycin (GIBCO, Invitrogen, Auckland, 
NZ), 55 μM 2-ME and 5% FBS. Medium was stored at 4°C for a maximum of two months. 
 
SDS lysing buffer 
SDS and DMF were added to ddH2O to concentrations of 10% SDS and 45% DMF. The 
pH was adjusted to 4.7 using glacial acetic acid. Lysing buffer solution was stored at room 
temperature. 
 
Sodium Azide (NaN3) 
NaN3 (Sigma, St. Louis, MO, USA) was purchased in powder form and dissolved in dH2O at 
a stock concentration of 5%. The solution was stored at room temperature until used. 
 
Sodium Chloride (NaCl) 
NaCl was purchased from Sigma (St. Louis, Missouri, USA) in powder form, dissolved in 
dH2O at a concentration of 1.8% and stored at room temperature. 
 
Sodium dodecyl sulphate (SDS) 
SDS was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
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Sodium Hydroxide 
Sodium Hydroxide was purchased from BDH Laboratory Supplies (Poole, England) in 
powder form and dissolved in dH2O to form a range of buffers at varying concentrations. 
Different solutions were used to adjust the pH of buffers. 
 
Tris Buffer 
Tris Buffer was made by diluting 0.5902 g Tris in 50 mL dH2O. The pH was adjusted to 8.5 
and the buffer was stored at room temperature until used. 
 
Trypsin/EDTA 
Trypsin/EDTA solution containing 0.25% Trypsin and 1 mM EDTA in Hanks’ Balanced 
Salt Solution was purchased from GIBCO (Invitrogen, Auckland, NZ), and aliquots were 
stored at −20°C. In use aliquots were stored at 4°C. 
 
Tweenâ 20 and Tweenâ 80 
Tween 20 and Tween 80 were purchased from Sigma (St. Louis, Missouri, USA) and stored 
at room temperature until used. 
 
Uric Acid 
Uric acid was purchased from Sigma (St. Louis, Missouri, USA) in powder form, and stored at 
room temperature. The powder was dissolved in dH2O to make MSU crystals (see MSU). 
 
Wurzburger Buffer 
EDTA, FBS and DNase I were added to 500 mL dPBS to give final concentrations of 1% 
FBS, 0.5 M EDTA and 0.02 mg/mL. The buffer was stored at 4°C and used within two 
months. 
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2.1.3 Peptides/Antigens 
Ovalbumin (OVA) 
OVA was reconstituted in sterile dH2O, creating a stock concentration of 10 mg/mL. 
Reconstituted stocked were stored in aliquots −80°C. 
 
SIINFEKL 
SIINFEKL was dissolved in DMSO to give a stock concentration of 50 mM. Aliquots of 
reconstituted stocks were stored at −20°C. 
 
2.1.4 Cytokines and growth factors 
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 
Recombinant murine GM-CSF was produced using stationary phase cultures of the murine 
X63 cell line, modified to secrete the full-length murine GM-CSF protein (560). The modified 
murine X63 cell line was kindly provided by Dr. Antonius Rolink (Basel Institute for 
Immunology, Basel, Switzerland). 
 
Interleukin 2 (IL-2) 
Human recombinant IL-2 was generated in-house by culture of the IL2L6 cell line. 
Supernatant was stored at −80°C until used, then stored at 4°C. 
 
Interleukin 4 (IL-4) 
Recombinant murine IL-4 was produced using stationary phase cultures of a Chinese 
Hamster Ovary cell line (CHO), modified to secrete the full length murine IL-4 protein. The 
IL-4 producing CHO cell line was kindly provided by Dr. Antonius Rolink (Basel Institute for 
Immunology, Basel, Switzerland). 
Cytokines were collected by growing adherent cells in cIMDM, harvesting the culture 
supernatants and filtering through a 0.2 µm serum filter. The cytokines were titrated using 
bone-marrow derived DC (BMDC) cultures (GM-CSF and IL-4) to determine the optimal 
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amount for good cell recovery. The cytokines were stored as aliquots at −80°C. In use 
aliquots were stored at 4°C for up to 2 weeks. 
 
2.1.5 Antibodies and fluorophores 
2.1.5.1 Antibodies 
Antibodies specific to murine antigens were either purchased from BD Pharmingen (San 
Diego, California, USA), eBioscience (San Diego, California, USA), BioLegend (San Diego, 
California, USA), AbD Serotec (Morphosys, Kidlington, U.K) or purified in-house and 
labelled with the appropriate flurophore. 
 
Table 2.2: Antibodies 
Specificity Clone Fluorophore Supplier 
B220 RA3-6B2 BV650 BD Biosciences 
B220 RA3-6B2 PerCP BD Biosciences 
B220 RA3-6B2 PE-Cy7 eBioscience 
CD3 145-2C11 BV785 BD Biosciences 
CD3 145-2C11 APC BD Biosciences 
CD3 145-2C11 BUV395 BD Biosciences 
CD4 RM4-5 BV605 BD Biosciences 
CD8 2.43 AF647 purified in-house 
CD8 2.43 FITC BD Biosciences 
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Specificity Clone Fluorophore Supplier 
CD8 53-6.7 Pacific Blue purified in-house 
CD11b M1/70 BUV737 BD Biosciences 
CD11b M1/70 PE BD Biosciences 
CD11b M1/70 AF700 BioLegend 
CD11b M1/70 PerCPCy5.5 BD Pharmingen 
CD11c NA18 PerCPCy5.5 BioLegend 
CD11c HL3 BV650 BD Biosciences 
CD11c NA18 AF647 purified in-house 
CD24 M1/69 BV650 BD Biosciences 
CD44 IM7 APC eBioscience 
CD44 IM7 APCelf780 eBioscience 
CD45 30-F11 BV786 BD Biosciences 
CD45 30-F11 FITC BioLegend 
CD45.1 A20 APC eBioscience 
CD45.1 A20 PerCPCy5.5 eBioscience 
CD49b DX5 PE BD Pharmingen 
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Specificity Clone Fluorophore Supplier 
CD62L MEL-14 PE BD Biosciences 
CD62L MEL-14 FITC BioLegend 
CD62L MEL-14 PE-Cy7 eBioscience 
CD64 X54-5/7.1 APC BioLegend 
CD103 M290 PE BD Pharmingen 
CSF1R (CD115) AFS98 PE eBioscience 
FcyRII/III 
(CD32/CD16) 
2.4G2 none purified in-house 
F4/80 BM8 APC-efl780 eBioscience 
FoxP3 FJK-16s PE eBioscience 
IL-12p40/70 RatIgG1 PE BD Biosciences 
iNOS BM8 AF647 eBioscience 
Ly6B 7/4 FITC AbD Serotec 
Ly6C HK1.4 BV570 BioLegend 
Ly6G 1A8 APC BD Biosciences 
MHC II (I-Ab) 3JP AF647 purified in-house 
MHC II (I-A/I-E) M5/144.15.2 Pacific Blue BioLegend 
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Specificity Clone Fluorophore Supplier 
NK1.1 PK136 PE eBioscience 
PD-1 J43 BV421 BD Biosciences 
TNFα MP6-XT22 FITC eBioscience 
 
Isotype controls were used to help identify positive staining. 
 
Table 2.3: Isotype controls 
Specificity Isotype Fluorophore Supplier 
iNOS Rabbit IgG1 AF647  eBioscience 
TNFα eBRG1 IgG1 FITC eBioscience 
IL-12p40.70 MRK-1 Rat IgG1 PE BioLegend 
 
Streptavidin (SA)- Fluorophore conjugates 
SA-Alexa Fluor 555 was purchased from Invitrogen (Auckland, NZ) and stored in aliquots at 
−20°C. In use aliquots were stored at 4°C. SA-FITC, SA-PE, SA-PerCP, SA-PETR and SA-
APC were purchased from BD Pharmingen and stored at 4°C. 
 
2.1.5.2 Cell viability dyes 
4,6-Diamidino-2 Phenylindole Dihydrochloride (DAPI)  
DAPI was purchased as a lyophilized powder from Invitrogen (Auckland, NZ) and dissolved 
in dH2O to a concentration of 5 mg/mL. This solution was then further diluted to a stock 
solution of 200 μg/mL in FACs buffer and stored in aliquots at 4°C until used. 
  2 Materials and Methods 68 
Live/Dead® fixable Blue 
Live/Dead® fixable dead cell staining kit blue was purchased from Invitrogen (Auckland, NZ) 
and stored at −20°C. The lyophilised dye powder was dissolved in 50 μL DMSO per vial as 
per manufacturer’s instructions and stored at 4°C for a maximum of 6 weeks. 
 
Propridium Iodide (PI) 
PI was purchased from BD Biosciences (Bedford, MA, USA)	as a solution composed of 50 µg 
PI/mL in PBS (pH 7.4). The solution was stored undiluted at 4°C. 
 
2.1.6 Mycobacteria 
The mycobacterial strain Mycobacterium smegmatis mc2155 was kindly provided by Dr. Ronan 
O’Toole (School of Biological Science, Victoria University of Wellington, NZ). 
 
2.1.7 Tumour cell lines 
GL261 
The murine glioma cells line GL261 cell line was obtained from the DCTD Tumour 
Repository (NCI, Frederick, MD).  
 
B16.OVA/B16.F1 
The B16.OVA melanoma tumour cell line was generated by Drs. Edith Lord and John G. 
Frelinger, University of Rochester, Rochester, New York, USA (561) and kindly gifted by Drs. 
Roslyn Kemp and Dick Dutton, Trudeau Institute, New York, USA. The parental melanoma 
tumour cell line B16.F1 was purchased from American Type Culture Collection (ATCC, 
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4T1 
The breast carcinoma line 4T1 is a 6-thioguanine resistant cell line selected from the 410.4 
tumour without mutagen treatment (562). The 4T1 cells were obtained from ATCC (access 
number CRL-2539, ATCC, Manassa, Virgina, USA). 
 
Tumour cell lines were stored in 90% FBS, 10% DMSO at −80°C. Before use in 
experiments, tumour cells were cultured in their specific complete media to obtain cells in 
exponential growth. OVA expressing cell lines were cultured in the presence of 0.5 mg/mL 
Geneticin® selective antibiotic. Adherent cells were detached by trypsinisation at 37°C. 
Proteolysis was stopped by addition of abundant cIMDM. After collection, cells were washed 
3 times in PBS before inoculation. 
 
2.1.8 Mice 
2.1.8.1 Ethical approval 
All experimental protocols were approved by the Victoria University Animal Ethics 
Committee and all procedures were carried out in accordance with the guidelines of Victoria 




BALB/cByJ breeding pairs were originally obtained from the Jackson Laboratories (Bar 
Harbour, ME, USA). 
 
BATF3 KO 
Basic leucine zipper transcription factor, ATF-like 3 (BATF3) KO mice lack exons 1-2 of the 
Batf3 gene, which is required for the development of CD103+ dendritic cells (76,78). BATF3 
KO breeding pairs were originally obtained from Ken Murphy from Washington University 
& Howard Hughes Institute then backcrossed with C57BL/6 mice at the Malaghan Institute 
of Medical Research (MIMR). 
  2 Materials and Methods 70 
 
Pmel-1 TCR (B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J) 
The melanocyte protein (Pmel-1 or gp100) is often overexpressed in human melanomas and 
can be used as a model antigen. These Thy1.1 congenic mice have rearranged T cell 
receptors specific for recognition of gp100 and will be referred to as pmel-1 TCR mice 
hereafter. Pmel-1 TCR breeding pairs were originally obtained from the Jackson Laboratories 
(Bar Harbour, ME, USA) 
 
C57BL/6  
C57BL/6 breeding pairs were originally obtained from the Jackson Laboratories (Bar 
Harbour, ME, USA). 
 
Clec9A-DTR  
C-type lectin domain family 9 member A (Clec9A) is expressed on CD8α+ and CD103+ 
dendritic cells (563,564). Clec9A-DTR mice harbour a dtomato-DTR construct, allowing 
detection and depletion of Clec9A+ populations upon DT administration. Breeding pairs were 
kindly gifted from Klaus Erik Karjalainen and Christiane Ruedl from the Nanyang 
Technological University, Nanyang Singapore. Clec9A-DTR mice were backcrossed with 
BALB/cByJ mice at MIMR and PCR testing was undertaken to determine transgenic litters.  
 
NOD/SCID (NOD.CB17-Prkdcscid) 
Severe combined immune deficiency on a non-obese diabetic background (NOD/SCID) mice 
have impaired T and B cell development. Breeding pairs were initially obtained from the 
Hercus-Taieri Research Unit, University of Otago, New Zealand. 
 
OT-I (B6.SJL-Ptprca/OT-I) 
OT-I mice were backcrossed with B6.SJL mice to obtain OT-I CD45.1+ congenic mice. 
Therefore, cells from C57BL/6 and B6 congenic mice can be distinguished on the basis of 
CD45.1 and CD45.2 expression, respectively. T cells from OT-I mice express Vα2Vβ5.1/5.2 
TCRs specific for OVA257-264 presented on H2-Kb. B6.SJL-Ptprca mice were originally 
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obtained from Jackson Laboratories (Bar Harbour, ME, USA) and OT-I mice were originally 
obtained from Dr. Sarah Hook, School of Pharmacy, Dunedin, NZ, with the permission of 
Prof. Frank Carbone, Melbourne University, Australia.  
 
2.1.8.3 Maintenance 
All mice were bred and maintained on sterile standard laboratory food and acidified water ad 
libitum in the Biomedical Research Unit of the Malaghan Institute of Medical Research. Mice 
were housed in a Specific Pathogen Free (SPF) environment and health was monitored to 
maintain SPF colonies. Mice strains were maintained by mating between siblings. Mice in 
experiments were between 6-15 weeks of age, preferentially with gender and age-matched 
controls. 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Culture of tumour cell lines 
All cells were cultured at 37°C with 5% CO2 and 95% humidity in PC2 facilities at the 
Malaghan Institute of Medical Research, Wellington. Cell work was carried out in biological 
safety cabinets with HEPA air filters.  
B16.OVA cells were grown in cIMDM containing 0.5 mg/mL G418. B16.F1 were grown in 
cIMDM without G418. GL261 cells were grown in cDMEM. 4T1 cells were maintained in 
cRMPI media. 
Tumour cells were passaged once they reached ~70% confluence. 4T1 was passaged at 40-
50% confluence. 
 
2.2.1.2 Harvesting adherent tumour cells 
To harvest adherent cells, cell culture medium was removed and cells were washed with sterile 
PBS. Cells were incubated with Trypsin- EDTA for 2-3 min at 37°C and proteolysis was 
stopped by excess medium. Cells were collected by centrifugation and resuspended before 
reseeding. All tumour cells were washed 3 times in PBS before injection into mice. 
 
2.2.1.3 Mycoplasma testing 
Cultured cells were tested yearly for Mycoplasma contamination using the Intron Mycoplasma 
PCR Detection Kit, as per the manufacturer’s instructions. 
 
2.2.1.4 Culture of mycobacteria 
M.smegmatis 
M.smegmatis was cultured in sterile LB medium containing 0.1% Tween 80. One frozen 
aliquot was thawed, inoculated into 30 mL medium and cultured over night at 37°C and 
200 rpm. The culture was then split into two 400 mL cultures and again grown over night. 
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M.smegmatis was pelleted by centrifugation at 3,115 xg for 30 min at 4°C and washed 3 times 
in PBS containing 0.05% Tween 80. Single use aliquots were stored at −80°C. 
 
Enumeration of bacterial titer (CFU) 
M.smegmatis was tested by culturing on an LB plate for 1-2 days to ensure the cultures were not 
contaminated by other bacterial or fungal species. To enumerate colony forming units (CFU), 
bacteria were thawed, sonicated twice for 20 sec and serial 10-fold dilutions were plated. 
 
2.2.1.5 Generation of dendritic cells from bone marrow precursors 
C57BL/6 mice were euthanised and hind legs were detached at the hips and collected in 
IMDM. Once the muscle and connective tissue was removed, knee joints were separated and 
the end of femurs and tibias cut off to gain access to the bone marrow (BM). The BM was 
flushed out with IMDM using a 25-gauge needle attached to a 10 mL syringe. Cell clumps 
were disrupted by vigorous pipetting and cells were filtered through 70 µm nylon gauze. Cells 
were pelleted by centrifugation at 320 xg for 5 min. Red blood cells (RBC) were lysed by 
incubation in 5 mL ACT buffer per mouse for 5 min at 37°C. Lysis was stopped by addition 
of an equal volume of IMDM. Cells were pelleted again and live cells were identified by 
trypan blue exclusion and counted using a haemocytometer. Cells were pelleted, resuspended 
in cIMDM and plated in 6-well plates. 
BM cells were plated 2x106 cells/well containing 10 ng/mL GM-CSF and 20 ng/mL IL-4. 
Cells were cultured at 37°C for 7 days. Cells were supplemented with nutrients on days 3 and 
5 by replacing 2 mL of medium containing GM-CSF and IL-4. 
 
2.2.2 Cell isolation/purification 
2.2.2.1 Tissue preparations 
2.2.2.1.1 Blood 
Blood was collected either from the tail vein or the submandibular vein. For tail vein bleeding, 
mice were warmed up with a heat lamp, put into restrainers and tail veins were nicked with a 
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sterile scalpel blade. For cheek bleeding, mice were restrained and the submandibular vein 
was punctured with a 4 nm Goldenrod Animal Lancet. 
Blood collected for flow cytometry was collected in 1.7 mL microtubes containing at least an 
equal volume of Alsever’s Solution. The blood samples were centrifuged at 420 xg for 2 min 
and the supernatant was discarded. Pellets were resuspended in 1 mL ACT buffer and 
incubated 37°C for 10 min to lyse RBC. Cells were centrifuged again for 2 min at 420 xg and 
resuspended in 1 mL ACT buffer at room temperature for 5 min. Cells were centrifuged 
again for 2 min at 420 xg and resuspended in 1 mL in FACS buffer. 
Blood collected for serum was collected into empty 1.7 mL micro tubes. Samples were left 
overnight at 4°C to clot. Cells were pelleted by centrifugation at 420 xg for 2 min. The 
supernatant was transferred to fresh 1.7 mL micro tubes and clarified by centrifugation at 
420 xg for 2 min. Serum samples were stored in 0.6 mL tubes at −20°C until further analysis. 
 
2.2.2.1.2 Lungs 
Lungs were collected from sacrificed mice into 12-well plates containing HBSS. Lungs were 
blotted on paper towels before weighing. After weighing lungs were minced with scissors. 
Lung tissue was digested in HBSS containing 0.5 mg/mL Liberase TL and 0.25 mg/mL 
DNase for 45 min at 37°C. Digested lungs suspensions were drawn up 5-8 times through a 
5 mL syringe with an 18 gauge needle before being filtered through 70 µM cells strainers 
using the tip of a 10 mL pipette. Cells were washed with either HBSS or FACs buffer, 
depending on further use. If further culture was required, cells were washed 3 times in HBSS. 
Lungs processed for flow cytometry underwent RBC lysis before resuspension in FACs buffer. 
 
2.2.2.1.3 Lymph nodes 
LNs were collected from sacrificed mice into 24-well plates containing IMDM. To release 
DCs, LNs were pulled apart using 18 gauge needles and then digested enzymatically in 
IMDM containing 0.1 mg/mL Liberase TL and 100 µg/mL DNase for 25 min at 37°C. 
Digestion was stopped by addition of EDTA to a final concentration of 10 nM. Subsequently, 
LNs were pressed through 70 µM cell strainers using the plunger of a 1 mL syringe. Cells were 
washed with either IMDM or FACs buffer, depending on further use. If the release of DCs 
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was not required, LNs were directly processed into single-cell suspensions by pressing through 
cell strainers without digestion. Cells were stored on ice until further use. 
 
2.2.2.1.4 Spleens 
Spleens were collected into 12-well plates containing IMDM. To release DCs, spleens were 
injected with 1 mL of digestion solution containing 0.1 mg/mL Liberase TL and 100 µg/L 
DNase in IMDM. Spleens were digested for 25 min at 37°C. Digestion was stopped by 
addition of EDTA to a final concentration of 10 mM. Spleens were then processed into single-
cell suspensions by pressing through a 70 µM cell strainer using the plunger of a 1 mL syringe. 
Cells were pelleted by centrifugation at 400 xg for 4 min. The cell pellet was resuspended in 
ACT buffer (5 mL for naïve spleen, 10 mL for 4T1 tumour burdened mouse) and incubated 
at 37°C for 10 min to lyse RBC. 5 mL IMDM was added and the spleen cells were 
centrifuged again as above. Subsequently, spleen cells were washed in the appropriate buffer 
for each experiment and stored on ice until further use. 
 
2.2.2.1.5 Tumours  
For flow cytometry analysis and cell culture, tumours were collected into 12-well plates 
containing IMDM. Tumours were blotted on paper towels before weighing. After weighing, 
B16 tumours were broken up with tweezers; 4T1 tumours were chopped up using either size 
10 or 22 sterile carbon steel surgical blade. Tumours were digested in IMDM containing 
0.5 mg/mL Liberase and 0.25 mg/mL DNase for 45 min at 37°C. Digestion was stopped by 
addition of EDTA to a final concentration of 10 mM. Tumours were then processed into 
single-cell suspensions by pressing through 70 µM cell strainers using the plunger of a 1 mL 
syringe. Cells were pelleted by centrifugation at 250 xg for 10 min. 
 
2.2.2.2 Magnetic Cell Separation (MACS) 
Lymphocyte suspensions were prepared from spleens and lymph nodes (2.2.2.1.3 and 
2.2.2.1.4) and enriched for specific cells populations (e.g. CD8+ T cells, CD4+ T cells, DCs) 
using the MACs Dynabead system.  
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Cells were resuspended at 5x107 cells/mL in Wurzburger buffer and 50 µL of FlowComp 
antibody was added per 5x107 cells. The cell-antibody mixture was incubated for 4°C for 
10 mins. Cells were washed with Wurzburger buffer and resuspended in 1 mL of buffer. 
15 µL of FlowComp Dynabeads was added per 5x107 cells and incubated at 4°C for 15 min 
with slow rotation. The tube was placed in the Dynabead magnet for at least 1 min before 
removing the negative fraction. The cells were resuspended in 1 mL of buffer and the 
magnetic separation was repeated. The positive fraction was then resuspended in 1 mL 
FlowComp Release Buffer and incubated for 10 min at room temperature. The tube was 
again placed in the Dynabead magnet for at least 1 min and cells were then collected. For DC 
enrichment, negative isolation was used and after the Dynabead incubation. 
 
2.2.3 Flow cytometry 
2.2.3.1 Cell surface staining 
Single cell suspensions were counted and washed once in FACs buffer. For staining, 1-3x106 
cells were dispensed into a 96-well round-bottomed plate. Cells were pelleted by 
centrifugation at 250 xg for 2 min and supernatants were removed by flicking the plate once. 
Pellets were resuspended by vortexing the plate at low speed. If fixation of the cells was 
required before flow cytometry acquisition, staining with live/dead fixable blue was 
performed by incubating the cells for 15 min in a 1:1000 dilution of the stock solution on ice. 
Cells were then pelleted and resuspended again. To block unspecific binding by Fcγ receptors 
II and III, cells were incubated in FACs buffer containing 2.4G2 antibody at a predetermined 
saturating concentration for 10 min on ice. Fluorescently or biotin-labelled antibodies against 
the surface markers of interest were then added at the appropriate dilutions and the cells were 
incubated a further 10 to 15 min on ice. Cells were washed once in FACs buffer and then 
incubated with a fluorochrome-conjugated streptavidin at the appropriate concentration for 
10 min on ice, when required. After labelling, cells were washed twice in FACs buffer. Cells 
were resuspended in 200 µL FACs buffer and kept on ice. Directly before analysis by flow 
cytometry, the cell viability dye DAPI was added at a final concentration of 0.003 µg/mL. 
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2.2.3.2 Intracellular/nuclear staining 
Cells were labelled with antibodies against surface markers (2.2.3.1). After washing in FACs 
buffer, cells were fixed using the FoxP3 Transcription Factor Staining Buffer (eBioscience, 
San Diego, CA, USA) to allow for intracellular staining. Cells were fixed by incubating in 
200-500 µL of 1x Fix/Perm for 18 h at 4°C in the dark. Without washing 200-500 µL of 
1x Perm Buffer was added and samples were centrifuged at 300-400 xg for 5 min. Cells were 
washed once in FACs buffer, resuspended in FACs buffer and stored on ice for up to 2 h or at 
4°C overnight before flow cytometry analysis. 
Cells were then washed twice in BD Perm buffer and incubated in this buffer for 15 min. Cells 
were pelleted, resuspended and stained for 30 min on ice with the appropriate dilutions of 
antibodies for intracellular markers or isotype controls. Cells were washed twice in 
Perm/Wash buffer and incubated another 30 min in Perm/Wash buffer to reduce 
background staining. Cells were washed once in FACs buffer, resuspended in FACs buffer 
and stored on ice for up to 2 h or at 4°C overnight before flow cytometry acquisition. 
 
2.2.3.3 Acquisition and analysis 
Data was acquired using a LSR Fortessa or LSRII SORP flow cytometer (Beckton-Dickinson, 
San Jose, CA, USA) and recorded with BD FACS Diva software. Data was analysed with 
FlowJo version 9.9 software (Treestar Inc., CA, USA).  Cytometer set-up and tracking was 
performed daily to ensure calibration. Experiments requiring cell sorting were run using a BD 
Influx (Beckton-Dickinson, San Jose, CA, USA). For cytometer instrument details, please see 
Appendix A. 
Live cells were identified based on their forward scatter (FSC) and side scatter (SSC) 
properties as well as on their ability to exclude the viability dyes live/dead fixable blue, DAPI 
or PI. Unlabelled cells were used to adjust voltage settings. Cells labelled with a single 
antibody or dye and antibody-labelled CompBeads were labelled for 10 min at room 
temperature in FACs buffer containing the same antibody used in the experiment at a 1:10 
dilution respective to the concentration used for cell labelling. Unbound antibody was diluted 
by excess buffer and labelled CompBeads were stored up to two weeks at 4°C. In some 
experiments, matched isotype control antibodies were used to control for background 
fluorescence due to non-specific antibody binding. Where combination of many different 
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fluorophores caused a rise in background staining or possible stained populations were hard to 
identify, fluorescence minus one (FMO) controls were used to determine gate positions. 
 
2.2.4 Gene expression analysis 
2.2.4.1 RNA extraction and quality assessment 
The NucleoSpinâ RNA extraction kit was used according to the manufacturer’s instructions. 
Briefly, cells were lysed in Buffer RA1 and 2-ME and lysate filtered through a NucleoSpinâ 
Filter by centrifugation at 11,000 xg for 1 min. The NucleoSpinâ Filter was then discarded, 
70% ethanol was added to the lysate and mixed before both the lysate and ethanol were 
loaded onto a NucleoSpinâ RNA Column and centrifuged at 11,000 xg for 30 sec. The 
column was placed into a new tube and Membrane Desalting Buffer was added to the column 
membrane before centrifugation at 11,000 xg to dry the membrane. DNA was digested by the 
addition of DNase reaction mixture directly onto the silica membrane and samples were 
incubated at room temperature for 15 min before the column was washed again. RNA was 
eluted from the column by addition of RNase-free waster and centrifugation at 11,000 xg for 
1 min. 
RNA concentration and quality was determined on a NanoDrop ND-100 Spectrophotometer 
by absorption at 230, 260 and 280 and 340 nm. The 260:280 ratio was generally >2 and the 
260:230 ratio was >2.2, indicating that there was little contamination with DNA or protein, 
respectively. Absorption at 340 nm was zero. 
 
2.2.4.2 Reverse-Transcription 
The SuperScript Viloä kit (Invitrogen, Auckland, NZ) was used according to the 
manufacturer’s instructions to synthesise cDNA. Appropriate amounts of reaction mix and 
enzyme were combined with 10 µg of RNA in PCR 8-strips. Controls with DEPC water 
instead of enzyme were also included. Reverse transcription was performed for 60 min at 
42°C, followed by enzyme inactivation at 85°C. cDNA samples were stored at −80°C. 
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2.2.4.3 Real-time quantitative PCR  
The Taqmanâ 96-well plate inflammatory mouse array, as well as individual Taqmanâ 
assays were used in conjunction with the Taqmanâ Expression Master Mix for real-time 
PCR (all from Applied Biosystems, Foster City, CA, USA). For the plate-based array, 20 ng to 
40 ng RNA were placed into the wells that already contained the lyophilised primers and 
probes. DEPC water and master mix were added and the plates were sealed with optical 
adhesive covers. For individual Taqmanâ assays, stock solutions of the lyophilised primers 
and probes were prepared according to manufacturer’s instruction and stored at −20°C. 
Primers/probes were combined with the master mix and distributed in 96-well PCR plates. 
20 ng to 40 ng cDNA and DEPC water were added to a final volume of 25 µL. Non-reverse-
transcribed and water controls were also included. Real-time PCR was run on an Applied 
Biosystems 7500 system. Samples were incubated for 2 min at 50°C, followed by 15 min at 
95°C and 40 cycles of 15s at 95°C and 1 min at 60°C. Cycle threshold (CT) values were 
determined automatically and ΔΔCT values (normalised to 18S, compared to untreated 
controls) were calculated for all samples. 
 
2.2.4.4 Primers for Real-time PCR 
All primers were TaqManâ Gene Expression Assays, used in conjunction with the 
PowerUPäSYBRâ Green Master Mix, all purchased from Applied Biosystems (Foster City, 
CA, USA). 
 
Table 2.4: RT-PCR primers 
Target gene Name Assay ID Reference sequence 
accession number 
18s 18s ribosomal RNA qMm03928990_g1 NR_003278.2 
Abcg2 ATP-binding cassette, 
sub-family G 
(WHITE), member 2 
qMmuCID0009104 NC_000072.6 
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Target gene Name Assay ID Reference sequence 
accession number 







Lymphocyte antigen 6 
complex, locus A 
qMmuCED0003761 NC_000081.6 
 
2.2.5 Tumour models 
2.2.5.1 Tumour challenge and growth monitoring 
Tumour cells grown in vitro were harvested during their exponential growth phase and washed 
three times in PBS. B16F1, B16F10 or B16.OVA tumour cells were inoculated into the flank 
of C57BL/6 mice by subcutaneous (s.c.) injection of 1-2x105 cells. 4T1 breast cancer cells 
were injected into the mammary fat pad of female BALB/cByJ mice at either 1-3x104 cells. 
Tumour growth was monitored at least three times a week by palpation for very small 
tumours and measuring the bisecting diameters using calipers for tumours >3mm. Mice were 
euthanized when tumour size exceeded 150mm2 for B16 tumours and 130mm2 for 4T1 
tumours. 
 
2.2.5.2 Adjuvant treatment 
Adjuvant treatment was administered by peritumoural injection in a maximal volume of 100 
µL PBS for tumours. For tumours >25mm2, adjuvants were injected on 2 sites around the 
tumour. Doses were 4x106  CFU live M.smegmatis + 500 µg MSU crystals or 50 µg poly I:C. 
All adjuvants were diluted freshly in PBS prior to injection. Bacteria and MSU crystals were 
sonicated 3 times for 10 sec before usage. Combination treatment was given in separate 
injections of the two adjuvants at the same site, mainly to avoid clumping of MSU crystals 
with Mycobacteria. Adjuvant treatment was generally administered after the appearance of 
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palpable tumours every second day for 4 times in total. In some experiments, different 
treatment schedules were used as stated in the figure legends. 
 
2.2.5.3 Adoptive cell transfer 
T cells were purified from either TCR transgenic mice or adjuvant-treated tumour bearing 
mice (2.2.2.1). In some instances, cells were labelled with CFSE to assess in vivo proliferation 
(2.2.6.2). Cells were washed 3 times in IMDM and injected intravenously (i.v.) into the lateral 
tail vein of the recipient mice. 
 
2.2.5.4 Drug-induced depletion in vivo 
2.2.5.4.1 GW2580 
The small molecule CSF-1 inhibitor, GW2580, was used to inhibit moDCs. 4T1 tumour 
bearing mice were given 160 mg/kg GW2580 in a solution of 0.5% methylcellulose and 0.1% 




PLX3397 is a tyrosine kinase inhibitor of CSF-1R and is administered by mixing with chow. 
4T1 tumour bearing mice were given feed containing 45 mg/kg PLX3397 from 5 days 
following tumour inoculation. Specialty SF14-156 irradiated @25kGy feed from Specialty 
Feeds (WA, Australia) was used. Freshly made feed was given ad libitum from day 5 onwards 
and refreshed daily for the continuation of the experiments. Feed without PLX3397 was 
administered to controls. 
 
2.2.5.5 In vivo antibody depletion 
CD8+ T cells were depleted by intra-peritoneal (i.p.) injection of purified 2.43 antibody. On 
day -1 and 0 with respect to the tumour inoculation, 200 µg 2.43 was injected. Tumours were 
inoculated at day 0 and adjuvant treatment was performed from day 8 to day 14. Cell 
depletion was assessed by flow cytometry staining of the blood on days 0, 7 and 15. CD8+ T 
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cells were 99% depleted at each of these time points. Anti-KLH Rat IgG2b (clone LTF-2) 
isotype was used as a control. 
αCCL2 (2H5) and αCSF-1 (5A1) were administered by i.p. injections to assess the impact on 
monocyte-derived dendritic cells. On day 0, 4T1 tumours were inoculated and 100 µg 
αCCL2 and 300 µg αCSF-1, were administered on day 8. 24 h later, draining lymph nodes 
and tumours were assessed for depletion. Anti-KLH Rat IgG2b (clone LTF-2) isotype was 
used as a control. 
 
2.2.5.6 Chemotherapy in vivo 
Doxorubicin (EBEWE Pharma, NSW, Australia) was diluted in a sterile 0.9% NaCl solution 
to obtain either 5 or 8 mg/kg concentration. Mice bearing 4T1 tumours were given 
doxorubicin either via i.p. or i.v. injection on days 2, 8, 14 and 20 post tumour injection. 
Control mice received 0.9% NaCl alone. Mice were weighed prior to administration and 
weight loss was monitored every other day after the commencement of treatment.  
 
2.2.5.7 Metastatic lung colony assay 
Lungs from 4T1 tumour bearing mice were harvested and processed into single cell 
suspensions (2.2.2.1.2). Cells were resuspended in cRPMI containing 10 µg/mL 6-
thioguanine. Lung cells were then seeded at 10-fold, 100-fold and 1000-fold dilutions into 10 
cm tissue culture plates and incubated at 37°C, 5% CO2 for 14 days. Following incubation, 
culture medium was discarded and 4T1 colonies were fixed for 5 min in methanol. Cells were 
washed in ddH2O, stained with 0.03% methylene blue solution for 5 min and washed again in 
ddH2O. Plates were allowed to air dry before 4T1 colonies were counted. Each colony is 
counted as a direct measure of the number of metastatic tumour cells in the lung, as 
previously described (565). Metastatic burden is calculated as the number of colonies/g of 
tissue. 
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2.2.6 In vitro assays 
2.2.6.1 Annexin V staining assay 
Exponentially growing cells were harvested (2.2.1.1). Cells were then seeded at a density of 
1x105 cells per well in a 12-well plate. The plates were incubated at 37°C for 6 h for the cells 
to adhere. Doxorubicin was added at a range of concentrations and the plates were incubated 
for a further 12-36 h. 6 h prior to harvesting plates, 5 µM Staurosporine (diluted in cRPMI) 
was added to a control well, to provide a positive control for apoptosis. 
 
2.2.6.2 Cross-presentation assay 
Mice were treated with 50 µg of poly I:C on day 0. On day 1, mice received another dose of 
poly I:C either with or without 250 µg of OVA. LNs were harvested on day 2 (2.2.2.1.3) and 
preparations were pre-enriched for DCs using Dynabeads® Mouse DC (Dendritic Cell) 
Enrichment kit (2.2.2.2). The positive fraction was then stained and sorted using a BD Influx 
(see Appendix A). 
Total LNs were harvested from OT-I mice and purified for CD8+ cells using Dynabeads® 
Untouched™ Mouse CD8 Cells kit. Cells were then stained with 100 nM of CFSE by 
incubating for 10 min at 37°C. Staining was stopped by adding equal amounts of FCS and 
cells were then washed in cIMDM. OT-I cells were plated at 1x105 cells per well with DC 
subsets in a range of titrations (2,000-16,000). Cells were harvested 3 days after plating and 
assessed for OT-I proliferation by flow cytometry analysis. 
 
2.2.6.3 Doxorubicin in vitro 
4T1 cells were plated at a concentration of 1.25x104 cells per well into a 6-well plate. 
Doxorubicin (EBEWE Pharma) was diluted in cRMPI media and added to each well at a 
concentration of 1 µM for 16-18 h. Cells were collected and plated in T75 flasks to monitor 
growth. For some experiments the supernatant was collected 18 h post Doxorubicin 
treatment. 
For long-term doxorubicin treatment, 4T1 cells were plated in 6-well plates and treated with a 
range of doxorubicin concentrations in duplicate (1-120 nM). Two days later, duplicates were 
pooled and total cells were plated with the appropriate concentration of doxorubicin in 
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cRPMI in T75 flasks. All concentrations 20 nM and upwards were dead and discarded. 1, 5 
and 10 nM flasks were split and were plated either in the same concentration of doxorubicin, 
or 2x the previous concentration. Cells were plated at a concentration of 3x105 and were drug 
treated as described each time cells were passaged.  
 
2.2.6.4 MTT dye reduction assay 
The colourimetric MTT assay was used to measure enzymatic reduction of MTT. The yellow 
MTT dye is reduced to blue formazan crystals by metabolically active cells, therefore the 
intensity of the blue colour was used as an indication of the number of live cells (566). 
Growing cells were harvested (2.2.1.1) and cells were seeded at a density of 2.5x103 cells per 
well in a 96-well, flat-bottom plate and incubated overnight. Doxorubicin was added at a 
range of concentrations (10 nM-100 µM) and the plates were incubated for an additional 48 
h. Dye reduction was initiated by adding 20 µL of 2.5 mg/mL MTT dissolved in HBSS to 
each well and plates were incubated for 2 h. Cells were lysed with 100 µL of SDS lysis buffer 
added to each well and incubated for 24 h. MTT reduction was measured at an absorbance of 
570 nm using a multi-well plate reader (FLUOstar Optima, BMG, Labtech, Australia). 
 
2.2.6.5 Antigen uptake in vivo  
Fluorescently labelled OVA was used to investigate antigen uptake by myeloid cell 
populations in the draining lymph node. C57BL/6 mice were primed with 50 µg of poly I:C 
on day 0, followed by another dose of poly I:C 24 h later, either with or without 50 µg of 
AF647+ labelled OVA. 16-18 h following the last treatment the dLN and non-dLN were 
harvested, processed and stained for flow cytometry analysis. 
B16.OVA cells were used to analyse uptake of cell-associated antigen. Cells were labelled with 
cell tracker orange (CTO) by incubating at 37°C for 15 min. Cells were spun down and 
resuspended in warm IMDM and incubated for a further 20 min at 37°C. Cells were then 
washed twice in PBS before irradiation with 150 gray. 5x106 cells per mouse were 
administered subcutaneously into C57BL/6 mice, who received either poly I:C 
immunotherapy or PBS as a control. Another group received B16.OVA cells and poly I:C a 
day after the first group. Two days following the first group, dLNs were harvested and 
analysed for uptake of B16.OVA material. 
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2.2.6.6 Cytokine production 
Cytokine production was either analysed by intracellular staining or multiplex bead assay 
from Biorad (Hercules, CA, USA) of culture supernatant or serum. For intracellular staining, 
cells were isolated, plated in cIMDM containing 1 µg/mL GolgiStop (BD, San Diego, CA, 
USA) and/or Brefeldin A (eBioscience, San Diego, CA, USA) and incubated for 3-6 h at 
37°C, 5% CO2. Subsequently, cells were harvested by pipetting and stained for intracellular 
cytokines (2.2.3.2). 
For cytokine detection from whole tumour lysate, tumours were harvested and processed 
(2.2.2.1.5). Once in single cell suspension, cells were plated in a 24-well plate at a 
concentration of 1x106 in 2 mL cIMDM containing 1 µg/mL GolgiStop and incubated for 6 
h at 37°C. For CD3/CD28 re-stimulation, αCD3 was diluted to 5 µg/mL and 300 µL was 
added per well in a 24-well plate and incubated overnight at 4°C. The following day, the plate 
was washed twice with PBS and once with IMDM. Tumour cells were resuspended and 
plated in the aCD3-coated plate at a concentration of 1x106 cells per well in 2 mL of cIMDM 
that contained 1 µg/mL GolgiStop, 2 µg/mL of αCD28 and 102 U/mL of IL-2. Following the 
6 h incubation, cells were harvested and stained for intracellular cytokines (2.2.3.2). 
For cytokine detection in culture supernatant or serum, multiplex polystyrene-bead kits from 
Invitrogen (Auckland, NZ), Biorad (Hercules, CA, USA) and Millipore (Merck Millipore 
Corporation, Billerica, MA, USA) were used as per the manufacturer’s instructions. Serum 
was collected (2.2.4.1) and samples and reconstituted standards were added to pre-wet 96-well 
filter plates and incubated with samples on a plate shaker. Subsequently, samples were stained 
with Streptavidin-PE, washed 3 times and then resuspended by vigorous shaking. Samples 
were then transferred into flat-bottom 96-well plates and read on a Bio-Plex™ system (Biorad, 
Hercules, CA, USA). Cytokine concentrations were calculated against the commercial 
standards using the provided software (Bio-Plex™ manager software, Biorad, Hercules, CA, 
USA). 
 
2.2.6.7 In vivo cytotoxic T lymphocyte killing assay 
The CTL assay, also known as the VITAL assay, allows analysis of cytotoxic activity in vivo 
(567). Mice were injected subcutaneously with 500 µg of OVA or 250 µg OVA with 25 µg of 
poly I:C on day 0. Control mice received sterile PBS. On day 7, the mice received CFSE 
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labelled splenocytes. Spleens were processed into single-cell suspensions by pressing through a 
70 µM cell strainer and lysed using ACT buffer. Splenocytes were then either pulsed with 
10 nM or 100 nM of ovalbumin peptide OVA257-264 (SIINFEKL) by incubating at 37°C for 1 
h and then washed in cIMDM. Cells were stained with either 10 nM or 100 nM CFSE at 
37°C for 10 min then stopped with equal amounts of FCS. Cells were washed once with 
cIMDM and once again with PBS. Control splenocytes were unpulsed and labelled with 
CTO by incubating at 37°C for 15 min. Cells were spun down and resuspended in warm 
IMDM and incubated for a further 20 min at 37°C. Cells were then washed twice in PBS. 
The three preparations were then mixed at equal ratios and 6x106 cells were administered 
intravenously per mouse. 18 h later the draining and non dLNs were harvested and processed 
to single cell suspension by pressing through a 70 µM cell strainer. Cells were stained with 
DAPI and then analysed by flow cytometry to determine the survival of antigen-loaded 
splenocytes compared to control cells. Specific lysis was calculated as follows: 
 





2.2.6.8 Proliferation assays in vitro 
2.2.6.8.1 Mixed lymphocyte reaction (MLR) 
Lymphocytes were collected from BALB/cByJ mice and plated with LPS-stimulated BM-DCs 
from C57BL/6 mice. DCs were titrated starting from 2.5x105. Supernatant from untreated or 
doxorubicin treated cells was titrated from 0.8-25% of the total well volume. Supernatant was 
collected from 4T1 or GL261 cells that were treated with 1 µM of doxorubicin for 16-18 h. 
Supernatant was either collected and use immediately or frozen in −70°C until further use. 
Media containing 1 µM of doxorubicin was used a control. 3 days after plating, a final 
concentration of 100 µCi/mL 3H-thymidine (PerkinElmer, MA, USA) was added per well 
and left overnight to allow the incorporation of 3H-thymidine into the DNA of the 
proliferating cells. On day 8 cells were harvested onto filter paper using a cell harvester 
(TOMTEC, Germany). Betaplate scintillation fluid (PerkinElmer) was added to the dried filter 
paper and the beta radioactivity was measured using a 1450 MICROBETA PLUS Liquid 
Scintillation Counter (WALLAC, PerkinElmer Inc.) 
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2.2.6.8.2 T cell proliferation from CD3/CD28 stimulation 
Spleens were taken from naïve C57BL/6 and CD4+ T cells were purified by Dynabeads® 
Mouse CD4. Purified cells and Dynabeads® Mouse T-Activator CD3/CD28 beads were 
plated at a 1:1 ratio at 4x104 cells per well. Supernatant from untreated or doxorubicin 
treated 4T1 cells was titrated down from 25% of total well volume. Media containing 1 µM 
doxorubicin was used as a control. The following day cells were harvested and the beta 
radioactivity was measured (2.2.6.8.1). 
 
2.2.7 Proliferation assays in vivo 
2.2.7.1.1 T cell proliferation in vivo 
C57BL/6 or BATF3 KO mice received 2x105 B16.F10 tumour cells on d0. On day 7, total 
LNs from gp100-TCR mice were processed and labelled with CFSE (2.2.6.2). Cells were 
adoptively transferred at a concentration of 2x106 cells per mouse. Mice received poly I:C 
immunotherapy on days 8 and 10 and draining and non-draining lymph nodes were 
harvested on day 12 and analysed by flow cytometry for proliferation measured by CFSE 
dilution. 
 
For OT-I proliferation, total LNs were collected from OT-I mice and processed, then purified 
for CD8+ cells using Dynabeads® Mouse CD8. 1x105 cells were injected i.v. into the lateral 
tail vein of C57BL/6 or BATF3 KO mice in a total volume of 100 µL. The following day, 
mice were primed with 100 µg of OVA or 100 µg of OVA with 25 µg of poly I:C administred 
s.c. Blood was taken by cheek bleeding and analysed for OT-I population expansion on days 4 
and 7 post adoptive transfer. 
 
2.2.8 Data analysis 
2.2.8.1 Software  
FlowJo version 9.9 software (Treestar Inc., CA, USA) was used to analyse flow cytometry data 
and to create flow cytometry plots and tables with percentages of gated cells. Microsoft Excel 
(2010) for Mac OS (Microsoft Corporation, Washington, USA) and GraphPad Prism version 
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6 for Mac OS X (GraphPad Software, San Diego California, USA) were used to create tables 
and graphs for statistical analysis. 
 
2.2.8.2 Calculation of cell numbers 
Viable cells were identified in single cell suspensions from processed organs by trypan-blue 
(GIBCO, Invitrogen, Auckland, NZ) exclusion and counted using a haemocytometer. 
Numbers of specific cell populations were calculated using the percentage of the cell type of 
interest among live cells obtained by flow cytometry analysis and the live cell counts obtained 
by trypan-blue exclusion. 
 
2.2.8.3 Statistical calculations 
Statistical tests used are stated in figure legends and p<0.05 was considered the threshold for 
significance, unless otherwise specified in the figure legend. Gaussian distribution was not 
assumed, therefore analyses examining a single parameter of two groups were performed 
using the non-parametric two-tailed Mann-Whitney test. Analyses examining a single 
parameter in three or more groups were carried out using the Kruskal-Wallis test with Dunn’s 
post test.  
Experiments with two independent variables, including tumour growth curves, were analysed 
by two-way ANOVA with Bonferonni post-test. MTT results were analysed to calculate the 
IC50 and generate a dose-response curve, using a non-linear regression model plotting 
log(inhibitor) versus normalised dose response. Survival analysis was done using the log-rank 
(Mantel-Cox) test with Bonferroni’s correction for multiple comparisons. Standard error of 
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3.1 Introduction 
Chemotherapy is one of the first-line treatments used in cancer treatment today. It achieves 
success through non-specific DNA damage, which contributes to toxic side effects. 
Doxorubicin is one of the oldest anthracycline drugs that were initially derived from a fungus 
and found to have anti-tumour effects (460). Treatment causes intercalation of DNA and 
ultimately leads to cell death. However, the use of doxorubicin can lead to drug-resistance 
that renders treatment ineffective (509). 
A common method tumour cells use to increase resistance, is upregulation of efflux pumps 
that are able to displace chemotherapy molecules out of the cell. A well-characterised group of 
pumps are the ATP-binding cassette (ABC) transporters. ATP-binding cassette, sub-family G 
(WHITE), member 2 (Abcg2) and ATP-binding cassette, sub-family C (CFTR/MRP), 
member 1 (Abcc1) can both contribute to drug-resistance. Abcc1 encodes for a protein 
involved in multi-drug resistance, and Abcg2 has been associated with resistance specifically to 
anthracyclines, such as doxorubicin (513).  
It is well-reported that within tumour cell populations, there are subsets of cells that are radio-
resistant (568). These cells are frequently given the term “cancer stem cells” (CSC), referring 
to an ability to self-renew. However, it is still debated whether these cells can be identified 
early in tumourgenesis, and even specifically targeted (569). A common marker used to 
delineate cancer stem cells is Ly6A/E, also known as stem-cell antigen-1 (Sca-1). Ly6A/E is a 
phosphatidylinositol cell surface protein which is part of the Ly6 gene family and is associated 
with progenitor cells (570). Studies have shown that Ly6A/E is involved in tumour cell 
proliferation and has tumour propagating potential (570-572). CD44 is another marker to 
identify CSC, particularly breast CSC (573) that display a phenotype of CD44+CD24-(569). 
Chemokine receptor CXCR3 is part of the CXC chemokine receptor family and has been 
implicated as a marker for metastatic tumour cells (574). Therefore, it was of interest to 
investigate if treatment of 4T1 cells with doxorubicin stimulated changes in a sub-population 
of stem-like cells, or influenced change in efflux pump expression as a mechanism of 
doxorubicin-resistance. The 4T1 tumour cell line is derived from a murine mammary tumour 
and is considered an appropriate model of triple negative breast cancer in patients, due to the 
lack of expression of hormone receptors and HER-2, and the ability of the 4T1 cells to readily 
metastasise to multiple sites around the body (562,575). 
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Despite ablation of tumour cells with chemotherapeutic treatment, often cells can remain that 
will no longer respond to therapy. With a new wave of immunotherapy treatments, it is 
thought that chemotherapy-resistant cells might respond to immunotherapy, as the 
mechanisms and targeting of tumour cell killing differ considerably. Moreover, treatment with 
doxorubicin has also been shown to induce immunogenic cell death, whereby the release of 
factors from dying tumour cells can act to stimulate the immune system. Therefore, there is 
increased interest in the combination of chemotherapy with immunotherapy, working in 
tandem to achieve optimal responses (482,536). 
Stimulation of the immune response using immunotherapy can occur through multiple targets 
and treatments. This thesis investigated polyriboinosinic-polyribocytiylic acid (poly I:C) and 
combination of monosodium urate crystals (MSU) with the Mycobacterium M.smegmatis. Poly I:C 
is a well-known TLR3 ligand that causes maturation and activation of DCs (346,576). It can 
also activate RIG-I and MDA-5 receptors, which are important in the production of type I 
IFNs induced from poly I:C administration (363). Mycobacteria are important for stimulating 
immune responses, with M.smegmatis acting as a ligand for TLR2, as well as TLR9 through 
CpG motifs (71,343). Use of bacterial ligands is an effective mechanism to target DCs as they 
express multiple TLRs (577). MSU induces local inflammation and previous work has shown 
synergy between combination treatment over single agent (352,578). 
It was of interest to study the effectiveness of doxorubicin in vivo at reducing tumour growth. 
Furthermore, investigations into combination treatment with doxorubicin and 
immunotherapies would provide insight into the immunogenicity of doxorubicin and the 
sensitivity of doxorubicin-treated cells to immunotherapeutic intervention. 
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3.1.1 Aims 
The purpose of this chapter was to assess doxorubicin treatment of 4T1 cells to investigate the 
development of chemotherapy-resistance. Furthermore, it was of interest to examine whether 
treatment with poly I:C and MSU+M.smegmatis immunotherapies would effectively treat 4T1 
tumours following chemotherapy treatment. The hypothesis was that doxorubicin-treated 
tumours would be sensitive to immunotherapy. 
The specific objectives were: 
• To generate a doxorubicin-resistant 4T1 cell line in vitro 
• To investigate the effects of supernatant from doxorubicin-treated cells on immune cell 
proliferation 
• To determine the effectiveness of doxorubicin in vivo as chemotherapy in the 4T1 
model  
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3.2 Results 
3.2.1 4T1 cells are susceptible to doxorubicin in vitro. 
Chemotherapy induces DNA damage, with toxic effects to the cell, often leading to death. 
Tumour cell lines will respond differently to chemotherapeutic treatment; therefore, initial 
experiments were performed to characterise the in vitro sensitivity of the 4T1 mammary cancer 
cell line to doxorubicin. Cells were treated with doxorubicin and monitored via microscopy.  
Cells were exposed to media containing doxorubicin for 16 hours, in a range of doses from 0.4 
µM to 1 µM. This treatment induced drastic changes in morphology. The cell became 
fibroblast-like, with the cytoplasm becoming stretched and forming extrusions and blebs. The 
nucleus fragmented and many cells had become detached (Figure 3.1 A). This morphology is 
typical of senescent cells (579). Cell viability was measured indirectly using an MTT assay. 
Metabolically active cells reduce the MTT tetrazolium salt to an insoluble formazan in a 
colourimetric reaction. The reduction is roughly proportional to the number of viable cells in 
culture and can therefore be used as an indirect measure of cell proliferation (566). MTT 
reduction was plotted as a percentage of the DMSO treated controls, and the half maximal 
inhibitory concentration (IC50) was determined. Doxorubicin- treated 4T1 cells had an IC50 of 
0.53 µM (Figure 3.1 B), which is comparable to previous work (580). 
To investigate whether lowering the concentration of doxorubicin would decrease toxicity and 
enable survival in prolonged exposure, 4T1 cells were treated with lower doses of doxorubicin 
for an extended period of time and monitored for survival. Cells treated with doxorubicin in a 
range of doses from 0.5-2 µM were already changing morphology compared to the control 
cells by 16-18h after treatment. By day three, treated cells had increased in size, with extended 
cytoplasm and had started to bleb and die. 4T1 cells treated with a low dose (0.05 µM) of 
doxorubicin looked similar to control cells at day one following treatment, but by day three 
had succumbed to the drug and were senescent in their morphology as described (Figure 3.1 
C).  
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Figure 3.1: 4T1 sensitivity to doxorubicin in vitro culture. A) 4T1 cells were 
cultured in cRPMI as detailed in 2.2.1.1. 4T1 cells were treated with a range of doxorubicin 
concentrations made up in cRPMI. Photos were taken 16 hours after treatment with 
doxorubicin. Photos are representative of at least two experiments. From top left to bottom 
right: Untreated control, 0.4 µM, 0.8 µM and 1.0 µM. B) 4T1 cells were plated 2.5x103 per 
well in a 96-well plate and and treated with a range of doxorubicin concentrations (12 nM-
100 µM) of doxorubicin made up in cRPMI for 48 hours as detailed in 2.2.6.3. MTT 
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reduction is shown as a percentage of DMSO treated control. Each symbol represents the 
mean ± SEM of the triplicate. Curves were generated by non-linear regression analysis. Data 
are pooled from two experiments. C) 4T1 cells were treated with a range of doxorubicin 
concentrations. Photos were taken on day 1 (left column) and day 3 (right column) after 
treatment. From top to bottom: untreated, 0.05 µM, 0.5 µM and 2 µM. 
 
To decrease toxicity and investigate whether a different treatment schedule could lead to the 
development of resistance to doxorubicin, 4T1 cells were treated with very low nanomolar 
doses in culture. When cells became 60-70% confluent, the cells were passaged and the 
doxorubicin concentration was doubled, using a method previously described (581).  
Two weeks following the initial doxorubicin exposure, cells in a concentration of 80 nM had 
died. The culture contained debris and the very few cells that were still adherent had 
senescent morphology. Cultures in a concentration of 40 nM doxorubicin were similar, with 
most of the cells dead and floating in the culture. Concentrations of 20 nM and below had 
4T1 cells that were surviving, but had different morphology to control cells. They had an 
increased size and started to resemble cultured fibroblasts. 
These experiments showed that when a higher concentration of doxorubicin was used for 16-
18h, many cells would become senescent and others would die. However, lowering the 
concentration of doxorubicin in combination with increasing the length of exposure did not 
reduce toxcitiy. After two weeks in culture, any concentration higher than 20 nM would prove 
lethal to 4T1 cells and all cells in the flask would die. To investigate the contribution of cell 
density to the sensitivity to the drug, experiments were conducted with varied cell density. 
Plating cells at a higher concentration to achieve greater confluency caused a delay in the 
effects of doxorubicin, but eventually the 4T1 cells succumbed to the toxic treatment.  
It was investigated whether doxorubicin-exposed 4T1 cells would recover if cultured in drug-
free media. 4T1 cells exposed to 10 nM of doxorubicin were split into two populations. One 
was cultured with 10 nM of doxorubicin and the other was cultured in cRPMI media. The 
drug-exposed 4T1 cells that were plated in normal media looked more comparable to 
untreated control cells than the cells that remained in 10 µM of doxorubicin. Cells that were 
initially treated with up to 10 µM of doxorubicin, relieved for a period of time in cRPMI, and 
then re-exposed to doxorubin, were still sensitive to the drug as their morphology showed 
drug-induced damage. 
Taken together, these results suggest that the 4T1 cell line is sensitive to doxorubicin in vitro. 
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3.2.2 Doxorubicin induces senescent morphology and 
upregulation of stem cell marker Ly6A/E 
We wanted to investigate whether treatment with doxorubicin would enhance the expression 
of CSC markers in the 4T1 population. 4T1 cells were treated with 1 µM of doxorubicin 
overnight, replated in drug-free media and then harvested and stained for flow cytometry 
analysis two days following treatment (Figure 3.2 A). Singlets and live cells were gated before 
analysing expression of Ly6A/E, CD44 and CXCR3. Side-scatter (SSC-A) measures the 
granularity of a cell, as an increase in the refraction of light is dependent on the number of 
particles the laser beam hits as a cell passes through the focus (582).  
Doxorubicin caused 4T1 to undergo a large increase in side-scatter compared to untreated 
cells. This reflects the morphological changes observed by microscopy. When analysing the 
DAPI+ (dead cell) population, there was no difference between the number of DAPI+ cells 
between the untreated and doxorubicin-treated 4T1 cells (Figure 3.2 B). Live cells were 
analysed for expression of CD44, CXCR3 and Ly6A/E. FMO controls using doxorubicin-
treated 4T1 cells were used to assess positive staining. Doxorubicin causes a slight whole-
population increase in CD44 expression compared to untreated controls. However, positive 
staining for CXCR3 was not obtained. A fraction of the 4T1 population that was treated with 
doxorubicin increased expression of Ly6A/E (Figure 3.2 C). It is important to note that 
doxorubicin treatment caused increased autofluorescence that may impair the detection of 
expression of certain cell surface markers. 
These results show that treatment with doxorubicin induces changes to cell morphology as 
measured by side scatter, and causes a portion of the 4T1 population to up regulate Ly6A/E. 
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Figure 3.2: Doxorubicin changes morphology of 4T1 cells and causes 
upregulation of Ly6A/E. A) 4T1 cells were treated with 1 µM doxorubicin overnight and 
replated the following day. Two days following initial treatment, cells were collected and 
stained for flow cytometry analysis. B) FACs plots represent gating on singlets and live cells. C) 
Expression of cell surface markers. The FMO control was doxorubicin-treated and is 
represented in solid grey. Untreated and doxorubicin-treated 4T1 cells are shown in black 
and red, respectively. Data are representative of at least two experiments. 
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3.2.3 Doxorubicin increases transcription of Ly6A/E 
One mechanism that cancer cells can employ to increase resistance to chemotherapy, is 
upregulation of efflux pumps used to rid the cell of toxic molecules (510,511). To investigate 
the expression of these efflux pumps, doxorubicin-treated 4T1 cells were analysed for 
expression of Abcg2 and Abcc1 transcripts, as well as expression of transcripts for the CSC 
marker, Ly6a. Drug-treated cells were collected two days following doxorubicin or seven days 
following doxorubicin, to investigate changes in mRNA expression with increased recovery 
time by quantitative-PCR (q-PCR) (Figure 3.3 A). The relative expression of each gene was 
calculated relative to 18S control levels and then assessed as fold-change over untreated 4T1 
control cells. 
There was no increase in relative expression of Abcc1 pump transcripts, and no change 
between two or seven days following doxorubicin. However, Abcg2 transcripts had higher 
relative expression two days’ post-treatment, which dropped by day seven (Figure 3.3 B). The 
relative expression of Ly6a transcripts was increased from day two post-treatment, indicating 
that doxorubicin exposure enhanced Ly6a transcripts. Interestingly, the relative expression of 
Ly6a transcripts increased over 50% from day two post-treatment, to day seven (Figure 3.3 B).  
These results show that doxorubicin had minimal impact on transcripts of efflux pumps in the 
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Figure 3.3: Increased levels of Ly6a transcripts in 4T1 cells treated with 
doxorubicin. A) 4T1 cells were treated with 1 µM of doxorubicin overnight and replated 
the following day. Cells were collected at days 2 and 7 following treatment and RNA was 
isolated and analysed by q-PCR. Cells were passaged between collection at least once. B) 
Relative expression of cell surface markers compared to the control.  
 
3.2.4 Doxorubicin-treated 4T1 cells produce factors that inhibit T 
cell proliferation in vitro 
It is clear that doxorubicin treatment affects 4T1 cell morphology and phenotype. One study 
found that 4T1 cells treated with doxorubicin in culture caused them to produce soluble 
factors that can contribute to immune suppression (496). Another study found that 
doxorubicin-treated cells released a range of growth factors (583). Therefore, we wanted to 
investigate whether 4T1 cells that have been exposed to doxorubicin, were producing 
molecules or cytokines that would affect T cell function. An allogenic mixed lymphocyte 
reaction (MLR) was set up with the addition of supernatant from doxorubicin-treated cells. 
Stimulator cells (BMDCs) were plated in culture with allogenic responder cells. 3H-thymidine 
was added to measure cell proliferation, as it is incorporated into newly synthesised DNA. 
Therefore, the radioactivity counted can be used as a direct measurement of cell proliferation. 
4T1 and GL261 cells were treated with 1 µM of doxorubicin overnight, cells were spun down 
the following day and supernatant was collected. GL261 is a murine glioblastoma cell line, 
which is known to be immunosuppressive (584,585) and was included as a positive control. A 
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doxorubicin control was added to account for any effect directly related to doxorubicin. 
Supernatant was added to make up 25% of the total volume, or titrated down from 25%. 
Peak cell division occurred with ~8,000 BMDCs and dropped significantly with 
concentrations higher then 30,000.  
Supernatant from doxorubicin-treated 4T1 cells inhibited T cell proliferation compared to 
untreated control supernatant, as measured by a decrease in CPM. However, this inhibition 
was lost in cultures with >30,000 DCs. Inhibition of T cell proliferation was not seen with the 
doxorubicin control (Figure 3.4 A). When compared to supernatant from doxorubicin-treated 
GL261 cells, the inhibition with 4T1 supernatant was comparable (Figure 3.4 B).  
We then investigated whether the inhibition to lymphocyte proliferation was dependent on 
the dose of supernatant added to the culture. To do this, CD4+ T cells were purified and 
plated with αCD3/CD28 beads in culture. Supernatant from untreated or doxorubicin- 
treated 4T1 cells were titrated down from 25% of the total volume of the well and cRPMI 
containing doxorubicin was added as a negative control. Cells were cultured for a day before 
adding 3H-thymidine on day two. Cells were harvested the following day and assessed for 
proliferation as measured by CPM. Surprisingly, at low volumes, the supernatant from 
doxorubicin-treated 4T1 cells was enhancing proliferation. However, supernatant at higher 
volumes inhibited T cell proliferation (Figure 3.4 C).  
These results show that supernatant from doxorubicin-treated 4T1 cells can have an 
inhibitory effect on T cell proliferation in vitro. 
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Figure 3.4: Supernatant from doxorubicin-treated 4T1 cells inhibits T cell 
proliferation in vitro. A) Lymphocytes were collected from BALB/cByJ mice and plated 
with LPS-stimulated BMDCs from C57BL/6 mice. BMDCs were titrated from 2.5x105. 
Supernatant (SN) from untreated, or doxorubicin-treated cells was added to make 25% of the 
total volume. Media containing doxorubicin was added as a control. Plates were left to 
proliferate for 3 days before 3H-thymidine was added and left overnight. The following day, 
cells were harvested and the beta radioactivity was measured and graphed as counts per 
minute (CPM). Data are representative of two experiments. B) SN from doxorubicin-treated 
GL261 cells was compared to 4T1 in the same experimental set-up as A). C) CD4+ T cells 
were purified from spleens and plated with αCD3/CD28 beads. SN from untreated, or 
doxorubicin-treated 4T1 cells was titrated down from 25% of the total volume of the well. 
Media containing doxorubicin was used as a control. The following day, cells were harvested 
and the beta radioactivity was measured and graphed as CPM. Each symbol represents the 
mean ± SEM of the triplicate. Statistical analysis of CPM in A) was by two-way ANOVA with 
the Bonferroni post hoc test. Statistical evaluation was between untreated and 4T1. *p<0.05, 
**p<0.01, ***p<0.001. 
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3.2.5 Cell death induced by doxorubicin is not through apoptosis  
Doxorubicin treatment caused 4T1 cells to produce one or more soluble factors that were 
inhibiting T cell proliferation, which may have been released as a result of cell death. It is well 
recognised that chemotherapy can induce cell death through apoptosis (479). By investigating 
the type of cell death induced from doxorubicin-treatment of 4T1 cells, there could be better 
understanding of suppressive factors released. 4T1 cells were treated with a range of 
doxorubicin concentrations (0.1-5 µM) and collected at various time points to assess viability 
and Annexin V staining. Annexin V binds to phosphatidylserine that is located on the 
cytosolic side of the plasma membrane of healthy cells, but becomes exposed in early 
apoptosis (586,587). Co-staining with Annexin V and propidium iodide (PI) was used to 
resolve live, early apoptotic and necrotic/dead cell populations. Live cells are double negative 
and cells undergoing early apoptosis were characterised as PI-, Annexin V+. Staurosporine 
was included as a positive control, as it is a known apoptotic inducer (588,589) (Figure 3.1 A). 
With increasing amounts of doxorubicin, there was a corresponding decrease of viability, seen 
in all time points. The length of exposure to doxorubicin also decreased viability, with an 
increase in the number of PI+ cells as the length of culture increased (Figure 3.5 B). However, 
the proportion of cells in apoptosis did not change with increased exposure to doxorubicin. 
Cells undergoing apoptosis would be expected to become Annexin V+ before transitioning to 
double positive (PI+, Annexin V+). However, the population of 4T1 cells shifted from PI- to 
PI+, independently from Annexin V staining. As shown in the bar graph, there was no change 
in the apoptotic population in any time point investigated (Figure 3.5 C). 
These results suggest that doxorubicin may not be causing cell death through apoptosis, but 
via another mechanism. 
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Figure 3.5: Doxorubicin-induced 4T1 cell death does not involve an apoptotic 
phase. A) 4T1 cells were treated with a range of doxorubicin concentrations (0.1-5 µM) at 
various time points. Cells were collected and cell viability and Annexin V staining was 
analysed by flow cytometry. FACs plots represent gating on singlets, live (PI-, Annexin V-), 
early apoptotic (PI-, Annexin V+) and dead (PI+, Annexin V+). Total PI+ is gated in red. B) 
The percentage of total PI+ cells with increasing concentrations of doxorubicin. C) Proportion 
of live, early apoptotic or dead cells. Each symbol represents the mean ± SEM of the triplicate 
Ear bar represents the mean of triplicates. Data are representative of two experiments. 
 
3.2.6 Doxorubicin in vivo decreases 4T1 primary tumour size 
Doxorubicin has been reported to have a number of side effects, including cardiotoxicity, but 
is still effective at reducing tumour mass (462,534). Two routes of administration were 
compared to assess impact on tumour growth. BALB/cByJ mice bearing 4T1 tumours were 
treated with either 8 or 5 mg/kg of doxorubicin via intraperitoneral (i.p.) or intravenous (i.v.) 
injection. Treatments were given on days 2, 8, 14 and 20 after tumour inoculation (Figure 3.6 
A). Both doses of doxorubicin were successful at slowing primary tumour growth in the 4T1 
model (Figure 3.6 B). However, administration of doxorubicin via i.p. proved to be toxic to 
the mice. Mice became unwell and those receiving doxorubicin via i.p. injection lost weight 
drastically and had to be culled before the fourth dose.  
Doxorubicin administered i.v. was effective at controlling 4T1 tumour growth, with no 
significant difference between the 5 mg/kg or 8 mg/kg dose. However, when monitoring the 
tumour growth in the surviving mice, differences were observed between the doses of 
doxorubicin. The higher dose was more effective at slowing tumour growth than the lower, 
although this was not statically significant (Figure 3.6 B). I.p. administration was also effective 
at both concentrations. However, due to toxicity seen in changes in physical appearance and a 
drop in >10% body weight, mice had to be culled after day 15 (Figure 3.6 C). 8 mg/kg 
doxorubicin administered i.v. had higher toxicity compared to the lower dose of 5 mg/kg, 
where mice remain at a healthy weight. These results show that not only does the route of 
administration contribute to the severity of toxicity, but there is also a dose-dependent effect. 
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Figure 3.6: Administration of doxorubicin through intravenous route reduces 
toxicity and effectively delays tumour growth. A) Mice bearing 4T1 tumours were 
treated with 8 or 5mg/kg doxorubicin either via intraperitoneal injection or intravenously 
through the tail vein on days 2, 8,14 and 20 following tumour injection. B) Tumour growth 
curves with doxorubicin administered by either i.v. or i.p. C) Mice were weighed prior to 
receiving chemotherapy and monitored following chemotherapy and throughout for changes 
in weight. Weight is graphed as percentage change over baseline for each individual mouse. 
Data are representative of two or more experiments with 6 mice per group, expressed as mean 
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± SEM. Statistical evaluation of tumour growth curves was by two-way ANOVA with the 
Bonferroni post hoc test. **p<0.01, ****p<0.0001. 
 
This finding reveals that doxorubicin administered i.v. or i.p. is successful at slowing 4T1 
tumour growth in vivo. However, i.p. administration of doxorubicin had increased toxicity 
compared to i.v. administration. 
 
3.2.7 Doxorubicin-treated tumours are sensitive to immunotherapy  
To investigate whether 4T1 cells that have encountered doxorubicin chemotherapy are still 
sensitive to treatment with immunotherapy, mice bearing 4T1 tumours were treated with two 
rounds of doxorubicin i.v. before immunotherapy with either poly I:C or combinational 
treatment MSU+M.smegmatis (Figure 3.7 A). Doxorubicin treatments were spaced 5 days apart 
to allow time for recovery. To verify that poly I:C and MSU+M.smegmatis are sufficient to 
decrease primary tumour size, controls were established whereby 4T1-tumour bearing mice 
received immunotherapy without prior doxorubicin exposure (Figure 3.7 A). Controls were 
inoculated with 4T1 tumours 6 days later to account for the slowed tumour growth in mice 
receiving doxorubicin, and permitting concurrent monitoring. 
Poly I:C and MSU+M.smegmatis immunotherapies were successful at slowing primary tumour 
growth in the 4T1 model, which translated to prolonged survival compared to controls (Figure 
3.7 B). Doxorubicin alone was able to slow 4T1 tumour growth, as seen previously. However, 
two treatments of doxorubicin within the first week of tumour inoculation was not as 
successful as four treatments spaced over a longer period of time (Figure 3.6 B). 
MSU+M.smegmatis immunotherapy slowed tumour growth compared to untreated controls; 
however, there was no additional benefit compared to doxorubicin alone. Interestingly, the 
effects of doxorubicin and poly I:C treatment were additive, with enhanced slowing of tumour 
growth compared to single therapies (Figure 3.7 C). This enhanced response also lead to 
prolonged survival, ~1.5x longer than with poly I:C treatment alone.  
 
3 Doxorubicin-treated 4T1 tumours are sensitive to immunotherapy 107 
 
 
Figure 3.7: Doxorubicin works additively with poly I:C immunotherapy. A) 1) 
Mice bearing 4T1 tumours were treated with 5mg/kg doxorubicin intravenously on day 3 
and 8 following tumour implantation. Poly I:C or MSU+M.smegmatis was administered via 
subcutaneous injections on days 9, 11, 13 and 15 following tumour implantation. 2) 
Immunotherapy controls were inoculated with tumours on day 6 compared to the 
doxorubicin-treated mice. Immunotherapy was administered via peritumoural injections on 
days 9,11, 13 and 15 following tumour implantation. Mice were monitored for tumour growth 
and survival. B) Tumour growth curves. C) Percent survival. Data are representative of two 
experiments with 7-9 mice per group, expressed as mean ± SEM. Statistical evaluation of 
tumour growth curves was by two-way ANOVA with the Bonferroni post hoc test. 
****p<0.0001 from day 21. Survival curves were analysed by the Mantel-Cox test using a 
Bonferroni correction threshold. B) *p<0.016. C) *p<0.0083, **p<0.00166, ***p<0.00016. 
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It is important to note that there is a difference in tumour size on day 9 between the 
combination doxorubicin and poly I:C group, compared to the other groups. This difference, 
although not statistically significant, is observed before treatment has commenced. Therefore, 
the enhanced slowing of tumour growth that doxorubicin and poly I:C display, may be less 
pronounced than these results suggest. 
These results show that poly I:C and MSU+M.smegmatis immunotherapies were successful at 
slowing primary tumour growth, comparable to doxorubicin alone. However, combination of 
doxorubicin and poly I:C immunotherapy was additive, showing enhanced anti-tumour 
immune responses than those observed with single therapies. 
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3.3 Discussion 
The results in this chapter show that 4T1 cells were sensitive to doxorubicin in vitro. 
Doxorubicin induced cell senescence, as well as cell death and therefore a doxorubicin-
resistant cell line was unable to be generated. Investigations into the mechanism of cell death 
suggested that 4T1 cells did not die through apoptosis. Doxorubicin treatment caused an 
increase in the CSC marker Ly6A/E in a proportion of the 4T1 population. It also caused 
4T1 cells to produce factors that were suppressive to T cell proliferation in vitro. Use of 
doxorubicin as therapy for tumour treatment in vivo was effective at reducing primary tumour 
size; however, i.p. administration caused severe toxicity. In combination with poly I:C and 
MSU+M.smegmatis immunotherapies, doxorubicin provided no additional benefit with 
MSU+M.smegmatis. In contrast, combination treatment with doxorubicin and poly I:C had an 
additive effect, with increased anti-tumour responses. 
 
Effects of doxorubicin on 4T1 cells in vitro 
4T1 cells treated with doxorubicin underwent cell death and cell senescence. Overnight 
cultures with a dose as low as 1.0 µM caused cells to have senescent and fibroblast-like 
morphology with a flattened cytoplasm filled with vacuoles (Figure 3.1). Treatment with lower 
doses of doxorubicin took longer to take effect, but by day 3 cells would succumb. Attempts at 
lowering doses of doxorubicin for long-term culture still caused cell death and any surviving 
cells had changed morphology compared to untreated 4T1 cells. Doxorubicin-exposed 4T1 
cells that were returned to drug-free media seem to recover by observations in morphology. 
However, when cells were re-exposed to doxorubicin they were still sensitive to the drug, and 
therefore did not develop resistance. This would suggest that the cells are under stress when 
exposed to doxorubicin, but the stress can be reversed when those cells are no longer cultured 
in the presence of doxorubicin. Nevertheless, 4T1 cells that were previously drug-treated still 
exhibited signs of toxicity upon drug exposure, suggesting that they were still sensitive to 
doxorubicin. 
Other studies were successful in generating 4T1 doxorubicin resistant cultures. Rong et al., 
used 4 repeated treatments of doxorubicin in vitro to generate a doxorubicin-resistant 4T1 cell 
line, however they never disclose how they assessed the acquired resistance (496). Another 
group cultured 4T1 cells for 6 months in a 50 ng/mL concentration, and associated 
doxorubicin resistance was measured by an increase in the efflux pump, P-glycoprotein (580). 
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These results suggest that 4T1 cells need to be cultured for longer than 2 weeks to develop 
resistance, and low doses of doxorubicin need to be used to avoid cell death. However, 
another group used a 16-hour treatment of 1 µM doxorubicin to select intrinsically drug-
resistant 4T1 cells. The treatment killed most cells, but those remaining went through one 
round of division before further analysis showed they had developed breast CSC properties 
(590). 
CSC are known to be resistant to chemotherapy (591); therefore, changes in CSC cell markers 
were investigated to assess whether exposure to doxorubicin induced changes in the 4T1 
population. Cells were treated with doxorubicin overnight then cultured in drug-free media 
until analysis, two days after treatment. Ly6A/E has been shown to delineate a population of 
cells that are tumour-initiating and self-renewing (571). Expression of Ly6A/E measured by 
flow cytometry showed that a small portion of the total population increased expression of 
Ly6A/E in response to doxorubicin (Figure 3.2). There was no increase in the DAPI+ 
population with doxorubicin compared to the control cells. As previously suggested, this 
implies that 4T1 cells that have been exposed to doxorubicin and are then cultured in drug-
free media, are able to recover and survive.  
When investigating the mRNA of Ly6a, the relative expression increased after doxorubicin 
treatment compared to untreated cells (Figure 3.3). This doxorubicin-induced increase in Ly6a 
expression is comparable to previously published results (590). One study found that Ly6a 
expression was correlated to higher cell migration in vitro (570), suggesting that short exposure 
to doxorubicin followed by recovery in drug-free media may be advantageous for tumour 
cells. Further investigation is necessary to understand the connection between longer recovery 
and increased Ly6a mRNA. There was a modest increase in relative expression for Abcg2 
transcripts; however, this did not correlate to increased resistance to doxorubicin. Further 
investigation is required as mRNA transcripts do not necessarily correspond to the level of 
protein expressed, and therefore may not accurately represent biological events. 
 
Immunosuppressive factors released after treatment with 
doxorubicin  
Studies have shown that supernatant from doxorubicin-treated cells can contain factors that 
contribute to immune suppression (496). We found that addition of supernatant from 
doxorubicin-treated 4T1 cells into a MLR caused inhibition of T cell proliferation, which was 
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comparable to a GL261 control known to be suppressive (495) (Figure 3.4). To discount any 
potential of a direct affect by doxorubicin, a drug-control was added and was found to have 
no inhibitory effects. This result suggests that doxorubicin does not directly inhibit 
proliferation. Rather, that the drug-treatment alters the 4T1 cells, causing production of 
factors that have an inhibitory effect. Supernatant from doxorubicin-treated 4T1 cells also 
inhibited proliferation of αCD3/CD28 stimulated CD4+ T cells in a dose-dependent manner 
(Figure 3.4).  
One study found that GL261 cell treated with chemotherapy increased immune suppression, 
which was mediated in part by PGE2 (495). PGE2 inhibits T cell proliferation by suppressing 
the synthesis of IL-2 and the IL-2 receptor, which impairs attempts at reversing inhibition 
with the addition of exogenous IL-2 (592). Indeed, PGE2 release from doxorubicin-treated 
4T1 cells has been published (496), and could be one mechanism involved in the suppression 
observed in these results. However, PGE2 release is associated with programmed apoptotic 
cell death induced by chemotherapy (593), which was not observed with doxorubicin-treated 
4T1 cells (Figure 3.5). Further studies are required to examine the factors present in 
supernatant from doxorubicin-treated 4T1 cells. When the concentration of BMDCs was 
>30,000, T cell proliferation was inhibited independently of the addition of supernatant. 
There are a number of reasons why this could occur. It has been shown previously that 
extensive cell-cell adhesion can prevent activation of key cell receptors, inhibiting growth 
(594). It could also be due to density-dependent inhibition of growth, where cells are 
competing for a limited resource, like platelet-derived growth factor (595).  
Interestingly, low volumes of supernatant had a stimulatory effect, with a slight enhancement 
in CD4+ T cell proliferation. One study found that 4T1-conditioned medium contained 
several pro-inflammatory cytokines, including IL-3, IL-12 and IFNγ (596). Although 4T1 cells 
were not treated with doxorubicin in Kano’s experiment, these cytokines may be present in 
the supernatant from our studies and could activate T cells when provided in low doses. 
Nevertheless, higher doses of supernatant induced decreased proliferation of T cells, further 
validating the results from the MLR experiments. Taken together, these results suggest that 
doxorubicin-treatment of 4T1 cells induces the release of one or more soluble factors that 
have inhibitory effects on T cell proliferation.  
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Doxorubicin induces apoptosis-independent cell death of 4T1 cells 
in vitro 
Doxorubicin has been shown to induce immunogenic cell death, whereby the release of 
factors and proteins contribute to the recognition by the immune system to stimulate an active 
response (22,23,479). One form of cell death that can stimulate immune responses is 
apoptosis. Through apoptosis, intracellular phosphatidylserine gets exposed to the cell surface, 
which Annexin V can bind (597). Therefore, Annexin V is often used as a marker denoting 
apoptotic-cell death (587). Increasing doses of doxorubicin decreased the viability of 4T1 cells, 
which was seen at all time points investigated (Figure 3.5). This was measured as an increase 
of PI+ cells; however, no changes to Annexin V+ staining was observed with increased 
concentrations of doxorubicin. These results suggested that 4T1 cells may not undergo death 
through apoptosis. To confirm this result, further experiments need to be undertaken 
investigating other apoptotic-induced cell death markers, such as calreticulin (481).  
It has been documented that chemotherapies can also induce non-apoptotic forms of cell 
death (475,598). One paper found that chemotherapeutic treatment with imatinib on human 
leukemic cells induced programmed necrosis, which released a serine protease, known as a 
mediator of necrotic cell death (599). Necrotic cell death is recognised by APCs, which can 
stimulate effective anti-tumour responses in vivo (600). Another form of cell death called 
paraptosis, was found to generate protective immunity against glioma (601). Therefore, it is 
possible that doxorubicin is inducing another form of immunogenic cell death, which was 
further investigated in vivo with doxorubicin in conjunction with immunotherapeutic agents. 
 
Doxorubicin is effective at reducing 4T1 growth in vivo and works 
additively with poly I:C immunotherapy 
Similar to effective treatment in the clinic, mice bearing 4T1-tumours that received 
doxorubicin had significantly reduced tumour growth compared to untreated controls (Figure 
3.6). However, it is well documented that doxorubicin has toxic side effects, (462,534) and 
following administration of doxorubicin via i.p. injection, mice exhibited toxicity effects. 
Administration via i.v. injection was investigated to examine whether route of administration 
would exacerbate or alleviate toxicity. Reduced symptoms were observed, as well as successful 
slowing of tumour growth (Figure 3.6). There was a slight enhanced effect on the reduction of 
4T1 tumour growth using a higher dose of doxorubicin i.v., but the finding was not 
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significant. These results suggest that both route of administration and concentration of 
doxorubicin can contribute to toxicity. Further work is required to elucidate appropriate 
regimes to get the optimal response to doxorubicin, with the lowest toxic effects. 
Tumours that survive treatment with chemotherapy often acquire resistance to not only the 
chemotherapeutic agent used, but other chemotherapies using parallel mechanisms (511,518). 
Immunotherapy operates through stimulating the immune system, rather than direct toxic 
effects to tumour cells. Therefore, using immunotherapeutic agents following chemotherapy 
may provide success in targeting chemotherapy-resistant tumour cells. One study found that 
combination treatment with doxorubicin and IL-2 was successful at delaying tumour growth 
in murine models of breast cancer and lymphoma (558). Other studies combined doxorubicin 
with an αFAS antibody, which was effective at treating bladder and renal cancer cell lines 
(556,557). 
To investigate combination therapy, mice bearing 4T1 tumours were treated with 
doxorubicin twice, before either poly I:C or MSU+M.smegmatis immunotherapy. Control mice 
treated with immunotherapy alone, revealed that both poly I:C and MSU+M.smegmatis 
immunotherapies were successful at slowing 4T1 tumour growth and prolonging survival 
(Figure 3.7). Combination treatment of doxorubicin and MSU+M.smegmatis provided no 
additional benefit to monotherapies. Doxorubicin used in conjunction with poly I:C 
immunotherapy produced additive effects, with increased survival and reduced tumour size 
compared to either treatment alone. The use of the term “additive” when describing the 
effects of combination treatment of poly I:C and doxorubicin, is used cautiously since a 
definitive description is unfeasible based on limited dose response experiments. 
Taken together, these results imply that only certain immunotherapies may be beneficial to 
use in combination with, or following chemotherapy treatment.  
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3.3.1 Conclusions 
In this chapter I have shown that 4T1 cells are sensitive to treatment with doxorubicin in vitro 
and in vivo, with successful slowing of tumour growth in mice bearing 4T1 tumours. 
Treatment of 4T1 cells with doxorubicin in vitro revealed that 4T1 cells are sensitive to 
doxorubicin, with nanomolar doses inducing cell senescence and death. Therefore, generation 
of a doxorubicin-resistant 4T1 cell line was unable to be achieved. Doxorubicin increased 
expression of the CSC marker Ly6A/E, but did not alter expression of the ATP-binding 
cassette efflux pumps Abcg2 and Abcc1. The toxic effects on 4T1 cells caused release of one 
or more soluble factors present in the supernatant. Addition of the supernatant into an MLR 
or αCD3/CD28 stimulation caused inhibition of T cell proliferation in vitro. Therefore, 
doxorubicin-treatment of tumour cells in vitro can induce immunosuppressive factors. 
Investigation into the type of cell death induced by doxorubicin showed that 4T1 cells were 
not dying through apotosis, as measured by Annexin V staining. 
Doxorubicin used as a chemotherapeutic treatment for 4T1 tumours in vivo was successful at 
slowing primary tumour growth. Investigation into the combination of doxorubicin with poly 
I:C and MSU+M.smegmatis immunotherapies found that no additional benefit was served with 
doxorubicin in combination with MSU+M.smegmatis. Both therapies alone were successful at 
reducing tumour growth and prolonging survival. In contrast, only poly I:C in combination 
with doxorubicin acted additively, with enhanced slowing of tumour growth and prolonged 
survival. 
These results show that 4T1 cells are sensitive to treatment with doxorubicin, and 





Chapter 4  
Immunotherapies require 
adaptive immunity yet differ 
on their dependency on 
specific DC subsets 
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4.1 Introduction 
Tumour immunotherapy can be used to activate immune cell populations to either initiate a 
new response, or boost an existing inadequate response. DCs play a critical role in anti-
tumour immune responses and are often targeted by therapies to increase activation, thereby 
driving more efficient T cell responses (8,602). CD8+ T cells are an essential part of the 
adaptive immune system. Naïve T cells can recognise antigen and receive co-stimulation 
signals via DCs to become activated and mature into CTLs, which are important for effective 
anti-tumour responses (9).  
In patients, higher amounts of TILs in the tumour have been correlated with increased 
progression-free survival (603,604). Therefore, a therapy to activate and mature DCs so they 
better prime CD8+ T cells, is an attractive mechanism for achieving proper T cell activation. 
There are numerous immunotherapies that are known to target and activate DCs. Those 
investigated in this thesis are poly I:C and combination therapy of MSU+M.smegmatis that 
were introduced in Chapter 3. Poly I:C causes maturation and activation of DCs through 
TLR3 and or/ RIG-I and MDA-5 receptors, and is known for stimulating production of type 
I IFNs (346,576). MSU crystals activate the inflammasome and cause local inflammation, 
while M.smegmatis is a Mycobacterium recognised by TLR2 and TLR9 (71,343).  
While poly I:C and MSU+M.smegmatis immunotherapies are known to activate DCs, it is 
unknown which specific DC populations are most influenced and whether these 
immunotherapies are dependent on certain subsets. It has been published that poly I:C and 
MSU+M.smegmatis immunotherapies can influence monocytes to differentiate into monocyte-
derived DCs (moDCs) (141,605). MoDCs were first implicated as critical cells for host-defense 
against bacterial infections (96-98); however, more recently they have been shown to be 
involved in anti-tumour responses (142,606,607). There are also other DC subsets known to 
have specialised functions within the anti-tumour immune response, such as cross-presenting 
DCs. CD8α+ and CD103+ DCs are classified as professional cross-presenting DCs (608-610) 
and as such, they can present cell-associated and soluble antigen to CD8+ T cells (73,611).  
Due to the expression of  endocytic receptors, such as DEC-205 and Clec9A, CD8α+ and 
CD103+ DCs are skilled at uptake of necrotic material (52,54). CD103+ DCs have recently 
been shown to preferentially take cell-associated antigen back to the dLN, compared to other 
DC populations, and were required for expansion of tumour-specific CD8+ T cells (129). 
CD8α+ DCs in the small intestine were found to express TLR9, and drive Th1 responses and 
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CTL activity (612). In addition, microbial extracts recognised by TLR2 can prime DCs to 
support the development of Th1 cells (613). CD8α+ and CD103+ DCs are also known to 
express high levels of TLR3 (614,615); thus, it was hypothesised that poly I:C immunotherapy 
might influence these particular DCs. Therefore, through recognition of adjuvants via PRRs, 
cross-presenting DCs play an important role in antigen-presentation and consequently T cell 
activation.  
To investigate the role of specialist cross-presenting DCs in the efficacy of immunotherapy, 
Clec9A-DTR transgenic mice were used. Clec9A+ is highly expressed on the CD8α+ and 
CD103+ cross-presenting DCs, with low expression found on pDCs (52,109). Upon DT 
administration, all CD8α+ and CD103+ DCs are depleted. Clec9A-DTR mice have been 
previously used to show that in Plasmodium berghei infected mice, Clec9A+ DCs are necessary 
for the cross-priming of parasite-specific, IFNγ and granzyme B expressing CD8+ T cells and 
the development of experimental cerebral malaria (564). To my knowledge, my work is the 
first to use Clec9A-DTR mice to investigate tumour progression and response to cancer 
immunotherapy. One limitation of the Clec9A-DTR model is that there is a reduction in 
pDCs with DT treatment due to low expression of Clec9A (564,616). Another disadvantage of 
the Clec9A-DTR model is the lethality of repeated systemic DT injections, therefore limiting 
the number of administrations given or requiring the need for BM chimeras for long-term 
depletion (616). 
The critical role of specialist cross-presenting DCs in driving CTL responses emphasises the 
importance of targeting these populations for activation via immunotherapy. Therefore, it was 
imperative to assess the role of specialist cross-presenting DCs in the efficacy of poly I:C and 
MSU+M.smegmatis immunotherapies to drive anti-tumour responses in the 4T1 model. 
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4.1.1 Aims 
Cross-presenting DC have been shown to be critical for CD8+ T cell immune responses to 
tumours (76,129,130). In most cases, published studies examined steady-state immune 
responses to immunogenic tumours. The purpose of this chapter was to investigate the 
contribution of specialist cross-presenting DCs to the efficacy of immunotherapies such as poly 
I:C and MSU+M.smegmatis, which specifically targeted cross-presenting DCs. The hypothesis 
was that poly I:C and MSU+M.smegmatis immunotherapies would require the presence and 
activity of specialist cross-presenting DCs to be effective at reducing primary tumour growth, 
as well as prolonging overall survival. 
The specific objectives were: 
• To confirm the efficacy of poly I:C and MSU+M.smegmatis immunotherapies in the 
4T1 model 
• To investigate the role of innate and adaptive immune populations in the efficacy of 
poly I:C and MSU+M.smegmatis immunotherapies 
• To assess whether specialist cross-presenting DCs are required for successful poly I:C 
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4.2 Results 
4.2.1 Poly I:C and MSU+M.smegmatis immunotherapies are 
effective at slowing tumour growth 
Previous work has shown that poly I:C and MSU+M.smegmatis immunotherapies are effective 
at slowing B16 melanoma tumours in C57BL/6 mice, as well as 4T1 mammary tumours in 
BALB/cByJ mice (141). To validate and reproduce this finding in the 4T1 model, mice were 
administered 1-3x104 4T1 cells into the 2nd thoracic mammary fat pad (mfp) on their upper 
torsos. When tumours became palpable around day eight, poly I:C and MSU+M.smegmatis 
immunotherapies were administered around the tumour every other day starting from day 
eight with a maximum of four doses (Figure 4.1 A). B16 melanoma in C57BL/6 mice was 
included for comparison. 
The concentrations of poly I:C and MSU+M.smegmatis, as well as the timing of 
administration, have been previously confirmed to achieve maximal impact on both DC 
activation and slowing of B16 tumour growth (578). Following the treatment schedule 
described above, mice were monitored and tumours were measured as described in 2.2.5.1. 
Poly I:C and MSU+M.smegmatis immunotherapies were successful at slowing primary tumour 
growth in the 4T1 model (Figure 4.1 B), as well as the B16 model (Figure 4.1 C). 
 
4.2.2 Contralateral treatments with poly I:C and 
MSU+M.smegmatis are not successful at prolonging survival 
Poly I:C and MSU+M.smegmatis immunotherapies seek to activate tumour-antigen loaded DC 
by exposing them to appropriate stimuli, thus would be expected to be most effective when 
given at the tumour site. To test this hypothesis, we examined whether immunotherapy 
administered on the opposite flank to the 4T1 tumour would be effective at slowing tumour 
growth. Following the treatment schedule outlined in Figure 4.1, poly I:C or 
MSU+M.smegmatis immunotherapies were administered on the contralateral side to the 4T1 
tumour, and tumours were monitored for growth.  
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Figure 4.1: Poly I:C and MSU+M.smegmatis peritumoural treatments 
successfully slow tumour growth. A) Immunotherapy schedule for tumour-bearing 
mice. B) BALB/cByJ bearing orthotopic 4T1 tumours or C) C57BL/6 mice bearing B16 
tumours were administered either poly I:C or MSU+M.smegmatis via peritumoural injections 
on days 8,10,12 and 14 following tumour implantation. Data are pooled from two 
experiments with 6-8 mice per group, expressed as mean ± SEM.  Statistical evaluation of 
tumour growth curves was by two-way ANOVA with the Bonferroni post hoc test. 
****p<0.0001 from day 14 (4T1) and day 12 (B16). 
 
Contralateral treatments with poly I:C immunotherapy had a reduced ability to slow 4T1 
tumour growth compared to ipsilateral treatments (Figure 4.2 A). However, contralateral 
treatment with poly I:C was statistically significant when compared to the untreated control. 
When analysing the effect of ipsilateral and contralateral treatments on overall survival, poly 
I:C administered on the contralateral side was not effective at prolonging survival, despite a 
minimal yet statistical significant effect on slowing tumour growth (Figure 4.2 C). 
MSU+M.smegmatis immunotherapy administered on the contralateral side was not successful 
at slowing tumour growth (Figure 4.2 B) or prolonging survival compared to peritumoural 
treatments (Figure 4.2 D). 
These results show that MSU+M.smegmatis immunotherapy administered on the contralateral 
side to the tumour is not successful at slowing 4T1 tumour growth or prolonging survival, 
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suggesting that MSU+M.smegmatis immunotherapy needs to be administered locally to the site 
of the tumour to be successful. Poly I:C immunotherapy had a slight impact slowing 4T1 
tumour growth when administered on the contralateral side to the tumour, although reduced 
success compared to peritumoural treatments. Administration of poly I:C on the contralateral 
side did not contribute to increased overall survival. Therefore, for optimal impact of poly I:C 




Figure 4.2: Poly I:C and MSU+M.smegmatis immunotherapies are no longer 
effective when administered contralaterally. A&B) BALB/cByJ mice bearing 
orthotopic 4T1 tumours were administered either poly I:C or MSU+M.smegmatis via 
peritumoural or contralateral injections on days 8, 10, 12 and 14 days following tumour 
implantation. Data are pooled from two experiments with 3-5 mice per group, expressed as 
mean ± SEM. Statistical evaluation of tumour growth curves was by two-way ANOVA with 
the Bonferroni post hoc test. **p<0.01, ***p<0.001, ****p<0.0001 from day 14. C&D) Percent 
survival was analysed by the Mantel-Cox test using a Bonferroni correction threshold. 
*p<0.016, **p<0.003, ****p<0.00003. 
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4.2.3 Treatment with poly I:C causes an increase in serum CCL2  
We investigated the cytokines induced following poly I:C and MSU+M.smegmatis treatment. 
Serum was collected 2 hours post-treatment in BALB/cByJ mice and analysed using a Bio-
plexâ multiplex assay (Biorad, CA, USA) to investigate pro-inflammatory cytokine 
production.  
Treatment with poly I:C or MSU+M.smegmatis did not significantly affect the serum levels of 
IL12p40 or IL-10 (Figure 4.3 A). Poly I:C treatment caused a decrease in IL-1β compared to 
baseline levels and MSU+M.smegmatis treatment lowered the serum concentrations of IFNγ. 
The most noticeable change was a significant increase in CCL2 induced by poly I:C 
treatment, but not MSU+M.smegmatis (Figure 4.3 A).  
These data show that when observing changes in the serum two hours’ post-treatment, there 
were minimal detectable changes to levels of inflammatory cytokines, with the exception of 
CCL2.  
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Figure 4.3: Serum cytokine profiles after poly I:C and MSU+M.smegmatis 
immunotherapies. A) BALB/cByJ mice that were bearing orthotopic 4T1 tumours were 
administered either poly I:C or MSU+M.smegmatis via peritumoural injections on day 8. 
Serum was collected 2 hours post-treatment and analysed with Bio-Plex® Precision Pro™ 
Cytokine Assay. Data are representative of two experiments with 3-8 mice per group, 
expressed as mean ± SEM Statistical evaluation was by the Kruskal-Wallis test with the 
Dunn’s post hoc test. *p<0.05, **p<0.01. 
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4.2.4 Immunotherapies induce minimal changes in the immune 
cell infiltrate in 4T1 tumours  
Administration of poly I:C or MSU+M.smegmatis was effective at slowing 4T1 tumour growth. 
We next wanted to investigate how these peritumoural treatments influenced the immune cell 
infiltrate in the tumours. BALB/cByJ mice were treated as described in Figure 4.1, and 
tumours were harvested 7 days following the last treatment for analysis by flow cytometry. 
Adaptive and innate immune cell populations were identified by cell surface markers and 
intranuclear staining (Figure 4.4 A). Total numbers were calculated. 
Within 4T1 tumours, the largest population was CD4+ T cells, followed by Tregs, CD8+ T 
cells, Ly6G+ cells and DCs (Figure 4.4 B). The total numbers of cells in each population did 
not vary significantly between untreated and MSU+M.smegmatis or poly I:C immunotherapies. 
Treatment with MSU+M.smegmatis immunotherapy decreased FoxP3+ Tregs within the 
tumour, which has been previously seen in B16 melanoma (617); however, was not observed 
with poly I:C immunotherapy in the 4T1 model (Figure 4.4 D). There was no change in the 
number of pan-NK cells, as identified by the expression of CD49b. CD49b is used as a pan-
NK cell marker in BALB/cByJ mice that do not express NK1.1 (618), but will be referred to 
as NK cells hereafter. 
To investigate changes in the activation of the T cells within the tumour, CD4+ and CD8+ T 
cells were analysed for expression of CD62L, CD44 and PD-1 (Figure 4.4 C). PD-1 is a well-
known marker for T cell exhaustion (43). CD44 is upregulated on antigen experienced T cells, 
and a corresponding increase in CD44, and decrease in the lymph node homing molecule 
CD62L, is commonly used to delineate effector T cell populations (619,620). There was 
similar expression of CD44, CD62L or PD-1 on CD4+ T cells in mice treated with poly I:C or 
MSU+M.smegmatis immunotherapies or untreated. CD8+ cells also showed no changes in 
CD44, CD62L or PD-1 expression between treatments. (Figure 4.4 D).  
These results suggest that local immunotherapies induce minimal changes in the percentage of 
immune cell populations infiltrating 4T1 tumours. In addition, treatment with poly I:C or 
MSU+M.smegmatis immunotherapies did not change the frequency of effector T cells within 
the tumour. However, these data do not provide information on the function of the T cells 
present within the tumour.  
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Figure 4.4: Immune cell infiltration within 4T1 tumours after immunotherapy 
with poly I:C or MSU+M.smegmatis. A) BALB/cByJ mice bearing orthotopic 4T1 
tumours were administered either poly I:C or MSU+M.smegmatis via peritumoural injections 
on days 8, 10, 12 and 14 following tumour implantation. Tumours were collected 7 days 
following the last immunotherapy treatment. Representative gating of immune cell 
populations. Samples were divided into two equal aliquots, allowing two separate flow panels 
to be used. Samples investigating T cells were fixed with live/dead fixable blue and then 
stained to assess intracellular/nuclear markers. B) Total CD45+ cells were gated and 
separated into cells of interest. The proportion of populations shown is calculated as a 
percentage of CD45+ cells. Total Populations are as follows: DCs (MHCII+CD11c+), CD4+ 
(CD3+CD4+), CD8+ (CD3+CD8+), pan-NK cells (CD3-CD49b+), Tregs (CD3+CD4+FoxP3+), 
Ly6C+ (CD11b+Ly6C+), Ly6G+ (CD11b+Ly6G+). Statistical evaluation was by Kruskal-
Wallis with Dunn’s post test with no statistical different found. C) Following CD4+ and CD8+ 
gating, cells were analysed for PD-1, CD44 and CD62L expression. Representative gating on 
the CD4+ FoxP3- negative, and the CD8+ populations. Data are pooled from two experiments 
with 4-8 mice per group. D) Percentage of populations are shown as mean ± SEM. Data are 
pooled from two experiments with 4-8 mice per group. Statistical evaluation was by Kruskal-
Wallis with Dunn’s post test. *p<0.05. 
 
4.2.5 Immunotherapies induce a reduction of NK cells in the 
spleen  
Despite poly I:C and MSU+M.smegmatis immunotherapies having limited impact on the 
tumour infiltrate, there was potential for systemic effects. Therefore, we wanted to investigate 
how poly I:C and MSU+M.smegmatis immunotherapies influenced cell population changes 
within the spleen of BALB/cByJ mice with 4T1 tumours. Spleens were harvested 7 days 
following the last treatment, processed and analysed by flow cytometry. Adaptive and innate 
immune cell populations were identified (Figure 4.5 A), and changes in the proportions of cell 
types were investigated. 
True to what is published about the 4T1 model (621,622), a large population of Ly6G+ cells 
were found in the spleen (Figure 4.5 B). Treatment with poly I:C and MSU+M.smegmatis 
slightly reduced the Ly6G+ population, although not significantly. Both immunotherapies did 
not alter the proportion of CD4+ T cells and Tregs, but slightly increased the CD8+ T cell 
population. Surprisingly, poly I:C and MSU+M.smegmatis treatment caused a reduction in the 
proportion of NK cells (Figure 4.5 C).  
These results show that peritumoural treatment with poly I:C and MSU+M.smegmatis 
immunotherapies are able to induce changes in immune cell composition in the spleen. 
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Figure 4.5: Proportions of immune cell populations in the spleen after 
immunotherapy with poly I:C or MSU+M.smegmatis. A) BALB/cByJ mice bearing 
orthotopic 4T1 tumours were administered either poly I:C or MSU+M.smegmatis as detailed 
in Figure 4.4. Spleens were collected 7 days following the last immunotherapy treatment. 
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Representative gating of FACS data for both adaptive and innate immune cell populations. 
Samples were divided into two, allowing two separate flow panels to be used. Samples 
investigating T cells were fixed with live/dead fixable blue to allow for intracellular staining. 
B) Total CD45+ cells were gated and separated into cells of interest. The proportion of 
populations shown is calculated as a percentage of CD45+ cells. Populations are as follows: 
DCs (MHCII+CD11c+), CD4+ (CD3+CD4+), CD8+ (CD3+CD8+), NK cells (CD3-CD49b+), 
Tregs (CD3+CD4+FoxP3+), Ly6C+ (Ly6C+), Ly6G+ (Ly6G+). Data are pooled from two 
experiments with 4-8 mice per group. C) Percentage of populations are shown as mean ± 
SEM. Data are pooled from two experiments with 4-8 mice per group. Statistical evaluation 
was by Kruskal-Wallis with Dunn’s post test. ***p<0.001, ****p<0.0001. 
 
4.2.6 Material injected in the mammary fat pad drains to both the 
axillary and brachial lymph nodes 
Since the 4T1 tumour grows orthotopically in the mammary fat pad (mfp), it was important to 
identify which lymph nodes the tumour was draining to. BALB/cByJ mice were injected with 
India ink into the mfp. Mice were sacrificed 1 hour later and both the axillary and brachial 
lymph nodes were assessed for ink uptake. India ink was clearly visible in both the axillary and 
the brachial lymph nodes, with the axillary taking up more ink than the brachial, within a 1 
hour time frame (Figure 4.6 A). Due to the differential uptake of India ink, axillary or brachial 
lymph node cell populations were compared following poly I:C or MSU+M.smegmatis 
immunotherapies. Mice with 4T1 tumours were treated with poly I:C or MSU+M.smegmatis, 
and the axillary and brachial lymph nodes were processed and analysed separately (Figure 4.6 
B).  
Poly I:C treatment increased total cell counts in the axillary and brachial lymph nodes to a 
similar degree. Conversely, MSU+M.smegmatis had a greater impact on the axillary lymph 
node compared to the brachial, with a significant difference in total cell counts between the 
two (Figure 4.6 C). When gating on moDCs as a measure of successful immunotherapy, no 
significant difference was detected between total moDC counts in the axillary and brachial 
lymph nodes with poly I:C treatment. There was also no significant difference in the total 
number of moDCs in the axillary and brachial lymph nodes in mice treated with 
MSU+M.smegmatis, contrary to the increase in total cell counts (Figure 4.6 C). 
These results demonstrate that poly I:C and MSU+M.smegmatis immunotherapies that are 
administered locally to the mammary fat pad, both drain to the axillary and brachial lymph 
nodes. No significant difference was detected in the number of moDC with poly I:C or 
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MSU+M.smegmatis treatment between the axillary and brachial lymph nodes, therefore both 




Figure 4.6: Mammary fat pad injections drain to both the axillary and brachial 
lymph nodes. A) BALB/cByJ were injected with a 15% solution of India ink into the mfp. 
Lymph nodes were collected 1 hour later and assessed for ink uptake. B) BALB/cByJ bearing 
orthotopic 4T1 tumours were administered either poly I:C or MSU+M.smegmatis via 
peritumoural injections on days 8, 10, 12 and 14 following tumour implantation. C) Axillary 
and brachial lymph nodes were harvested on day 15. Total counts and moDC numbers are 
expressed as the mean ± SEM. Data are pooled from two experiments with 2-3 mice per 
group. Statistical evaluation was by two-way ANOVA with the Bonferroni post hoc test. 
**p<0.01, ***p<0.001, ****p<0.0001. 
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4.2.7 Immune cell proportions in the dLN after treatment with 
immunotherapy  
The large increase in total cell counts in the axillary and brachial lymph nodes induced by 
poly I:C and MSU+M.smegmatis immunotherapies prompted further investigation into 
population changes within the dLNs of BALB/cByJ mice with 4T1 tumours. dLNs were 
harvested 7 days following the last immunotherapy treatment, processed and analysed by flow 
cytometry. Adaptive and innate immune cell populations were identified (Figure 4.7 A), and 
total numbers were investigated. 
Treatment with poly I:C and MSU+M.smegmatis did not change the proportions of CD4+ and 
CD8+ cell populations in LN (Figure 4.7 B). To further characterise these cells, I examined 
expression of CD44 and PD-1, which are markers expressed by antigen experienced and 
exhausted CD8+ T cells, respectively (Figure 4.7 C). There were no significant changes 
observed in CD44+CD4+ T cells, or CD44+CD8+ T cells following poly I:C or 
MSU+M.smegmatis immunotherapies. Immunotherapies did not decrease the proportion of 
naïve T cells, identified with CD62L expression, which remained around 40% of both CD4+ 
and CD8+ T cells (Figure 4.7 D). PD-1+ CD4+ T cells were significantly reduced with 
MSU+M.smegmatis treatment. PD-1+ CD8+ T cells followed a similar trend, with both poly 
I:C and MSU+M.smegmatis treatment trending towards a lower proportion of CD8+ PD-1+ 
cells, which was more pronounced with MSU+M.smegmatis treatment (Figure 4.7 D). 
Thus, poly I:C and MSU+M.smegmatis immunotherapies induce changes to the immune cell 
populations within the tumour dLNs. 
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Figure 4.7: Proportions of immune cell populations in tumour draining lymph 
node (dLN) after immunotherapy with poly I:C or MSU+M.smegmatis. A) 
BALB/cByJ mice bearing orthotopic 4T1 tumours were administered either poly I:C or 
MSU+M.smegmatis as detailed in Figure 4.4. dLNs were collected 7 days following the last 
immunotherapy treatment. Representative gating of FACS data for both adaptive and innate 
immune cell populations. Samples were divided into two, allowing two separate flow panels to 
be used. Samples investigating T cells were fixed with live/dead fixable blue to allow for 
intracellular staining. B) Total CD45+ cells were gated and separated into cells of interest. The 
proportion of populations shown is calculated as a percentage of CD45+ cells. Populations are 
as follows: MHCIIhi (MHCIIhiCD11cint), CD11chi (CD11chiMHCIIint), CD4+ (CD3+CD4+), 
CD8+ (CD3+CD8+), NK cells (CD3-CD49b+), Tregs (CD3+CD4+FoxP3+), Ly6C+ 
(CD11b+Ly6C+). C) Following CD4+ and CD8+ gating, cells were analysed for PD-1, CD44 
and CD62L expression. Representative gating on the CD4+ FoxP3- negative, and the CD8+ 
populations. Data are pooled from two experiments with 4-8 mice per group. D) Percentage 
of populations are shown as mean ± SEM. Data are pooled from two experiments with 4-8 
mice per group. Statistical evaluation was by Kruskal-Wallis with Dunn’s post test. **p<0.01. 
 
4.2.8 Poly I:C and MSU+M.smegmatis immunotherapies induce 
monocyte-derived DCs 
Previous investigations in our lab have shown that poly I:C and MSU+M.smegmatis 
immunotherapies administered in C57BL/6 mice with B16 tumours induces a population of 
cells, called moDCs. As mentioned previously, moDCs have been shown to be involved in 
anti-tumour immune responses (142,606). 
We wished to investigate whether poly I:C and MSU+M.smegmatis immunotherapies induce 
the same moDC population in BALB/cByJ mice with 4T1 tumours. Following the same 
experimental design described in Figure 4.1, dLNs were collected one day after the last 
immunotherapy treatment (Figure 4.8 A). MoDCs were identified as 
MHCintCD11cintCD11b+Ly6C+CD64+ (Figure 4.8 B). Poly I:C and MSU+M.smegmatis 
immunotherapies induced expansion of moDCs in the dLNs as shown by total counts (Figure 
4.8 C). Interestingly, poly I:C immunotherapy induced more moDCs than MSU+M.smegmatis, 
albeit the difference was not significant. MoDCs were also found within 4T1 tumours, with 
MSU+M.smegmatis treatment inducing a greater number of moDCs compared to the 
untreated control. However, there was no significant difference in total moDC number 
between tumours from poly I:C or MSU+M.smegmatis treated mice (Figure 4.8 C). 
These results show that poly I:C and MSU+M.smegmatis immunotherapies are capable of 
inducing moDCs in the 4T1 tumour and tumour dLN. 
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Figure 4.8: Poly I:C and MSU+M.smegmatis immunotherapies induce moDCs 
within the tumour and the dLNs of tumour bearing mice. A) BALB/cByJ bearing 
orthotopic 4T1 tumours were administered either poly I:C or MSU+M.smegmatis via 
peritumoural injections on days 8, 10, 12 and 14 following tumour implantation. dLNs were 
harvested on day 15. B) Cells were previously gated for singlets and live. Representative FACs 
plot showing moDC gating. C) Total number of moDCs in the dLN and tumour, 18 hours 
after the fourth treatment of PBS, poly I:C or MSU+ M.smegmatis. Data are pooled from two 
experiments with 3-5 mice per group. Absolute moDC numbers are expressed as mean ± 
SEM, and statistical evaluation was by Kruskal-Wallis with Dunn’s post test. *p<0.05, 
**p<0.01. ***p<0.001. 
 
4.2.9 MoDCs produce iNOS, TNFα and IL-12 in vivo 
Studies have shown that moDCs are producers of iNOS, as well as TNFα and IL-12 (96,623). 
Therefore, we wanted to investigate cytokine production in moDCs that are induced in mice 
on a BALB/cByJ background, as we know that administration of poly I:C and 
MSU+M.smegmatis into C57BL/6 mice have different effects compared to BALB/cByJ mice. 
Mice were administered two treatments of poly I:C and MSU+M.smegmatis immunotherapies 
and moDCs were harvested from the dLNs one day after the last treatment (Figure 4.9 A). 
MoDCs were identified as previously described (Figure 4.8), with the exception that Ly6B was 
used instead of CD64 for gating on moDCs (Figure 4.9 B).  
MoDCs induced by poly I:C and MSU+M.smegmatis are able to produce iNOS, with moDCs 
from poly I:C treatment producing marginally more iNOS compared to moDCs induced by 
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MSU+M.smegmatis treatment (Figure 4.9 C). In a separate experiment following the same 
experimental design, moDCs were analysed for production of TNFα and IL-12 (Figure 4.9 
D). MoDCs from poly I:C and MSU+M.smegmatis produced TNFα and IL-12, with no 
distinguishable differences between moDCs from the two immunotherapies (Figure 4.9 E).  
These results show that poly I:C and MSU+M.smegmatis immunotherapies in BALB/cByJ 
mice are able to induce moDCs that are capable of producing iNOS, TNFα and IL-12. 
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Figure 4.9: MoDCs produce iNOS, TNFa and Il-12. A) BALB/cByJ were injected with 
either poly I:C or MSU+M.smegmatis immunotherapies into the mfp on days 0 and 2. dLNs 
were harvested 24 hours later. B) Cells were previously gated for singlets and live. 
Representative FACs gates showing moDC gating and iNOS+ cells according to the isotype 
control. Data are representative of experiments repeated at least twice with 3 mice per group.  
C) Numbers of moDCs and iNOS+ moDCs are expressed as mean ± SEM. D) A separate 
experiment following the same experimental design investigated production of TNFa and IL-
12 by moDCs. Representative FACs plots are shown and gates were drawn according to 
isotype controls. E) Numbers of moDCs and TNFa and IL-12-producing moDCs are 
expressed as mean ± SEM. Data are representative of experiments repeated at least twice 
with 3 mice per group. Statistical evaluation was by Kruskal-Wallis with Dunn’s post test. 
*p<0.05. 
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4.2.10 CD8+ T cells are required for successful poly I:C and 
MSU+M.smegmatis immunotherapies  
As shown in Figure 4.1, poly I:C or MSU+M.smegmatis immunotherapies are both successful 
at delaying primary tumour growth in the murine 4T1 mammary cancer model. CD8+ T cells 
are known to be important in successful immunotherapy, and previous research has shown 
that poly I:C and MSU+M.smegmatis immunotherapies are dependent on CD8+ T cells in a 
B16.OVA model (141). Therefore, the CD8+ T cell contribution to the observed anti-tumour 
activity in the 4T1 model was investigated, as it has not yet been established  
4T1 tumour growth in immunocompetent BALB/cByJ mice was first compared to 
immunodeficient NOD/SCID mice. NOD/SCID mice lack T and B cells, with additional 
defects reported in the NK cell population (624). 4T1 tumours in the NOD/SCID mice were 
faster growing than those in immunocompetent mice, suggesting that T, B or NK cells have a 
role in controlling 4T1 tumour growth (Figure 4.10 A). To explore further, CD8+ T cells were 
specifically depleted, leaving other adaptive populations and the innate immune system intact. 
Mice were administered intraperitoneal injections of 2.43 monoclonal antibody one day prior 
to tumour inoculation and another dose seven days later (Figure 4.10 B).  
2.43 antibody was effective at depleting CD8+ T cells in the blood (Figure 4.10 C) and 
successful slowing of 4T1 tumour growth from MSU+M.smegmatis and poly I:C 
immunotherapies was lost in the absence of CD8+ T cells (Figure 4.10 D). This was also 
reflected in survival, with poly I:C and MSU+M.smegmatis immunotherapies no longer 
prolonging survival in the absence of CD8+ T cells (Figure 4.10 E). However, in the absence 
of CD8+ T cells, the anti-tumour immune response with poly I:C immunotherapy was not 
completely abrogated, rather, it showed an intermediate phenotype in both in the slowing of 
tumour growth and survival.  
These results show that CD8+ T cells were required for the efficacy of MSU+M.smegmatis and 
poly I:C immunotherapies, although other immune cell populations were also playing some 
modest role in poly I:C immunotherapy.  
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Figure 4.10: CD8+ T cells are required for the anti-tumour effects of poly I:C 
and MSU+M.smegmatis. A) 4T1 tumour growth curves are shown in Balb/cByJ and 
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NOD/SCID mice. B) Schematic of experimental layout with in vivo antibody dosing schedule. 
Depletion was checked 18-20 hours after α2.43 monoclonal antibody administration. C) 
Blood was collected 24 h after α2.43 injection, and CD8+ T cell depletion was analysed by 
flow cytometry. D) Tumour growth curves are shown in Balb/cByJ mice bearing orthotopic 
4T1 tumours. Mice were administered peritumoural injections of the indicated treatments on 
days 8, 10, 12, and 14. α2.43 mAb and isotype control (200 µg each) was administered by 
intraperitoneal injection on day 1, and 100 µg on day 7. E) Percent survival from the above 
experiment. Data are pooled from two experiments with 4-5 mice per group, expressed as 
mean ± SEM. Statistical evaluation of tumour growth curves was by two-way ANOVA with 
the Bonferroni post hoc test. A) ****p<0.001 from day 16. D) *p<0.05, **p<0.01 on day 18. 
Percent survival was analysed by Mantel-Cox test using a Bonferroni correction threshold of 
*p<0.016. 
 
4.2.11 DT successfully depletes CD8α+ and CD103+ DCs in Clec9A-
DTR mice 
Cross-presenting DCs are important at inducing anti-tumour immunity (130), and are known 
to transport tumour antigen to the dLN (129,132). Therefore, the contribution of specialist 
cross-presenting DCs in poly I:C and MSU+M.smegmatis immunotherapies was investigated.  
In order to selectively deplete specialist cross-presenting DCs, 4T1 tumour-bearing Clec9A-
DTR mice were administered 20 ng/g DT via intraperitoneal injection every 3-4 days, with 
the first dose coinciding with the start of immunotherapy. Spleens and dLNs were harvested 
and analysed for depletion of Clec9A+ populations one day after the last DT treatment 
(Figure 4.11 A).  
Gating on the CD103+ and CD8α+ DCs from total MHCII+CD11c+ cells in the spleen, both 
populations were shown to be successfully depleted with DT treatment (Figure 4.11 B). Both 
the CD103+ and CD8α+ DCs within the tumour dLNs were also depleted (Figure 4.11 C). 
These results indicate that successful depletion of the CD103+ and CD8α+ DCs can be 
achieved with multiple DT treatments in the Clec9A-DTR model. 
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Figure 4.11: CD8α+ and CD103+ DCs are successfully depleted in Clec9A-DTR 
mice with the administration of diphtheria toxin. A) Clec9A-DTR mice bearing 
orthotopic 4T1 tumours were administered 20 ng/g of DT by intraperitoneal injection on 
days 8, 10, 14, 18 and 20 and immunotherapy as described in Figure 4.1. Organs were 
harvested on day 21 to assess DC depletion. B) Cells were gated for singlets and live. 
Representative FACs gates showing the profile of DC subsets in B) spleens and C) dLNs of 
DT treated Clec9A-DTR mice are shown. The total number of MHCII+ CD11c+ CD8α+ or 
CD103+ DC subsets from the draining lymph node and spleen are shown. Data are pooled 
from two independent experiments with 5-8 mice per group. Absolute DC numbers are 
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4.2.12 CD8α+ and CD103+ DCs are necessary for MSU+M.smegmatis 
immunotherapy and not poly I:C immunotherapy 
After confirming successful depletion of CD103+ and CD8α+ DCs, we examined how the 
absence of these DC populations impacted the success of immunotherapy on decreasing 
tumour growth. 
In the absence of CD103+ and CD8α+ DCs, MSU+M.smegmatis immunotherapy was no 
longer able to delay 4T1 primary tumour growth, suggesting that MSU+M.smegmatis relies on 
CD103+ and CD8α+ DCs to prime and maintain an anti-tumour response. However; 
depletion of CD103+ and CD8α+ DCs had no effect on poly I:C immunotherapy, which was 
still able to slow tumour growth in the 4T1 model (Figure 4.12 A).  
These results suggest that specialist cross-presenting DCs are necessary for the 
MSU+M.smegmatis induced activation of anti-tumour immunity; however, they are not 




Figure 4.12: CD8α+ and CD103+ DCs are necessary for the activation of anti-
tumour immunity induced by MSU+M.smegmatis but not poly I:C. A) Clec9A-
DTR mice bearing orthotopic 4T1 tumours were administered immunotherapy as described 
in Figure 4.1 and 20 ng/g of DT as described in Figure 4.7. Data are pooled from two 
experiments with 5-8 mice per group, expressed as mean ± SEM. Statistical evaluation of 
tumour growth curves was by two-way ANOVA with a Bonferroni post hoc test. 
****p<0.0001 on day 20.  
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4.2.13 Poly I:C and MSU+M.smegmatis immunotherapies decrease 
metastatic colonies in the lung  
The 4T1 mammary cancer cells readily metastasise to multiple sites, including the lung 
(562,575). Analysis of the colonies found in sites distant to the primary tumour provides a 
mechanism of assessing the effects of immunotherapy on metastatic disease. It was of interest 
to investigate whether poly I:C and MSU+M.smegmatis immunotherapies were impacting the 
metastatic capability of 4T1. A correlation between the size of the primary tumour and the 
number of lung colonies has been published (565). Therefore, it was hypothesised that the 
ability of poly I:C and MSU+M.smegmatis immunotherapies to reduce the primary tumour size 
would also affect the number of 4T1 colonies found in the lung. Due to the loss of efficacy of 
MSU+M.smegmatis in the absence of specialist cross-presenting DCs, we also investigated 
whether the absence of specialist cross-presenting DCs would impact the effects 
immunotherapy might have on the number of metastatic colonies in the lung. 
4T1 tumour-bearing Clec9A-DTR mice were administered 20 ng/g DT via intraperitoneal 
injection every 3-4 days, starting from the onset of immunotherapy on day 8 (Figure 4.13 A). 
DC depletion was confirmed by flow cytometry analysis of the dLN and spleen. Lungs were 
weighed, processed and plated in media laced with 6-thioguanine. 4T1 colonies, which are 
resistant to this toxic chemical, are able to survive and grow colonies in culture while other 
cells cannot survive. 4T1 colonies are then fixed, stained, and counted to establish the number 
of colonies per gram of lung or tumour tissue (Figure 4.13 B). Counts were log transformed 
and then normalised to the PBS control. 
Poly I:C and MSU+M.smegmatis were both successful at reducing tumour weight; however, in 
the absence of CD103+ and CD8α+ DCs, MSU+M.smegmatis was no longer able to reduce 
primary tumour size, as reflected in the tumour weight (Figure 4.13 C). Interestingly, there 
was no significant difference between the number of colonies counted with 
MSU+M.smegmastis treatment in the presence or absence of specialist cross-presenting DCs. 
This result is unexpected since the primary tumour size is significantly smaller when treated 
with MSU+M.smegmastis in the presence of specialist cross-presenting DCs (Figure 4.13 D). 
Poly I:C immunotherapy was successful at reducing the metastatic load in the lung and 
remained successful in the absence of specialist cross-presenting DCs. MSU+M.smegmatis 
immunotherapy followed a similar trend to poly I:C, with decreased metastatic load, although 
this was not statistically significant (Figure 4.13 E). 
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Figure 4.13: Poly I:C and MSU+M.smegmatis immunotherapies reduce the 4T1 
metastatic load in the lung. A) Clec9A-DTR mice bearing orthotopic 4T1 tumours were 
administered 20 ng/g of DT by intraperitoneal injection on days 8, 10, 14, 18 and 20 and 
immunotherapy, as described in Figure 4.1. Organs were harvested on day 21 to confirm DC 
depletion and lungs were processed to analyse metastatic 4T1 colonies. B) Lung colonies were 
analysed as described in 2.2.5.7. Briefly, single cells suspensions of lungs were plated with 
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media containing 6-thioguanine. The surviving 4T1 colonies were fixed, stained and counted. 
C) Tumour weight as mean ± SEM. Data representative of at least two experiments. D) Raw 
4T1 colony counts in the lung with total numbers expressed as the geometric mean. Data 
representative of at least two experiments. E) The number of colonies per gram of lung tissue 
was calculated, log transformed and then normalised to the PBS control. Data are pooled 
from two experiments with 6-8 mice per group and expressed as mean ± SD. Data from 
individual experiments are shown in Appendix B. Statistical evaluation was by Kruskal-Wallis 
with Dunn’s post test. **p<0.01. 
 
These results suggest that treatment with poly I:C or MSU+M.smegmastis around the primary 
tumour can successfully decrease the number of metastatic 4T1 colonies found in the lung 21 
days following tumour inoculation. 
 
4.2.14 DT treatment does not affect the moDC population in 
Clec9A+ DTR mice  
Specialist cross-presenting DCs were not required for the anti-tumour immune response 
induced by poly I:C immunotherapy. Therefore, we investigated whether other DC 
populations were affected by treatment. As mentioned previously, poly I:C immunotherapy 
induces a population of moDCs found in the dLN and 4T1 tumours (Figure 4.8) and we 
wished to establish whether this population was still present in the absence of the specialist 
cross-presenting DCs. 
Indeed, in Clec9A-DTR mice treated with MSU+M.smegmatis immunotherapy and depleted 
with DT, moDCs persisted in the dLN in the absence of CD8α+ and CD103+ DCs (Figure 
4.14 A). No significant difference of MHC II and CD11c expression was found between 
moDCs induced from poly I:C or MSU+M.smegmatis immunotherapies. Interestingly, 
monocytes and moDCs from mice treated with poly I:C expressed higher levels of Ly6C than 
those from MSU+M.smegmatis treated mice (Figure 4.14 B). 
These results indicate that moDCs are still present in Clec9A-DTR mice that have been 
treated with poly I:C and MSU+M.smegmatis immunotherapies, and depleted of CD8α+ and 
CD103+ DCs. MoDCs found in mice treated with MSU+M.smegmatis immunotherapy have a 
different phenotype to those induced by poly I:C immunotherapy, showing reduced Ly6C 
expression. 
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Figure 4.14: Depletion of CD8α+ and CD103+ DCs does not affect the population 
of MoDCs. A) Clec9A-DTR mice bearing orthotopic 4T1 tumours were administered 
MSU+M.smegmatis as described in Figure 4.1 and 20 ng/g of DT as described in Figure 4.11. 
The total number of CD8α+ DCs (MHCIIintCD11chiCD8α+), CD103+ DCs 
(MHCIIhiCD11cintCD103+), and moDCs (MHCIIint CD11cint CD11b+ Ly6C+ CD64) from 
the draining lymph node are shown. Gating strategy for DC populations were as shown in 
Figure 4.11. B) Monocytes (Ly6C+ CD64+ CD11b+ CD11c-) and moDCs (MHCIIint CD11cint 
CD11b+ Ly6C+ CD64+) in the dLN 15 days following tumour injection in 4T1-tumour 
bearing mice are presented. Median fluorescence intensity (MFI) was calculated in FlowJo. 
Absolute DC numbers shown in A) are expressed as the mean ± SEM. Data are pooled from 
two experiments with 3-7 mice per group and statistical evaluation was carried out by the 
Mann-Whitney test. ***p<0.001. MFI expressed as the mean ± SEM, are pooled from two 
experiments with 5 mice per group. Statistical evaluation was carried out by the Mann-
Whitney test. ***p<0.001, ****p<0.0001. 
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4.3 Discussion 
The results described in this chapter demonstrate that poly I:C and MSU+M.smegmatis 
immunotherapies are effective at slowing 4T1 tumour growth, despite minimal changes in 
immune cell infiltration within the tumour. Investigation into the involvement of the adaptive 
and innate immune systems in the efficacy of poly I:C and MSU+M.smegmatis 
immunotherapies, showed that both immunotherapies required CD8+ T cells for efficacy, 
however only MSU+M.smegmatis required Clec9A+ DCs. 
 
Poly I:C and MSU+M.smegmatis activate different pathways  
It is well established that using adjuvants for immunotherapy can successfully initiate an anti-
tumour immune response (625,626). However, there are multiple cell populations involved, as 
well as variety of mechanisms that can be targeted to achieve the same outcome: activation of 
an immune response against a tumour. The results of this chapter highlight differences 
between poly I:C and MSU+M.smegmatis immunotherapies.  
Poly I:C is a TLR3 agonist and acts through the TLR3/TRIF pathway. It can also act on 
RIG-I and MDA-5 receptors, causing production of large amounts of type I IFN, as well as 
IL-8 (362,627,628). IL-8 can act to recruit NK cells, and NK cell recruitment was observed in 
B16.F1 tumours after poly I:C immunotherapy (141); however, not in 4T1 mammary 
tumours (Figure 4.4). Type I IFNs have been shown to drive proliferation of CD44hi T cells, 
especially CD8+ T cells (545,629). However, poly I:C treatment did not cause an increase in 
CD44+ T cells in the tumour or dLN in the 4T1 model (Figure 4.4 and Figure 4.7). 
M.smegmatis is recognised by a number of receptors, including Clec4e that is expressed on 
macrophages (630,631). Treatment of C57BL/6 with M.smegmatis causes production of 
NOD2-dependent TNFα from peritoneal macrophages (632). Uric acid acts as a danger 
signal to activate dendritic cells (370) and also causes inflammasome activation, resulting in 
IL-1β activation (352).  IL-1β was important for the priming of tumour-specific CD4+ T cells 
during MSU+M.smegmatis immunotherapy in C57BL/6 mice (617), and IL-1β plays an 
important role in T cell priming (354). 
Despite the different molecular pathways activated by poly I:C, MSU and M.smegmatis, these 
adjuvants have shown efficacy at reducing primary tumour growth in multiple tumour 
models, including E.G7-OVA (371,605,633). Poly I:C and MSU+M.smegmatis 
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immunotherapies both trigger activation of DCs, resulting in upregulation of CD80 and 
CD86 and induction of moDCs (141,370) and both immunotherapies require CD8+ T cells 
for efficacy (Figure 4.10). These findings suggest that regardless of diverse modes of activation, 
both poly I:C and MSU+M.smegmatis immunotherapies activate similar effector mechanisms 
and can be used to achieve successful anti-tumour responses in a range of murine cancer 
models. 
 
Unsuccessful contralateral treatments of poly I:C and 
MSU+M.smegmatis  
Treatment of poly I:C and MSU+M.smegmatis immunotherapies administered into the 
contralateral side to 4T1 tumours, were not successful at slowing tumour growth and 
prolonging survival (Figure 4.2). Contralateral treatment of poly I:C immunotherapy showed 
a statistically significant difference compared to the untreated control, yet the physical 
difference in tumour size was in the range of 10-15mm2. This negligible difference 
demonstrates that contralateral treatments do not produce optimal anti-tumour responses. 
Indeed, when compared with poly I:C treatments administered peritumourally, it shows that 
poly I:C administered contralaterally was less successful (Figure 4.2). This minimal reduction 
in tumour size may still have long-term effects on metastases, as it is known that there is a 
correlation between the primary tumour size and the number of lung metastases (565). 
However, others have shown that immunotherapy must be administered close to the tumour, 
as distal injections had no effect on decreasing lung metastases (with the exception of i.v. 
(634)).  
 
Effects of poly I:C and MSU+M.smegmatis on systemic cytokines 
Poly I:C and MSU+M.smegmatis immunotherapies induce the release of cytokines, some of 
which can be detected systemically. In the 4T1 tumour-bearing BALB/cByJ mice, poly I:C 
treatment increased CCL2 levels in the serum, which has been found previously (635). 
Unexpectedly, MSU+M.smegmatis treatment caused a reduction in IFNγ and IL-1β (Figure 
4.3). These findings are contrary to what was found in a B16 melanoma model, where 
systemic IFNγ and IL-12 were increased after MSU+M.smegmatis (141). Others have also 
found that treatment with poly I:C, administered i.p., increased TNFα one-hour post-therapy 
and IL-6 and IFNα were detected 6 hours later (636). Another study showed that TNFα 
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induced from poly I:C administered i.p., increased 3 hours post-therapy and decreased to 
baseline levels by 6 hours (637). The variances between the strains could be responsible for the 
disparities in cytokines detected in the serum, as all the studies mentioned were conducted in 
C57BL/6 mice.  
The time of detection post-therapy could also be an important factor in analysing the cytokine 
response. Studies have detected changes in serum cytokines one hour following poly I:C 
treatment, others have shown no changes at that particular time point. Poly I:C is a soluble 
molecule and may enter the lymphatics more readily than M.smegmatis, which is likely to 
remain at the site of injection. The optimal window of time to detect cytokines in the serum 
induced by one treatment, may not necessarily be appropriate for another. It has been 
published previously that IFNγ was increased 3 hours following poly I:C treatment, yet was 
not detected one hour post-treatment. However, treatment with  MSU+M.smegmatis caused an 
increase in IFNγ one hour post-treatment, which had dropped by three hours (141). These 
results suggest that two hours following treatment with poly I:C could be too early to observe 
changes with IFNγ. Furthermore, specific cytokines will have different production rates and 
therefore when investigating multiple cytokines at any given time, detection of one may come 
at the expense of missing the peak of another. 
 
Changes to immune cell infiltrates following poly I:C and 
MSU+M.smegmatis immunotherapies 
When investigating the frequency of immune cell populations within the 4T1 tumour 
following poly I:C and MSU+M.smegmatis immunotherapies, most populations examined 
remained unchanged following treatment (Figure 4.4). The 4T1 model is a well-established 
solid tumour model (575,638). It could be that local immunotherapy does not efficiently 
penetrate within the tumour to induce changes in the number of populations as readily as in 
more accessible tumours. Previous studies have found that the infiltration of lymphocytes into 
4T1 tumours was minimal (638), compared to B16 tumours that have almost double the 
CD3+ infiltrate compared to 4T1 tumours (639). However, Forghani et al., found 4T1 
tumours treated with poly I:C had a reduction in MDSCs (640). Although there was marginal 
change in populations with the addition of immunotherapy, we found a large proportion of 
lymphocytes in 4T1 tumours. CD4+ T cells were the major population, as well as CD8+ T 
cells, Tregs and NK cells (Figure 4.4). CD8+ T cells were found to be necessary for poly I:C 
immunotherapy, thus subsequent investigations focused on CD8+ T cells. We also found that 
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MSU+M.smegmatis immunotherapy reduced the frequency of FoxP3+ cells, which has been 
previously observed in B16 tumours (617). This may be a potential mechanism that 
MSU+M.smegmatis immunotherapy uses to achieve successful anti-tumour responses, by 
minimising unwanted immune suppression from Tregs. However, one study has shown that 
Treg depletion with αCD25 antibodies also targeted and depleted antigen-specific T cells that 
had been activated by immunotherapy (641). Therefore, caution is needed when combining 
Treg depletion with immunotherapy strategies. The use of immunotherapies that have innate 
capabilities to overpower Tregs, in addition to stimulating effector T cell responses, may be 
more beneficial. More investigation into the impact MSU+M.smegmatis immunotherapy has 
on Tregs is needed.  
Despite minimal changes to the tumour composition, poly I:C and MSU+M.smegmatis 
immunotherapies still reduce 4T1 primary tumour size and prolong survival (Figure 4.1 and 
Figure 4.2). One mechanism of action investigated was an increase of effector T cells within 
the tumour or tumour dLN induced by poly I:C and MSU+M.smegmatis immunotherapies, as 
previous studies have shown that poly I:C induces effector T cells (629). However, the 
frequency of effector T cells did not change between treatments (Figure 4.4 and Figure 4.7). 
Investigation into other effector populations, like NK cells showed no difference in frequency. 
MSU+M.smegmatis immunotherapy decreased PD-1+CD4+ T cells in the dLN. A CD4+ 
helper subset called T follicular helper (Tfh) cells also express PD-1 and are involved in the 
activation of Ig-secreting B cells (642,643) and were not excluded in the analysis. Therefore, 
further investigation would be required to characterise the population and investigate the role 
in efficicay of MSU+M.smegmatis immunotherapy. 
In the spleen, poly I:C and MSU+M.smegmatis immunotherapies caused a decrease in the 
frequency of NK cells. This result was unexpected considering that poly I:C produces IFNα/β 
that can act to activate NK cells (644,645) and NK cells have been shown to be needed for 
CD8+ T cell responses (635). In NOD/SCID mice, 4T1 tumours grew faster than WT, which 
suggested that T, B and NK cells play a role in tumour control (Figure 4.10). Certainly, 
depletion of CD8+ T cells impacted the efficacy of both poly I:C and MSU+M.smegmatis 
immunotherapies. Primary tumours were no longer reduced with treatment and the survival 
of mice was significantly decreased. These results suggest that CD8+ T cells are important for 
optimal efficacy. There are also other populations of immune cells that weren’t investigated, 
such as ILCs, that could be contributing to the anti-tumour immune response (646,647). 
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MSU+M.smegmatis immunotherapy requires Clec9A+ DCs yet they 
are not necessary for poly I:C immunotherapy 
Cross-presenting DCs have been shown to play an integral role in anti-tumour responses, 
therefore it was important to investigate their role in poly I:C and MSU+M.smegmatis 
immunotherapies. By using the Clec9A-DTR mice, successful depletion of the specialist cross-
presenting subsets, the CD8α+ and the CD103+ DCs, was achieved (Figure 4.11). When 
Clec9A+ DCs were depleted, MSU+M.smegmatis immunotherapy could no longer delay 
primary tumour growth in the 4T1 model. Poly I:C immunotherapy however, still remained 
successful (Figure 4.12).  
It has been reported that CD8α+ and the CD103+ DCs are superior in their ability to respond 
to TLR3 adjuvants (394,648), therefore it was surprising that poly I:C immunotherapy was 
equally effective when CD8α+ and CD103+ DCs were absent. In addition to TLR3, poly I:C 
can also exert effects through RIG-I and MDA-5 receptors and it has been shown that the 
shorter form of poly I:C is preferentially recognised by RIG-I, and the longer form by MDA-5 
(360,361). This may contribute to different responses induced by poly I:C. RIG-I and MDA-5 
have differences in molecular signalling mechanisms, but both respond to RNA to induce 
IFNα/β production (649,650). One study found that poly I:C stimulated both TLR3 and 
MDA-5, which lead to activation of NK cells in vitro. Interestingly, this was mediated through 
CD8α+, and not CD8α- DCs (651). These findings suggest that although certain DCs may be 
particularly sensitive to poly I:C induced activation, redundancy within the IFN α/β pathway 
ensures a response is initiated in the absence of certain cell populations (650). 
In the absence of specialist cross-presenting DCs, MSU+M.smegmatis immunotherapy lost 
efficacy and could no longer slow primary tumour growth in 4T1 tumours (Figure 4.12). 
There are a number of potential mechanisms that may explain this observation. It is known 
that CD8α+ DCs have high expression of DEC-205, a receptor that is involved in binding 
apoptotic cells and CpG motifs (54,338,652). DEC-205 internalises bound material and allows 
CpG motifs to bind to TLR9, which is found in intracellular compartments (71). Mycobacterium 
DNA contains CpG motifs that lead to TLR9-induced DC activation (343). Therefore, 
absence of CD8α+ DCs that have high expression of DEC-205 could reduce the activity of 
M.smegmatis and provide an explanation for the loss of efficacy of MSU+M.smegmatis 
immunotherapy. M.smegmatis is also recognised by multiple PAMPS, including NOD2 (632), 
and others have shown that there is differential NOD expression in DC subsets found in rats 
(653). This implies that there may be differential expression of PRRs, including NOD2, in 
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murine DC subsets, which could influence the DC subset/s involved in the recognition of 
particular PAMPs. Furthermore, a study found that both CD8α+ and CD103+ DCs are 
reduced in Nod2-/- mice with an influenza A infection (654). Together, these findings could 
explain the lack of efficacy of MSU+M.smegmatis immunotherapy in Clec9A-DTR mice, as 
they imply that NOD2-dependent M.smegmatis activity requires specialist cross-presenting 
DCs. 
 
Poly I:C immunotherapy reduces lung metastases 
It is well established that the 4T1 tumours are metastatic and investigation into the effects of 
poly I:C and MSU+M.smegmatis immunotherapies on 4T1 metastatic colonies showed that 
both immunotherapies are effective at reducing the number of colonies in the lung (Figure 
4.13). MSU+M.smegmatis was less effective than poly I:C, with no significant difference 
compared to the PBS control. However, in the absence of specialist cross-presenting DCs, 
poly I:C trended towards an increase in number of colonies, suggesting that specialist cross-
presenting DCs may play a role in reducing metastases. 
There are several proposed models of the metastatic process, many of which are not mutually 
exclusive (655). One such model proposes that although all tumour cells have the ability to 
metastasise, only a small proportion of them are capable of doing so at any given time due to 
epigenetic events (656). If this is true of the 4T1 model, it would suggest that poly I:C and 
MSU+M.smegmatis immunotherapies are effective at targeting and reducing those metastatic 
tumour cells. Other studies have shown that the number of colonies in the lung is related to 
the size of the 4T1 primary tumour (565). My findings are contrary to this, as the absence of 
specialist cross-presenting DCs prevented MSU+M.smegmatis from reducing primary tumour 
size; however, therapy remained effective at reducing 4T1 colonies in the lung. In fact, no 
significant difference was detected in the number of lung colonies with MSU+M.smegmatis 
treatment either with or without the presence of Clec9A+ DCs (Figure 4.13), despite a 
reduction in the primary tumour size. Since cross-presenting DCs are important for T cell 
priming, this finding highlights that Clec9A+ DCs are involved in the effector T cell response 
induced with MSU+M.smegmatis that is required for reduced tumour growth; nonetheless, the 
absence of Clec9A+ DCs may have little to no impact on metastatic burden. 
The discussion around whether tumour cells metastasise in early or late-stage growth is a 
long-standing debate, with evidence for both arguments (657,658). The linear progression 
model suggests that after rounds of proliferation and accruing genetic mutations for increased 
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competitive fitness, cancer cells are able to leave the primary site to establish secondary 
metastases (657). My results showed that immunotherapy given 8 days after tumour 
inoculation, is successful at influencing 4T1 colonies in the lung. This could suggest that the 
direct effects of poly I:C immunotherapy reducing primary tumour size may account for 
reduced dispersion of 4T1 cells to the lung and consequently a reduction of colonies. 
However, this is not found with MSU+M.smegmatis immunotherapy. Another proposed model 
of metastases would suggest that 4T1 cells are able to disseminate from the site of injection to 
the lung early, before tumour establishment and immunotherapy (658). Two recent papers 
have shown this phenomenon in other tumour models. Hossenini et al., found that 
progesterone-induced signalling was responsible for the migration of cancer cells very early in 
development. Cells from early lesions showed more stem-cell like features and were 
responsible for >80% of metastases (659). The other study also investigated early 
dissemination, before a palpable tumour was present. It was revealed that p38 signalling was 
involved in regulating the number of circulating tumour cells (660). Due to immunotherapies 
decreasing the metastatic load in the lung, one mechanism could be through modification of 
the lung environment through cytokine induction, making it harder for cancer cells that had 
disseminated early to survive (658). The precise mechanisms through which poly I:C and 
MSU+M.smegmatis immunotherapies impact metastatic colonies is yet to be determined. 
 
Recruitment of moDCs to the dLN and tumour 
Depletion of CD8+ T cells showed a reduction in efficacy of poly I:C immunotherapy to 
prolong survival, yet produced an intermediate phenotype between the control and the poly 
I:C immunotherapy, which was not observed with MSU+M.smegmatis (Figure 4.10). This 
result may suggest that although CD8+ T cells are involved in poly I:C immunotherapy, other 
populations are also required for optimal efficacy. The role of specialist cross-presenting DCs 
in immunotherapies was investigated, as cross-presenting DCs have been shown to be 
important for anti-tumour responses (130). However, in the absence of specialist cross-
presenting DCs, poly I:C immunotherapy remained effective (Figure 4.12), therefore 
suggesting that Clec9A+ DCs were dispensable for efficacy of poly I:C immunotherapy. 
Poly I:C and MSU+M.smegmatis immunotherapies both induced a dendritic cell population 
within the tumour and tumour dLN called moDCs (Figure 4.8). These cells were capable of 
producing iNOS, TNFα and IL-12 (Figure 4.9), which is consistent with results from other 
groups (96,102). These effector cytokines can act upon tumour cells directly to exert cytotoxic 
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effects (661) or indirectly via activation of additional immune cell populations that contribute 
to an anti-tumour immune response (662). Production of iNOS from moDCs has been shown 
to play an important role in CD8+ T cell responses to viral infection (123) and microbiocidal 
killing in a Listeria infection (663). The role of iNOS in anti-tumour immune responses is 
debated, yet there is evidence that iNOS was required for IFN-β induced antitumoural effects 
in prostate cancer (664). TNFα and IL-12 have long been established as potent anti-tumour 
cytokines (665,666). 
Since poly I:C and MSU+M.smegmatis immunotherapies both induce moDCs, yet have a 
differential requirement of specialist cross-presenting DCs, we wanted to investigate whether 
moDCs persisted in the absence of Clec9A+ DCs. Indeed, moDCs were present in mice 
depleted of Clec9A+ DCs (Figure 4.14). Studies have shown that moDCs have the ability to 
cross-present (69,143); therefore, they may be responsible for the efficacy of poly I:C 
immunotherapy, as they could be cross-presenting antigen in mice deficient of Clec9A+ DCs. 
MoDCs are extremely plastic and therefore have many functions that overlap with DC 
populations (667). Since MSU+M.smegmatis immunotherapy also induces moDCs, yet requires 
specialist cross-presenting DCs for efficacy, we wanted to see whether there were 
dissimilarities between the moDCs induced from either therapy. When analysing Ly6C 
expression, moDCs from MSU+M.smegmatis had a significantly lower MFI of Ly6C compared 
to moDCs induced from poly I:C immunotherapy. It is currently unknown whether or how 
this might affect their function. MSU+M.smegmatis induced more moDCs within 4T1 tumours 
than poly I:C; conversely, poly I:C immunotherapy induced more moDCs in the tumour dLN 
than MSU+M.smegmatis (Figure 4.8). Taken together, these results imply that the moDCs from 
poly I:C and MSU+M.smegmatis immunotherapies may be different, and it is not yet known 
how this could impact the contribution they may have to the anti-tumour immune response.  
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4.3.1 Conclusions 
In this chapter I have shown that poly I:C and MSU+M.smegmatis immunotherapies are 
successful at slowing 4T1 primary tumour growth and prolonging survival. The efficacy of 
these treatments required local administration at the tumour site, as well as the presence of 
CD8+ T cells. 
Poly I:C and MSU+M.smegmatis immunotherapies in BALB/cByJ mice induced different 
responses to each other. Poly I:C increased systemic CCL2, whereas MSU+M.smegmatis did 
not. However, both immunotherapies successfully induced moDCs found in the tumour and 
the dLN, with moDCs from the dLN able to produce iNOS, TNFα and IL-12. 
MSU+M.smegmatis immunotherapy reduced Tregs in 4T1 tumours, as well as PD-1+CD4+ T 
cells in the dLN, whereas poly I:C immunotherapy had little effect on the proportion of 
immune cell populations within the tumour or dLN.  
Investigation into the role of specialist cross-presenting DCs contributing to the efficacy of 
poly I:C and MSU+M.smegmatis immunotherapies revealed that depletion of CD8α+ and 
CD103+ DCs rendered MSU+M.smegmatis ineffective. In contrast, poly I:C immunotherapy 
was still able to slow tumour growth and prolong survival 4T1 tumours. 
These results show that poly I:C and MSU+M.smegmatis immunotherapies are both successful 
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5.1 Introduction 
Cross-presenting DCs are central for cross-priming T cells (76,563). However, in Chapter 4, I 
showed that poly I:C immunotherapy was not dependent on specialist cross-presenting DCs to 
induce a sufficient anti-tumour response. This implies that functional T cell responses may still 
be primed in the absence of specialist cross-presenting DCs. 
CD103+ DCs are dependent on BATF3 for development and it was previously shown that 
CD8α+ DCs also required BATF3 for generation (75,76). However,  some studies have shown 
that CD8α+ DCs can develop in Batf3-/- mice not only during infection, but also at steady-
state (77,78,668). Tussiwand et al., found that IL-12 administration, or infection with the 
intracellular pathogens Toxoplasma gondii, Listeria monocytogenes and Mycobacterium tuberculosis, 
restored CD8α+ DCs in Batf3-/- mice. It was found that the genes Batf and Batf2 were able to 
compensate for the absence of BATF3 during infection, and the repopulation of CD8α+ DCs 
was mediated by IL-12 and IFNγ (77). Moreover, studies have found CD8α+ DCs persist in 
the spleen and LNs of steady-state Batf3-/- mice and only the transcription factor IRF8 is 
required for CD8α+ DCs development (78,668). It is important to note that genetic 
background seems to contribute, as initial studies showing Batf3 dependency for CD8α+ DCs 
were investigating Batf3-/- mice on a B6.129 background, whereas latter studies are 
undertaken on a C57BL/6 background. Nonetheless, BATF3 KO mice are often used to 
study the role of specialist cross-presenting DCs. One advantage in using BATF3 KO mice 
over Clec9A-DTR mice, is that BATF3 KO mice were available on a C57BL/6 background 
giving us the ability to work with well-established model antigens and transgenic T cells, 
which can only be used with mice on a C57BL/6 background. However, Clec9A-DTR mice 
have the advantage of inducible depletion and therefore, the control over the timing of 
depletion of Clec9A+ cells (564,616).  
As is the case in all animal models, both Clec9A-DTR and BATF3 KO mice have 
disadvantages. Clec9A-DTR and BATF3 KO mice are limited in their specificity. Clec9A is 
expressed at low levels on pDCs, therefore this DC subset is reduced alongside CD103+ and 
CD8α+ DCs (52,109). The gene Batf3 is not shown to be involved in pDC lineage and 
therefore pDCs remain in BATF3 KO mice. However, BATF3 KO mice are only deficient in 
CD103+ and not CD8α+ DCs, limiting interpretation of the role of cross-presenting DCs. 
Therefore, it is important to establish the DC cell profile in BATF3 KO mice, and ascertain 
whether Batf3-dependent DCs are required for successful poly I:C or MSU+M.smegmatis 
treatment of B16 tumours. CD11c-DTR mice have been a key model used to clarify the roles 
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of dendritic cells in immune processes (669). However, the CD11c promotor is also active in 
other immune populations, such as macrophages and NK cells (670,671). Moreover, these 
mice will only tolerate one injection of DT, requiring bone marrow chimeras to be made for 
pro-longed depletion (669,670). 
In Chapter 4, I showed that in the absence of specialist cross-presenting DCs, poly I:C 
immunotherapy remained effective, suggesting that successful T cell responses were still 
generated. Therefore, we wanted to investigate the impact of poly I:C immunotherapy on T 
cell proliferation in the absence of Batf3-dependent DCs. One mechanism used by activated 
CD8+ T cells to contribute to anti-tumour responses is the production of IFNγ (672,673). 
Stimulation of CD8+ T cells will drive IFNγ production, and certain DC subsets have been 
shown to promote T cell differentiation to favour IFNγ production in infection models 
(674,675). It has been published that poly I:C immunotherapy can increase IFNγ detected in 
the serum, as well as the production of IFNγ by CD8+ T cells within murine tumours (141). 
However, the involvement of specialist cross-presenting DCs in the poly I:C induced 
production of IFNγ from CD8+ T cells is uncertain. 
Another important function of activated T cells is the ability to develop cytolytic capabilities, 
allowing killing of target cells. T cells become primed to kill specific targets via presentation of 
antigen through MHC class I. Cross-presenting DCs specialise in this particular function and 
studies have shown that specialist cross-presenting DCs are required for CTL activation 
(76,144). In light of these studies, it was important to investigate CTL responses in mice 
lacking Batf3-depedent DCs and whether their capacity to kill was impaired. 
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5.1.1 Aims 
Results in Chapter 4 used Clec9A-DTR mice and the 4T1 mouse mammary carcinoma 
model to show that poly I:C immunotherapy requires CD8+ T cells, but is effective at driving 
anti-tumour responses in the absence of specialist cross-presenting DCs. Due to the lack of 
known CD8+ T cell epitopes in 4T1 tumours, it was not possible to directly demonstrate 
whether a tumour-specific CD8+ T cell response had developed in host mice. Therefore, the 
purpose of this chapter was to investigate the response of CD8+ T cells in BATF3 KO mice, 
as they offer the advantage of generating responses to OVA antigen, thus enabling the 
assessment of the priming of antigen-specific CD8+ T cell responses in the absence of CD103+ 
cross-presenting DCs. The hypothesis was that in the absence of Batf3-dependent DCs, the 
CD8+ T cell anti-tumour response to poly I:C immunotherapy would remain proficient.  
The specific objectives were: 
• To assess whether Batf3-dependent DCs are required for successful poly I:C and 
MSU+M.smegmatis immunotherapies 
• To investigate the tumour-specific T cell expansion after poly I:C immunotherapy in 
the absence of Batf3-dependent DCs  
• To investigate the priming of IFNγ-producing tumour-specific T cells in BATF3 KO 
mice following poly I:C immunotherapy 
• To examine the priming of CTLs in the absence of Batf3-dependent DCs following 
immunisation with OVA and poly I:C immunotherapy 
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5.2 Results 
5.2.1 Batf3-dependent DCs are necessary for MSU+M.smegmatis 
immunotherapy and not poly I:C immunotherapy 
In Chapter 4, MSU+M.smegmatis immunotherapy of 4T1 tumors was found to be dependent 
on specialist cross-presenting DCs, whereas poly I:C did not require Clec9A+ DCs to be 
effective. To investigate the role of cross-presenting DCs in the immunotherapy of B16 
tumours, BATF3 KO mice were utilised, which lack the cross-presenting CD103+ DC subset. 
Mice were challenged with B16.F1 tumors and treated with four peritumoural treatments of 
poly I:C or MSU+M.smegmatis immunotherapies every other day, starting from day eight with 
a maximum of four doses.  
Comparable to the 4T1 tumours in Clec9A-DTR mice, MSU+M.smegmatis could no longer 
slow B16 primary tumour growth in BATF3 KO mice. However, poly I:C immunotherapy 
remained effective. This result shows that CD103+ DCs are necessary for the efficacy of 





Figure 5.1: Batf3-dependent DCs are required for activation of anti-tumour 
immunity by MSU+M.smegmatis but not poly I:C. A) C57BL/6 and BATF3 KO 
mice bearing B16.F1 tumours were administered peritumoural injections of poly I:C or 
MSU+M.smegmatis immunotherapies on days 8, 10, 12, and 14. PBS group is a mixture of 
C57BL/6 and BATF3 KO mice. Data, expressed as the mean ± SEM, are pooled from two 
experiments with 6-8 mice per group. Statistical evaluation of tumor growth curves was by 
two-way ANOVA with a Bonferroni post hoc test. **p<0.01, ****p<0.0001 on day 14. 
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5.2.2 CD11c+ cells are required for successful immunotherapy 
with poly I:C  
To investigate whether other DC populations were contributing to the success of poly I:C 
immunotherapy, CD11c-DTR BM chimeras were used as they can be depleted of all DC 
populations by treatment with DT. C57BL/6 mice were irradiated and repopulated with 
bone marrow from either CD11c-DTR mice, or C57BL/6 mice for chimera controls. After 2 
months of recovery, mice were challenged with B16 tumors, and CD11c+ cells were depleted 
16-18 hours before immunotherapy by DT treatment. Poly I:C was administered 
peritumourally every other day starting from day eight, with a maximum of four doses (Figure 
5.2 A).  
Depletion of CD11c+ cells completely abrogated the effect of poly I:C on primary tumor size 
and on survival (Figure 5.2 B). These results indicate that CD11c+ cells are an absolute 




Figure 5.2: CD11c+ cells are required for the anti-tumour effect of poly I:C 
immunotherapy. A) C57BL/6 or CD11c-DTR BM chimeras were injected with B16 
tumors, treated every second day for four injections with poly I:C or PBS, and concurrently 
depleted of CD11c+ cells by DT treatment 16-18 hours before poly I:C. B). Tumor sizes from 
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day 18 are shown and percent survival. Data are pooled from two experiments with 4-5 mice 
per group. Additional mice were set up to check for depletion on day 14 in the dLN and 
spleen (see Appendix C). Statistical evaluation of tumor size was by Mann-Whitney and 
Kruskal-Wallis tests with Dunn’s post-tests. *p<0.05, ***p<0.001. ****p<0.0001. Percent 
survival was analysed by Mantel-Cox test using a Bonferroni correction threshold of 
*p<0.016. 
 
5.2.3 BATF3 KO mice lack CD103+ DCs 
To characterise the impact of BATF3 inactivation on cross-presenting DC subsets in our 
model, C57BL/6 and BATF3 KO mice were inoculated with B16.OVA tumours and treated 
with poly I:C or MSU+M.smegmatis immunotherapies as previously described (Figure 5.1). 
Cross presenting DCs in the spleen and LN were characterised by flow cytometry one day 
after the last immunotherapy treatment. 
CD8α+ and CD103+ DCs were decreased in the spleen of BATF3 KO mice compared to WT 
and treatment with poly I:C or MSU+M.smegmatis immunotherapies in BATF3 KO mice did 
not alter their numbers (Figure 5.3 A). When investigating the dLN, it was revealed that 
CD8α+ DCs were present in BATF3 KO mice in similar numbers to WT mice. However, 
CD103+ DCs were decreased (Figure 5.3 B). Immunotherapy with poly I:C or 
MSU+M.smegmatis increased the number of CD8α+ and CD103+ DCs in the dLN of 
C57BL/6 mice, although this was not statistically significant. In contrast, poly I:C or 
MSU+M.smegmatis immunotherapies did not alter the number of CD8α+ and CD103+ DCs in 
the dLN in BATF3 KO mice. 
These results show that BATF3 KO mice lack CD103+ DCs within the spleen and dLN. 
However, CD8α+ DCs are only absent in the spleen, but present in the dLN. Treatment with 
poly I:C or MSU+M.smegmatis immunotherapies did not affect the number of CD8α+ and 
CD103+ populations in BATF3 KO mice.  
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Figure 5.3: CD103+ DCs are absent in BATF3 KO mice. A) C57BL/6 or BATF3 KO 
were inoculated with B16.OVA tumours in the flank and were administered either poly I:C or 
MSU+M.smegmatis via peritumoural injections on days 8,10,12 and 14 following tumour 
implantation. Spleen and B) dLN were harvested on day 15. Cells were previously gated for 
singlets, live and CD45+. Absolute DC numbers are expressed as mean ± SEM. 
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5.2.4 Expansion of gp100 cells in BATF3 KO hosts 
We wanted to investigate tumour antigen-specific T cells in tumour-bearing mice to assess 
whether their ability to recognise the tumour and respond would remain intact in the absence 
of CD103+ DCs. We used CD8+ T cells from pmel-1 mice as these mice carry a transgenic 
TCR specific for the melanoma antigen glycoprotein 100 (gp100 or pmel-1), and express the 
congenic marker Thy1.1 that facilitates the identification of transgenic T cells after adoptive 
transfer.  
C57BL/6 and BATF3 KO mice with B16 tumours were administered CFSE-labelled gp100 
cells by adoptive transfer on day 7. Mice then received two doses of poly I:C immunotherapy 
on days 8 and 10. The tumor dLN and the inguinal LN from the opposite flank (non-dLN), 
were collected on day 14 and analysed for expansion of the adoptively transferred population 
(Figure 5.4 A). Gp100 Thy1.1+ cells were gated accordingly and CD8+ cells were assessed for 
CFSE dilution as a measure of proliferation. The gating strategy was based on control mice 
that did not receive gp100 cells, and mice treated with PBS (Figure 5.4 B). 
The proportion of divided Thy1.1+CD8+ cells increased in mice bearing tumours, compared 
to the tumour-free control. The addition of poly I:C immunotherapy increased proliferation 
in C57BL/6 mice (Figure 5.4 C). In the non-dLN, there was no difference in the proportion 
of divided Thy1.1+CD8+ cells between tumour-bearing and non-tumour-bearing mice. 
Nonetheless, poly I:C treatment increased the proportion of divided tumour-specific cells in 
the dLN (Figure 5.4 D). BATF3 KO mice followed the same trend as C57BL/6 mice, with an 
increased proportion of divided cells with poly I:C treatment compared to the PBS control, 
although not significant. There was no significant difference in the expansion of 
Thy1.1+CD8+ cells in poly I:C treated C57BL/6 and BATF3 KO mice.  
These results suggest that poly I:C treatment can enhance expansion of tumour antigen-
specific CD8+ T cells compared to untreated controls. Furthermore, the proliferation of 
tumour antigen-specific T cells after poly I:C immunotherapy is not impaired in the absence 
of CD103+ cross-presenting DCs in BATF3 KO mice. 
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Figure 5.4: Tumour specific gp100 cells proliferate in BATF3 KO mice. A) 
C57BL/6 or BATF3 KO were inoculated with B16.OVA tumours in the flank. Seven days 
later, lymphocytes processed from gp100TCR transgenic mice were labelled with CFSE and 
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adoptively transferred into hosts. Mice were treated peritumourally with poly I:C 
immunotherapy on day 8 and day 10, before the tumour dLN and non-dLN were harvested 
on day 14 to assess gp100 expansion. B) Cells were previously gated for singlets and live. 
Representative gating to identify adoptively transferred gp100 cells and examine proliferation 
by CFSE dilution. Gp100 cells are Thy1.1+. C&D) Percentage of divided Thy1.1+CD8+ cells, 
expressed as mean ± SEM. Data is representative of two experiments with 2-5 mice per 
group. Statistical evaluation was by two-way ANOVA with the Bonferroni post hoc test. 
*p<0.05, **p <0.01. 
 
5.2.5 CD8+ T cells within B16 tumours produce IFNγ in BATF3 KO 
mice 
Investigation into the expansion of antigen-specific CD8+ T cells revealed that the ability to 
proliferate was not impaired in the absence of specialist cross-presenting DCs. However, the 
functionality of antigen-specific T cells, such as cytokine production, was still unknown. 
Therefore, we wanted to assess whether the absence of cross-presenting DCs affected the 
priming of IFNγ producing CD8+ T cells. C57BL/6 and BATF3 KO mice with B16 tumours 
were treated with poly I:C as previously described (Figure 5.1). The tumours were harvested 
and cell samples were plated on CD3-coated plates and stimulated with CD28, or in uncoated 
plates and left unstimulated (Figure 5.5 A). IFNγ production was examined by intracellular 
staining, detected by flow cytometry. The gating strategy was based on the isotype control 
(Figure 5.5 B).  
Unstimulated CD8+ T cells produced detectable levels of IFNγ, although there was no 
significant difference of IFNγ production between untreated and poly I:C treated mice (Figure 
5.5 C). There was also no difference in IFNγ production by CD8+ T cells between C57BL/6 
and BATF3 KO mice. Tumour samples that were stimulated with CD3/CD28 restimulation 
had higher levels of IFNγ, although restimulation also increased background levels from 
untreated controls. Similarly, there was no significant difference in IFNγ production by CD8+ 
T cells when comparing the PBS control to poly I:C treated, and no difference between 
C57BL/6 and BATF3 KO mice. As seen previously (617), CD4+ T cells did not produce 
IFNγ whether unstimulated or CD3/CD28 stimulated (Figure 5.5 C). The MFI of IFNγ 
followed the same trend, with no significant difference between treatment or strains, 
suggesting that C57BL/6 and BATF3 KO mice produce comparable amounts of IFNγ. 
These results suggest that the CD8+ T cells present within the tumour are able to produce 
IFNγ, and mice that are deficient in specialist cross-presenting DCs have CD8+ T cells that 
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are functionally similar to those in WT mice. Unfortunately, these experiments failed to reveal 




Figure 5.5: CD8+ T cells produce IFNg in the absence of CD103+ DCs. A) C57BL/6 
of BATF3 KO mice were inoculated with B16.OVA tumours in the flank. Poly I:C was 
administered peritumourally on days 8, 10, 12 and 14. Tumours were harvested on day 15 
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and incubated with Golgi stop for 5 hours. Samples were divided into two, with one group 
receiving CD3/CD28 restimulation. Cells were collected and CD8+ T cells were analysed for 
IFNg production by flow cytometry. B) Cells were previously gated for singlets, live and 
CD45+. Representative gating for IFNg was based on the isotype control. C) Percentage of 
IFNg+CD8+ T cells from total CD8+ population and median fluorescence intensity (MFI) of 
IFNg+ is expressed as mean ± SEM. Statistical evaluation was by two-way ANOVA with the 
Bonferroni post hoc test. 
 
5.2.6 OT-I CD8+ T cells are capable of expansion in BATF3 KO 
hosts 
Due to the effective anti-tumour response induced in mice treated with poly I:C in the 
absence of specialist cross-presenting DCs, we wanted to investigate further how poly I:C 
treatment was impacting adaptive immunity. OVA was used as a model antigen as it produces 
robust T cell responses and provides a mode to investigate antigen-specific activity. 
To investigate whether the absence of specialist cross-presenting DCs affected proliferation of 
T cells to cognate antigen, purified CD8+ lymphocytes from OT-I mice were adoptively 
transferred into C57BL/6 and BATF3 KO hosts. The following day mice were primed with 
OVA or a combination of OVA and poly I:C (Figure 5.6 A). Seven days later OT-I expansion 
was analysed in peripheral blood. Total CD8+ T cells were gated, then CD45.1+ for the 
detection of OT-I cells, which was confirmed by Vα2 and Vβ5 expression (Figure 5.6 B).  
Expansion of the OT-I population was minimal in mice treated with OVA alone. 
Combination treatment with OVA and poly I:C induced expansion of the OT-I cells, which 
made up over half of the total CD8+ population in C57BL/6 mice (Figure 5.6 C). Expansion 
of OT-I cells was slightly reduced in OVA and poly I:C treated BATF3 KO mice compared 
to C57BL/6 mice. However, there was significantly more expansion in the mice treated with 
OVA and poly I:C compared to the OVA control in BATF3 KO mice (Figure 5.6 C).  
These results suggest that OVA and poly I:C stimulate expansion of CD8+ OT-I T cells and 
that the ability of CD8+ antigen-specific cells to respond to cognate antigen is similar in the 
absence of CD103+ DCs. 
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Figure 5.6: Expansion of OT-Is in BATF3 KO mice. A) Total LNs were collected from 
OT-I mice and purified for CD8+ cells, which were adoptively transferred into C57BL/6 or 
BATF3 KO hosts. The following day mice were administered OVA subcutaneously with or 
without poly I:C. Control mice received PBS. Blood was taken on day 7 following OVA 
injection and analysed for OT-I expansion. B) Cells were previously gated for singlets and live. 
Representative gating of FACs plots to identify adoptively transferred CD45.1+ OT-I cells. 
B6-SJ-OT-Is mice were included as a positive control. All OT-I cells were Vα2 and Vβ5 
positive. C) Percentage of CD45.1+ cells from total CD8+ population, expressed as mean ± 
SEM. Data are pooled from two experiments with 3-4 mice per group. Statistical evaluation 
was by two-way ANOVA with the Bonferroni post hoc test. *p<0.05, **p<0.01, ****p<0.0001. 
 
5.2.7 CTLs have impaired priming in mice lacking specialist cross-
presenting DCs. 
To investigate whether the absence of specialist cross-presenting DCs would affect the 
acquisition of cytotoxic function by T cells, C57BL/6 and BATF3 KO mice were primed 
with OVA with or without the addition of poly I:C. One week later, mice were tested for 
OVA-specific CTL activity using a VITAL assay (567) (Figure 5.2 A & B). 
Killing of a 10nM SIINFEKL loaded target population in C57BL/6 mice was ~70%, and 
increased to ~85% killing with a higher SIINFEKL concentration (Figure 5.7 C). There was 
minimal killing in mice with OVA alone, showing that poly I:C is required to activate the T 
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cells and induce cytolytic capabilities. In BATF3 KO mice, the killing was decreased by half 
compared to WT, yet still detectable (Figure 5.7 C).  
Since BATF3 KO mice retain CD8α+ DCs in the dLN, it was important to verify the results 
discovered in BATF3 KO mice with a model that was able to deplete both specialist cross-
presenting DC populations. Therefore, the VITAL assay was conducted in Clec9A-DTR 
mice crossed with C57BL/6 mice. These heterozygous mice allow for the depletion of 
Clec9A+ DCs, whilst maintaining the sensitivity to recognise and respond to OVA. Mice were 
treated with three doses of 20ng/g of DT prior to priming, and one more dose two days 
following priming (Figure 5.7 D). DC depletion was examined after three DT treatments in 
the spleen and dLN and successful depletion of both the CD103+ and the CD8α+ was 
achieved (Figure 5.7 E). In the absence of Clec9A+ DCs, killing induced with OVA in 
combination with poly I:C was significantly decreased compared to the corresponding Clec9A 
control (Figure 5.7 F).  
Taken together, these results suggest that in the absence of CD103+ DCs, the priming of 
CTLs is impaired but still present. However, the absence of both CD8α+ and CD103+ DCs 
rendered CTL killing undetectable. 
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Figure 5.7: Cytotoxic T cell responses have impaired priming in the absence of 
CD103+ DCs. A) C57BL/6 or BATF3 KO mice were primed subcutaneously with OVA or 
OVA+poly I:C on day 0. Target cells were injected i.v. on day 7. B) Cells were previously 
gated for singlets and live. Representative gating of FACs data used to calculate specific lysis. 
C) Specific lysis of CFSE labelled target populations is expressed as mean ± SEM. Data are 
pooled from two experiments with 3 mice per group. D) Clec9A-DTR x C57BL/6 mice were 
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administered 20 ng/g of DT 3 times before subcutaneous injection with OVA or OVA + poly 
I:C on day 0. BALB/cByJ x C57BL/6 mice were used as a control and were administered 20 
ng/g DT treatments. Experiment details from day 7 onwards were as described in A). E) 
Depletion of Clec9A+ DCs was analysed in the spleen and dLN on day 0 after 3 treatments of 
DT. Gating strategy as described in Figure 5.3. Analysis of other DC subsets was undertaken 
(see Appendix D). Total numbers are expressed as mean ± SEM. F) Specific lysis of CFSE 
labelled target populations is expressed as mean ± SEM. Data are pooled from two 
experiments with 3 mice per group. Statistical evaluation of DCs was by Mann-Whitney. 
*p<0.05. Statistical evaluation of lysis was by two-way ANOVA with the Bonferroni post hoc 
test. ****p<0.0001.  
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5.3 Discussion 
The results described in this chapter show that the use of poly I:C as an adjuvant can cause an 
effector CD8+ T cell response, with expansion of antigen-specific T cells that can produce 
IFNγ and have cytotoxic ability. The absence of CD103+ DCs does not affect the expansion 
or production of IFNγ from antigen-specific T cells; however, killing was impaired. Moreover, 
in the absence of both CD8α+ and CD103+ DCs, CTL killing was undetectable. 
 
CD8+ T cell responses develop in BATF3 KO mice  
Cross-presenting DCs have been shown to preferentially take up cell-associated antigen 
(73,129,676) and have been shown to be required for cross-priming to CD8+ T cells (76,563). 
Due to this specialised function, it was important to investigate the response of antigen-specific 
T cells in the absence of specialist cross-presenting DCs. OT-I cells adoptively transferred into 
BATF3 KO mice that were primed with cognate antigen and poly I:C, were able to 
proliferate and expand. However, expansion was slightly decreased compared to C57BL/6 
controls (Figure 5.6). Investigation into expansion of gp100 tumour antigen-specific T cells in 
B16 tumour-bearing mice showed a similar trend. There was a decrease in the frequency and 
number of Thy1.1+ cells in BATF3 KO mice compared to C57BL/6 mice, but no statistically 
significant difference between the two strains. Taken together, these results show that poly I:C 
treatment can induce expansion of antigen-specific CD8+ T cells and that the absence of 
CD103+ DCs does not prevent antigen-specific T cell proliferation. 
We also investigated IFNγ production by CD8+ T cells, but found no significant increase in 
IFNγ with poly I:C treatment compared to the control. CD3/CD28 restimulation increased 
IFNγ production and there was a trend for BATF3 KO mice to produce less IFNγ with poly 
I:C compared to the C57BL/6 control, however this was not significant (Figure 5.5). Further 
investigations would be required to determine if the absence of Batf3-dependent DCs impacts 
the production of IFNγ by CD8+ T cells. 
Another important function of CTLs is the ability to kill target cells. Using a VITAL assay to 
measure specific killing in vivo (567), we found that BATF3 KO mice had reduced levels of 
killing compared to WT mice, however; killing was still detectable, with 50% of targets killed. 
Conversely, the Clec9A-DTR mice had no detectable killing compared to controls (Figure 
5.7). These results highlight the difference between the BATF3 KO mice and Clec9A-DTR 
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mice and suggest that both CD8α+ and CD103+ DCs are important for the priming of CTLs. 
There is detectable killing in BATF3 KO that lack CD103+ DCs but retain CD8α+ DCs, 
which suggests that CD8α+ DCs in these mice are able to induce CTLs to some degree. 
However, killing is at a reduced capacity compared to C57BL/6 controls, showing that the 
CTL response is more effective when both CD8α+ and CD103+ DCs are present. This is 
further highlighted in Clec9A-DTR mice, where the absence of both CD8α+ and CD103+ 
DCs hinders CTL priming and killing is no longer detected. 
Investigation into the requirement of DCs for poly I:C immunotherapy found that depleted 
CD11c-DTR BM chimeras no longer responded to immunotherapy. One explanation for 
these results would be that CD11c+ cells are required for poly I:C immunotherapy. However, 
it is well-known that the CD11c-DTR model has diminished NK cells with reduced effector 
function (671). Therefore, it is possible that the anti-tumour effects of poly I:C 
immunotherapy is independent of DCs and acting directly through NK cells. Indeed, NK 
cells have been shown to be required for effective treatment with poly I:C and 
MSU+M.smegmatis immunotherapies in a B16 melanoma model (141). However, investigation 
into 4T1 tumours treated with poly I:C and MSU+M.smegmatis, did not reveal any changes to 
the NK populations found within the tumour or tumour dLN.  
Multiple studies have shown that CD8α+ are more efficient at cross-presentation than their 
CD8α- counterparts. Pooley et al., showed that CD8α+ DCs were the most effective subset at 
MHC class I-restricted presentation of soluble OVA to CD8+ T cells (676), with others adding 
that CD8α+ DCs, and not the CD8α-, were capable of cross-presentation with cell-associated 
antigen, leading to CTL responses (144). One study has shown that DEC-205+ DCs, a C-type 
lectin mainly expressed on CD8α+ DCs, were required for antigen-specific priming of CD8+ 
T cells (677). In agreement with these studies, our finding of no detectable CTL killing in 
Clec9A-DTR mice highlights their importance in priming of CTLs.  
In the absence of Clec9A+ DCs, killing from CTLs induced from poly I:C immunotherapy 
was undetectable. However, 4T1 tumours treated with poly I:C in the absence of Clec9A+ 
DCs have slowed primary tumour growth and prolonged survival (Figure 4.12). Therefore, an 
efficient anti-tumour response is still initiated. This could suggest that in the absence of 
Clec9A+ DCs, another DC population is able to take over the function of cross-presentation of 
tumour antigen and that there are redundant roles with multiple DC subsets (79,678). Studies 
have found that both the CD8+ and CD8- DCs, as well as moDCs, are able to prime effective 
CTLs in vivo (143,146,164). Furthermore, there may be other effector cell populations 
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involved in anti-tumour responses in addition to CTLs, as NK cells have been shown to 
contribute to poly I:C immunotherapy (141) and ILC1s have recently been shown to exhibit 
potent cytotoxicity against a murine mammary tumour model (679). 
Effective anti-tumour responses against B16 tumours in BATF3 KO mice were also observed, 
despite a reduction in killing by CTLs. I have shown, in accordance with other studies 
(77,78,668), that CD8α+ DCs are still present in BATF3 KO mice (Figure 5.3), a population 
associated with effective cross-presentation. As mentioned above, there are also other DC 
subsets that may be contributing to cross-presentation in BATF3 KO mice. Therefore, the 
influence of other DCs involved in CTL priming in the absence of Batf3-dependent DCs 
cannot be ignored. The DC subsets involved in antigen uptake and cross-presentation are 
explored further in Chapter 6. 
Another contributing factor to the uptake of antigen by DCs, is the type of antigen. Soluble 
antigen is freely accessible and will drain to the lymph node independent of cellular uptake 
(680,681). Therefore, the populations involved in presentation of soluble antigen may differ to 
those required for cell-associated antigen. It has been shown that uptake of cell-associated 
OVA was unaffected by a mannose receptor (MR) deficiency, an endocytic receptor. 
However, uptake of soluble OVA was impaired in MR-/- mice (682), highlighting differences 
between the two antigen types and mechanisms mediating antigen uptake. Indeed, cross-
presentation of soluble and cell-associated antigen is governed by distinct mechanisms, with 
an ITAM-signalling pathway involved in processing and presentation of cell-associated 
antigen, but not soluble (683). Therefore, the DCs involved in generating CTL responses in 
the context of soluble antigen may not accurately reflect the DCs involved in a tumour-
specific context that will be taking up and processing tumour antigen. 
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5.3.1 Conclusions 
In this chapter I have shown that in the absence of Batf3-dependent DCs, OVA-specific CTLs 
will proliferate in response to poly I:C immunotherapy. However, cytotoxic killing of targets is 
reduced compared to WT. Tumour-specific CTLs are capable of expansion in response to 
poly I:C immunotherapy, as well as producing IFNγ in the absence of Batf3-dependent DCs. 
Similar to Clec9A-DTR mice, MSU+M.smegmatis immunotherapy is no longer effective in the 
absence of Batf3-dependent DCs; whereas poly I:C immunotherapy remains successful at 
slowing B16.F1 tumour growth. However, DCs are still required for efficacy of poly I:C 
immunotherapy, as depletion of CD11c+ cells rendered poly I:C ineffective. 
Investigation into the T cell response in the absence of Batf3-dependent DCs, found that 
OVA-specific T cells were capable of proliferating in response to cognate antigen, when 
combined with poly I:C immunotherapy. However, when examining cytotoxic function, it 
was revealed that mice lacking Batf3-dependent DCs had a reduced capacity to kill target 
cells. When investigating tumour-specific CTLs in the absence of Batf3-dependent DCs, the 
production of IFNγ from CD8+ T cells remained comparable between BATF3 KO and 
C57BL/6 mice.  
Collectively these results show that in the absence of Batf3-dependent DCs, poly I:C 
immunotherapy contributes to effective CTL responses that induce an appropriate anti-







Chapter 6  
Multiple DC subsets are 
involved in uptake and  
cross-presentation of antigen 
during immunotherapy 
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6.1 Introduction 
In Chapter 5, I showed that in the absence of Batf3-dependent DCs, there is an effective anti-
tumour response in mice treated with poly I:C immunotherapy and effector responses of 
CD8+ T cells are sufficient. These results suggest that in the absence of Batf3-dependent DCs, 
there may be other DC subsets that are capable of fulfilling the required roles to achieve anti-
tumour CTL responses. 
Poly I:C immunotherapy induced a large population of moDCs compared to 
MSU+M.smegmatis immunotherapy. As mentioned previously, moDCs are effective producers 
of pro-inflammatory cytokines (664-666) and have also been found to cross-present soluble 
and cell-associated antigen to T cells (143,151). Since moDCs have been found to play an 
important role in an anti-tumour immune response (142), it was important to assess their 
contribution to poly I:C immunotherapy. Given that moDCs originate from monocytes, 
monocyte targets were investigated. CCL2 is part of the C-C chemokine family that acts to 
recruit monocytes to sites of inflammation and CSF-1 is a cytokine involved in the promotion 
of macrophage and myeloid cell differentiation (94,301,684). Small molecule inhibitors, such 
as GW2580 and PLX3397, have been designed against CSF-1R kinase and have been used in 
clinical studies to treat breast cancer (685), showing good depletion of F4/80+ macrophages. 
One study found that treatment with PLX3397 reduced an anti-tumour response induced 
with synthetic long peptide immunotherapy (686), suggesting that the populations affected by 
targeting these proteins or chemokines are important for anti-tumour responses.  
MoDCs, as well as other DC subsets have been shown to take up soluble and cell-associated 
antigen. However, it is yet to be determined which DC subsets are superior at antigen uptake 
(129,144,145). One study showed that CD8α+ DCs preferentially acquire cell-associated 
antigen from dying cells (687). However, a recent study found that CD103+ DCs (but not 
CD8α+) within a tumour can preferentially acquire apoptotic cell-associated antigen (129).   
DC subsets involved in the uptake of antigen may be involved in the cross-presentation of 
antigen to drive T cell responses. Although CD8α+ and CD103+ DCs are known as superior 
cross-presenting DCs, there are other DC subsets that can cross-present antigen. Studies have 
reported that CD8α+ but also CD8- DCs could cross-prime cell-associated antigen (145,146). 
MoDCs have been shown to cross-present soluble protein in vivo, comparable to cDCs (143), 
and CD11b+ DCs have also been implicated in cross-presentation of soluble and cell-
associated antigen to stimulate both CD4+ and CD8+ T cells, respectively (149,150). 
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These findings highlight the complexity of DC populations and the shared functions between 
different DC subsets. The environmental stimuli present, the type of antigen and the state of 
activation of the DC all contribute to the ability to uptake antigen. Therefore, it was 
important to investigate the DC subset/s involved in antigen uptake and cross-presentation 
when stimulated with poly I:C immunotherapy.  
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6.1.1 Aims 
Since poly I:C immunotherapy causes an effective anti-tumour response in the absence of 
Clec9A+/Batf3-dependent DCs, the purpose of this chapter was to investigate which DC 
subset/s were involved in the uptake and cross-presentation of antigen. The hypothesis was 
that a DC subset/s, other than the specialist cross-presenting DCs, would be able to take up 
and cross-present antigen. 
The specific objectives were: 
• To explore whether moDCs are required for successful poly I:C immunotherapy 
• To investigate the DCs involved in antigen uptake and cross-presentation in the 
absence of specialised cross-presenting DCs 
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6.2 Results 
6.2.1 Targeting CCL2 or CSF-1 is ineffective at reducing moDCs 
To determine whether moDCs are a vital DC population for the success of poly I:C 
immunotherapy, various mechanisms to deplete/block recruitment of the population were 
explored in a number of pilot experiments. These exploratory experiments were necessary as 
to date, there are no appropriate mouse models to achieve specific depletion of moDCs. CSF-
1 and CCL2 were attractive monocytic targets to attempt moDC depletion. CSF-1 is involved 
in myeloid cell differentiation and survival of monocytes and CCL2 plays an important role in 
the recruitment of monocytes in inflammatory conditions. In light of these roles, CSF-1 and 
CCL2 were investigated for efficacy in depletion of moDCs. BALB/cByJ mice with 4T1 
tumours were administered αCCL2, αCSF-1 or an appropriate isotype control via i.p. 
injection. Tumours and tumour dLNs were taken the following day to assess depletion of 
monocytes and moDCs (Figure 6.1 A). Monocytes were gated as CD11b+Ly6C+ and moDCs 
as MHCIIintCD11cintCD11b+Ly6C+Ly6B+ (Figure 6.1 B). 
The proportion of monocytes within the dLN was significantly reduced with αCCL2 
treatment, however total numbers remained unaffected (Figure 6.1 C). Similar results were 
found with αCSF-1 antibody treatment, with a decrease in the proportion of monocytes, yet 
no change in absolute monocyte number. The proportion of moDCs was slightly reduced 
with αCCL2 and αCSF-1 treatments, though this was not significant. However, the total 
number of moDCs remained the same as the isotype control (Figure 6.1 C). Within the 4T1 
tumour, αCCL2 and αCSF-1 decreased the proportion of monocytes, although monocyte 
numbers remained the same as the control in both antibody treatments. The proportion of 
moDCs within the tumour was not decreased with either αCCL2 or αCSF-1 treatment, and 
total numbers were unaffected (Figure 6.1 D). 
These results show that targeting of either CCL2, or CSF-1 can reduce monocytes within the 
4T1 tumour and tumour dLN. However, these antibodies are insufficient for the depletion of 
moDCs within the tumour or tumour dLN. 
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Figure 6.1: A single treatment with either aCCL2 or aCSF-1 was unsuccessful at 
depleting moDCs. A) BALB/cByJ mice bearing orthotopic 4T1 tumours were treated with 
aCCL2, aCSF-1 or an appropriate isotype control on day 8 following tumour injection. 
Depletion was checked in the tumour and dLN 24 hours later. B) Cells were previously gated 
for singlets and live. Populations were as follows: Monocytes (CD11b+Ly6C+), moDCs: 
(MHCIIintCD11cintCD11b+Ly6C+Ly6B+). C&D) Percentage and total number of populations 
within the tumour and dLN are shown as mean ± SEM. Statistical evaluation was by 
Kruskal-Wallis with Dunn’s post-test. *p<0.05.  
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6.2.2 Treatment with the CSF-1R inhibitor GW2580 is unsuccessful 
at reducing moDCs 
The small molecule CSF-1 inhibitor, GW2580, was reported to be successful at depleting 
moDCs in a B16 melanoma (142) as well as pancreatic cancer (688), and was therefore 
investigated in the 4T1 model. Tumour-bearing BALB/cByJ mice were administered 
pertitumoural treatments of poly I:C and received GW2580 by oral gavage, 4 hours prior to 
each immunotherapy treatment. Tumours and dLNs were harvested two days after the final 
immunotherapy treatment and analysed for depletion (Figure 6.2 A). Monocytes were 
identified as CD11b+MHCII+ and moDCs as MHCIIintCD11cintCD11b+Ly6C+ (Figure 6.2 
B).  
There was no difference between absolute dLN cell numbers in mice treated with poly I:C 
either with or without GW2580. Interestingly, GW2580 treatment significantly increased 
moDCs and monocytes over the PBS control (Figure 6.2 C). Poly I:C treatment did not 
induce an increase of moDCs within the dLN, which is atypical. Nonetheless, there was no 
difference in the monocytes and moDC counts between poly I:C alone, or in combination 
with GW2580 treatment. In the tumour, there was no significant difference in total cell counts 
or tumour weight between GW2580 and GW2580 with poly I:C (Figure 6.2 D). However, 
there was a trend for decreased tumour weight in poly I:C treated groups, both with and 
without GW2580. The number of moDCs between the PBS control and GW2580 treated 
mice was decreased, although not significantly. However, GW2580 treatment in combination 
with poly I:C led to an increased number of moDCs compared to GW2580 alone (Figure 6.2 
D). There was no difference to the number of monocytes between all groups. 
Targeting of CSF-1 with GW2580 was unsuccessful at depleting of monocytes or moDCs 
within the tumour and tumour dLN. There was a trend towards decreased moDCs in the 
tumour with GW2580 treatment, that was reversed with the addition of poly I:C treatment. 
This result suggests that any effect of GW2580 on the moDC population is not robust enough 
for depletion when in the presence of stimuli that increase moDCs, as in the case of poly I:C 
immunotherapy. The decrease in tumour weight with poly I:C immunotherapy in 
combination with GW2580 also suggests that poly I:C immunotherapy is still effective in the 
presence of GW2580. 
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Figure 6.2: Treatment with the CSF-1 inhibitor GW2580 does not reduce moDCs 
in 4T1 tumour or tumour dLN. A) BALB/cByJ mice bearing orthotopic 4T1 tumours 
were administered GW2580 starting from day 8 following tumour injection. GW2580 was 
made up in methylcellulose and administered by oral gavage 4 hours before immunotherapy. 
Poly I:C was administered peritumourally around the tumour on days 8, 10, 12 and 14. 
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Tumours and dLNs were harvested on day 16 and analysed by flow cytometry B) Cells were 
previously gated for singlets and live. Populations were as follows: Monocytes 
(CD11b+MHCII+), moDCs: (MHCIIintCD11cintCD11b+Ly6C+). C&D) Total numbers are 
shown as mean ± SEM. Statistical evaluation was by two-way ANOVA with the Bonferroni 
post hoc test. *p<0.05. 
 
6.2.3 Treatment with the CSF-1R inhibitor PLX3397 depletes 
multiple myeloid populations within B16 tumours 
Another potential mechanism of targeting moDCs for depletion was the CSF-1R tyrosine 
kinase inhibitor, PLX3397. PLX3397 has primarily been used to deplete tumour associated 
macrophages with great success (686,689). We wanted to investigate whether PLX3397 would 
successfully target and deplete moDCs induced with poly I:C treatment. C57BL/6 mice 
inoculated with B16 tumours were administered specialty feed containing PLX3397. Drug-
laced feed was administered daily from day five following tumour inoculation, and refreshed 
daily throughout the experiment. The tumour and tumour dLN was harvested two days after 
the last dose of poly I:C immunotherapy to assess depletion (Figure 6.3 A). Monocytes and 
moDCs were gated as previously described (Figure 6.1). DCs were gated from total 
MHCII+CD11c+ and macrophages were classed as F480+CD11b+ (Figure 6.3 C). MDSCs 
within the tumour were characterized as Ly6G+CD11b+. Due to limited drug availability, 
there was no PLX3397 control.  
Treatment of B16 tumours with poly I:C immunotherapy was successful at slowing tumour 
growth, which is observed as early as day 14 following tumour injection. The addition of 
PLX3397 did not affect the slowing of tumour growth, with a significant difference observed 
with PLX3397 + poly I:C compared to the untreated control (Figure 6.3 B). When 
investigating the myeloid populations in the dLN, PLX3397 drug treatment was successful at 
depleting the absolute number of macrophages in the dLN, as reported (686,689). However, it 
also depleted DCs and monocytes. There was a trend for less moDCs with poly I:C in 
combination with PLX3397, although not statistically significant (Figure 6.3 D). Within the 
tumour, PLX3397 treatment decreased total tumour cell count, as well as tumour weight. 
PLX3397 successfully decreased the total number of all myeloid populations investigated: 
MDSCs, monocytes, DCs and moDCs (Figure 6.3 E). However, in this experiment poly I:C 
treatment reduced the number of moDCs within the tumour, contrary to previous results 
(Figure 6.3 E). 
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Figure 6.3: PLX3397 depletes multiple myeloid subsets within the B16 tumour 
and tumour dLN. A) C57BL/6 mice were inoculated with B16 tumours in the flank. 5 days 
later feed containing PLX3397 was administered ad libitum and topped up daily for the 
continuation of the experiment. Poly I:C immunotherapy was administered peritumourally on 
days 7, 9, 11 and 1. Tumours and dLNs were harvested on day 15 and analysed by flow 
cytometry. B) Poly I:C treatment in combination with PLX3397 significantly reduced tumour 
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size. C) Cells were previously gated for singlets and live. Populations were as follows: 
Monocytes (CD11b+Ly6C+), moDCs (MHCIIintCD11cintCD11b+Ly6C+). Macrophages in 
the dLN (F480+CD11b+), MDSCs in the tumour (Ly6G+CD11b+). D&E) Total numbers are 
shown as mean ± SEM. Statistical evaluation was by Kruskal-Wallis with Dunn’s post-test. 
*p<0.05, **p<0.01. Statistical evaluation of tumour growth curves was by two-way ANOVA 
with the Bonferroni post hoc test. *p<0.05, ****p<0.0001 on day 14. 
 
These results suggest that PLX3397 is successful at reducing moDCs within the tumour and 
tumour dLN. However, all other myeloid populations investigated were also depleted, 
including DCs, macrophages and monocytes. Since DCs were shown to be vital to the success 
of poly I:C treatment (Figure 5.2), further experiments using PLX3397 were not undertaken.  
Targeting of CCL2, CSF-1 or CSF-1R via antibody depletion or small molecule inhibitors, 
was either unsuccessful at depleting monocytes and moDCs, or extremely efficacious, with 
multiple myeloid populations being targeted. Due to the difficulties with data interpretation 
when several DC subsets are absent, the pursuit to deplete moDCs was abandoned. 
 
6.2.4 Increased uptake of soluble OVA by CD11b+ DCs in mice 
treated with poly I:C immunotherapy 
Mice lacking specialist cross-presenting DCs had T cells that were capable of effector function 
and could therefore produce a successful anti-tumour immune response after poly I:C 
immunotherapy. However, DCs were necessary for efficacy of poly I:C immunotherapy, as 
shown by CD11c-DTR chimera experiments (Figure 5.2), thus indicating that other DC 
subsets are able to cross-present antigen in the absence of CD103+ DCs. Therefore, we 
wanted to investigate the DC populations that were capable of taking up soluble antigen. To 
examine this ability, C57BL/6 mice were primed with poly I:C immunotherapy to induce 
moDCs. The following day mice received another dose of poly I:C and were administered 
AF647-labeled OVA. Mice were injected with OVA alone as a control for the uptake of 
antigen that is not driven by poly I:C immunotherapy. The dLNs were harvested one day 
after the dose of OVA and populations were analysed for OVA uptake (Figure 6.4 A). DC 
populations were identified and gating was based on mice that did not receive OVA (Figure 
6.4 B).  
Poly I:C treatment significantly increased the number of CD103+, triple negative (TN), 
CD8α+ and moDCs DC populations in the LN.  




Figure 6.4: CD11b+ DCs show increased uptake of OVA in response to poly I:C. 
A) C57BL/6 mice were primed with poly I:C two days prior to harvest, followed by another 
dose of poly I:C and AF647-labeled OVA one day prior. OVA controls were administered 
OVA one day prior and dLNs were harvested the next day and analysed for OVA uptake by 
flow cytometry. B) Cells were previously gated for singlets and live. Representative gating of 
FACs plots on DC populations. C) Absolute DC numbers are expressed as mean ± SEM. 
Data are pooled from two experiments with 3-4 mice/group and statistical evaluation was by 
two-way ANOVA with the Bonferroni post hoc test. **p<0.01, ****p<0.0001 (Total counts). 
#p<0.05 (OVA+ counts). 
 
These DC populations were all capable of taking up OVA, and showed increased uptake with 
poly I:C treatment, although not significant. The CD11b+ subset significantly increased OVA 
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uptake with poly I:C treatment, with over half of the total number of CD11b+ DCs being 
OVA+ on average (Figure 6.4 C). 
These results show that CD103+, TN, CD8α+, moDCs and CD11b+ DCs are all capable of 
taking up soluble antigen. Nevertheless, these results also suggest that CD11b+ DCs are 
superior in their ability to take up soluble antigen as they were the population with the highest 
uptake. 
 
6.2.5 Multiple DC subsets are able to acquire cell-associated 
antigen 
To gain further insight into whether different DC subsets would preferentially take up cell-
associated antigen and to emulate what may be occurring in mice bearing tumours, we 
examined the uptake of fluorescently labelled tumour material. C57BL/6 mice were injected 
with irradiated CTO-labelled B16.OVA cells. Mice received either poly I:C immunotherapy 
or PBS as a control. The dLNs were harvested the following day and analysed for cell uptake 
(Figure 6.5 A). DC populations were identified as previously shown (Figure 6.4), with gating 
based on PBS mice that did not receive B16.OVA tumour cells (Figure 6.5 B).  
CD103+, TN, CD8α+, moDCs and CD11b+ DC populations were able to take up B16.OVA 
cells, as detected by CTO signal. There was a significant increase in B16.OVA uptake with 
poly I:C treatment compared to B16.OVA alone in all DC populations. There was no 
difference in the number of B16.OVA+ cells when comparing the groups receiving B16.OVA 
and poly I:C on either day -1 or -2 (Figure 6.5 C).  
These results show that the DC populations investigated, CD103+, TN, CD8α+, moDCs and 
CD11b+ DCs, can all take up cell-associated antigen. There was no one population 
preferentially taking up antigen compared to the other subsets (for proportions, see Appendix 
E). 
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Figure 6.5: Multiple DCs uptake cell-associated antigen. A) C57BL/6 mice were 
administered irradiated CTO-labeled B16.OVA subcutaneously either with or without poly 
I:C. One group was treated 2 days prior to harvest, the other one day prior. dLNs were 
harvested and analysed for B16.OVA uptake by flow cytometry. B) Cells were previously 
gated for singlets and live. Representative gating of FACs plots on DC populations. C) 
Absolute numbers of B16.OVA+ DC are expressed as mean ± SEM. Data are pooled from 
two experiments and statistical evaluation was by Kruskal-Wallis with Dunn’s post-test. 
*p<0.05, **p<0.01, ***p<0.0001, ****p<0.0001.  
 
6.2.6 CD11b+ and CD11b- DCs cross-present soluble antigen to 
induce OT-I proliferation 
To investigate the ability of different DC subsets to induce MHC class I restricted antigen-
specific T cell proliferation, C57BL/6 mice were treated twice with poly I:C and received 
OVA on the last treatment. Mice receiving poly I:C alone were included for controls. The 
dLNs were harvested one day following OVA (Figure 6.6 A) and DC populations were 
identified and sorted by the gating strategy shown (Figure 6.6 B). Three main subsets were 
investigated: CD11b- DCs, CD11b+ DCs and moDCs. According to previous results, all these 
subsets are capable of taking up soluble antigen. CD8+ T cells purified from OT-I mice were 
labelled with CFSE and plated with the DC cell populations, with a range of DC:T cell ratios. 
CD11b+ DCs sorted from poly I:C treated mice were plated with OVA protein in culture as a 
positive control. The cells were harvested three days later and OT-I cell proliferation was 
assessed by CFSE dilution (Figure 6.6 A). OT-I cells cultured in the absence of DCs had 
extremely poor viability, with few surviving cells that were not undergoing proliferation, 
allowing us to set appropriate gates for assessing the dividing population (Figure 6.6 C). OT-I 
cells were identified by gating on CD45.1+CD8+ cells. 
OT-I cells that were plated with CD11b+ or CD11b- DCs were able to survive and 
proliferate, with >80% of cells having divided, which was comparable to the positive control 
(Figure 6.6 D). There was no significant difference between CD11b+ or CD11b- DCs in the 
proportion of proliferated OT-I cells.  
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Figure 6.6: CD11b+ and CD11b- DCs were able to cross-present antigen loaded 
in vivo resulting in OT-I proliferation in vitro. A) C57BL/6 mice were primed with 
poly I:C on day 0, following by another dose of poly I:C the following day either with or 
without OVA. DC populations were sorted from the dLN the following day and plated with 
CFSE labelled CD8+ purified OT-I cells. Plates were harvested on day 3 and analysed for 
OT-I proliferation by CFSE dilution. CD11b+ DCs from poly I:C treated mice were plated 
with OVA as a positive control. OT-Is alone were plated as a negative control. B) Cells were 
previously gated for singlets and live. Representative gating of FACs plots on DC populations. 
All DCs were gated from total MHCII+CD11c+. Populations were as follows: CD11b- 
(MHCII+CD11c+), CD11b+ (MHCII+CD11c+ CD11b+Ly6B-Ly6C-), moDCs 
(MHCII+CD11c+ CD11b+Ly6B+Ly6C+). C) Cells were previously gated for singlets and live. 
Representative gating of FACs plots for OT-I cells and histograms showing CFSE dilution. D) 
Percentage of divided OT-I cells expressed as mean ± SEM. Statistical evaluation was by two-
way ANOVA with the Bonferroni post hoc test. ****p<0.0001. 
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MoDCs, however, did not cause OT-I cells to proliferate and there was a significant reduction 
in the percent divided population compared to those cultured with CD11b+ or CD11b- DCs 
(Figure 6.6 D).  
These results suggest that CD11b+ and CD11b- DCs are able to cross-present antigen to 
induce antigen-specific T cell proliferation. However, OT-I proliferation was not detectable 
after co-culture with moDCs. 
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6.3 Discussion 
The results described in this chapter show that attempts to deplete moDCs through antibody 
depletion or small molecule inhibitors were unsuccessful. We also show that multiple DC 
subsets are capable of the uptake of soluble and cell-associated antigen. However, CD11b+ 
DCs had the highest uptake of soluble antigen. Both CD11b+ and CD11b- DCs could cross-
present soluble antigen to induce T cell proliferation in culture; however, moDCs were 
unsuccessful. 
 
Depletion of moDCs using antibodies and inhibiting drugs 
There were a number of reasons contributing to the belief that moDCs might be playing an 
important role in poly I:C immunotherapy. First, poly I:C induces high levels of systemic 
CCL2, a driver of monocyte recruitment (98,690). MoDCs accumulated within the tumour 
and tumour dLN, and DCs were found to be necessary for efficacy of poly I:C 
immunotherapy; however, CD8α+ and CD103+ DCs specifically, were not required. 
Therefore, moDCs were investigated as the potential DC population responsible for effective 
anti-tumour immune responses.  
Targeted depletion of moDCs proved difficult, as all strategies would eliminate other 
monocyte or DC populations in addition. A molecule solely expressed on moDCs is yet to be 
discovered, and may not exist since moDC share cell surface markers with both monocytes 
and DCs (96,691). CCL2 and CSF-1 were targeted as they are involved in monocyte 
differentiation and recruitment to inflamed sites (94,684). However, in mice bearing 4T1 
tumours, neither αCCL2 or αCSF-1 were successful at depleting monocytes or moDCs 
(Figure 6.1). These mice did not receive any immunotherapy, therefore the population of 
moDCs was very small.  
There are multiple factors that may have contributed to lack of successful depletion, including 
the concentration of the antibodies and the number of administrations. Studies using αCCL2 
have achieved successful monocyte depletion using two, or even one dose of 100 µg per mouse 
(142,692). However, others have used higher concentrations and multiple doses (300). Anti-
CSF-1 used at a comparable dose of 300 µg has been shown to reduce TAMs; however, 
monocytes were not investigated and multiple doses were administered (693). Taken together, 
these results suggest that multiple administrations might be necessary to achieve successful 
depletion. However, further investigations within our group found that increasing both the 
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concentration of αCCL2 and αCSF-1, and the number of treatments, was still unsuccessful at 
moDCs depletion. This was not conducted in mice bearing 4T1 tumours; therefore, further 
investigations would be required. Another CSF-1R inhibitor, GW2570 has been used to 
deplete TAMs and MDSCs (694), and has also successfully depleted monocytes and moDCs 
(142). Use of GW2580 in BALB/cByJ mice bearing 4T1 tumours, showed no efficacy at 
reducing moDCs or monocytes in the tumour or tumour dLN (Figure 6.2). The studies 
mentioned were conducted in C57BL/6 mice, thus GW2580 may be less effective in mice 
with a different genetic background to C57BL/6 mice, such as BALB/cByJ mice. Different 
tumour models may also impact efficacy of treatment. Studies have shown that 4T1 and B16 
tumours have different myeloid infiltration, with 4T1 tumours showing increased infiltration 
with MDSCs and TAMs (639). Despite this increase, GW2570 was still unsuccessful. 
PLX3397, another CSF-1R inhibitor, has been used previously to deplete TAMs and was also 
found to decrease F4/80+ macrophages in the blood (686,689). Use of PLX3397 in C57BL/6 
mice bearing B16 tumours was successful at depleting macrophages, monocytes and moDCs; 
both within B16 tumour and dLN (Figure 6.3). However, DCs were also depleted, which 
would confound interpretation of results. 
Due to the lack of successful moDCs depletion with αCCL2, αCSF-1 and GW2580, and 
overall decrease in myeloid populations with PLX3397 treatment, the goal to deplete moDCs 
was halted and other research questions were pursued. 
 
Multiple DC subsets acquire and cross-present antigen 
DCs can take up both soluble and cell-associated antigen in vivo; however, there is debate over 
which subsets preferentially take up particular forms of antigen. One study found that only 
CD8α+ DCs, and not CD8- spleen DCs, could cross-prime T cells when investigating 
exogenous cell-associated antigen (144), whereas others have reported that both the CD8α+ 
and CD8- DCs can cross-prime cell-associated antigen (145,146). CD103+ DCs have been 
shown to preferentially take up antigen and bring it to the dLN, with others adding that 
CD103+ DCs preferentially acquire apoptotic cell-associated antigen (73,129). However, 
another study showed that CD8α+ DCs can also preferentially acquire cell-associated antigen 
from dying cells (687). It is clear that the environment and the type of antigen influence the 
acquisition of antigen, and rather than one specialised population, the ability to obtain antigen 
is shared among the DC family (148,695). In light of this, it was important for us to investigate 
the DC subsets that were involved in the uptake of antigen in the context of poly I:C 
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immunotherapy. Using fluorescently labelled OVA protein that was administered 
subcutaneously, we found that CD8α+, CD103+, TN, CD11b+ and moDCs were all capable 
of taking up OVA. Cells within the dLN that were not DCs, most likely B cells, also took up 
OVA. Interestingly, over half of the CD11b+ DCs in the dLN after poly I:C treatment had 
taken up OVA (Figure 6.4).  
There are a number of factors that could be contributing to this result. One study found that a 
population of LN-resident CD11b+ DCs reside in the lymphatic sinus endothelium, and can 
capture and present antigen to T cells (169). It is also known that soluble antigen can freely 
drain to the LN, independent of transport through cells (680,681). Therefore, it could be that 
the CD11b+ DCs are some of the first cells to be in contact with OVA due to proximity to the 
lymphatics, and consequently take a large quantity of the available protein. If this were the 
case, then CD11b+ DCs may not necessarily be superior to other subsets in their ability to 
take up soluble antigen. Rather, the considerable antigen uptake may reflect a benefit due to 
an advantageous position.  
When looking at cell-associated antigen uptake by DCs, we found that CD8α+, CD103+, TN 
CD11b+ and moDCs were all capable of taking up B16.OVA material, and no one subset had 
increased uptake over another (Figure 6.5). In addition to the studies mentioned above, others 
have shown that moDCs can take up antigen (151,696). One paper argued that moDCs were 
better at taking up soluble protein than CD141+ DCs; however, the CD141+ DCs were more 
efficient at uptake and cross-presentation of cell-associated antigen than moDCs (696).  
Therefore, in agreement with previously published work, we have shown that multiple DC 
subsets are capable of the uptake of cell-associated antigen. However, the ability of a DC to 
take up antigen does not necessarily predict the processing and presentation of that antigen by 
the DC. Studies have shown that migratory DCs that have acquired antigen are not 
necessarily the subset to present it, and there can be passing of antigen to other DCs 
(167,168,697). Therefore, further investigations need to be undertaken to determine whether 
antigen transfer is occurring in poly I:C treated mice. 
Once DCs have acquired antigen, they process and present it on MHC class I, a process 
known as cross-presentation (608). Just as there is debate over specialisation of DC subsets for 
antigen uptake, it is similarly controversial when categorising DC subsets that are able to 
cross-present antigen. Previous studies focused on CD8α+ and CD103+ DCs, which are still 
referred to as the “superior” cross-presenting DCs (52,144,164,611). However, it has been 
proposed that moDCs can be included as a subset that can cross-present both soluble and cell-
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associated antigen. One study found moDCs superior at cross-presentation to both CD8+ and 
CD4+ T cells (143). Yet others found moDCs to be less efficient than cDCs for CD4+ T cell 
proliferation (151). To investigate cross-presentation, DC subsets were sorted from mice that 
were treated with OVA and poly I:C in vivo. DCs were plated with CD8+ purified OT-I cells 
to assess antigen-specific proliferation. The CD11b+ and CD11b- DC subsets induced 
successful and comparable OT-I proliferation. However, moDCs did not induce OT-I 
proliferation (Figure 6.6). 
There could be a number of explanations for why moDCs did not induce OT-I proliferation 
in our model. First, we and others have shown that moDCs can take up antigen; however; 
processing and presentation of antigen may differ between moDCs and cDCs. Others have 
shown that moDCs were less efficient than cDCs at direct or indirect antigen presentation to 
induce CD4+ T cell proliferation, which was partially dependent on NO (151). Indeed, it has 
been found that production of NO can have an inhibitory effect on T cell proliferation (698). 
Another study has shown that there are inherent differences between the pathways of cross-
presentation between cDCs and moDCs, as they are dependent on the insulin-regulated 
aminopeptidase and mannose receptor for OVA transport and MHC I loading, respectively 
(699). These differences in processing and presentation of antigen could significantly affect the 
corresponding T cell response.  
These differences in the ability to process and present antigen could change the number of 
DCs required to elicit T cell proliferation. The efficacy of moDCs may differ from other DCs, 
therefore a specific number of moDCs might be required to reach a certain “threshold” 
required to achieve detectable T cell proliferation. However, Cheong et al., used as few as 200 
moDCs in culture and saw successful T cell proliferation, with soluble and cell-associated 
antigen (143).  
The survival of the DCs in culture was not investigated, thus there is the possibility that 
moDCs have not survived the purification and sorting steps as well as the other DC subsets, 
potentially affecting the proliferation of OT-I cells. However, one study showed that antigen 
recognition by T cells in vitro can occur rapidly, with DC:T cell interactions lasting on average 
12 minutes (700). This would suggest that if moDCs were unable to survive ex vivo, there may 
have been enough time where they could present antigen to prime OT-I cells. 
Upon injection of AF647-labeled OVA, it was found that CD11b+ DCs took up the largest 
quantity. However, when DCs were plated with OT-I cells to assess cross-presentation, both 
the CD11b+ and the CD11b- induced comparable OT-I proliferation. Taken together, this 
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could suggest that the CD11b- DCs, which included the CD8α+ and the CD103+ DCs, were 
superior in their ability to present antigen to T cells, despite a lower amount of antigen taken 
up when compared to the CD11b+ DCs. Although CD11b+ DCs are mostly known for 
inefficient cross-presentation when compared to CD8α+ DCs (611,699,701), there is evidence 
to suggest they can cross-present. One study found that although CD8α+ DCs had 
preferential uptake of soluble and cell-associated antigen, it was the CD8α-CD11bhi DC subset 
that had higher stimulation of OVA+CD4+ T cells (149). Another group found that in skin 
allografts, it was host CD11b+ DCs that infiltrated the graft to capture antigen and cross-
prime graft CD8+ T cells (150). These results show that CD11b+ DCs are capable of antigen 
uptake for cross-presentation.  
It is also important to note that DC uptake of cell-associated antigen from tumour cells that 
have been injected s.c., is not necessarily reflective of uptake of antigen from an established 
tumour. Suppressive factors from the tumour microenvironment, location and activation of 
DCs, as well as access to antigen would all influence the ability of a DC to take up tumour 
material for transport to the dLN. Therefore, distinction between the two is required when 
drawing comparisons. 
These results show that multiple DC subsets are capable of the uptake and cross-presentation 
of antigen, which suggests that in the absence of Clec9A+/Batf3-dependent DCs, other DC 
subsets may be sufficient to cross-prime T cells to achieve effective anti-tumour responses in 
vivo. 
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6.3.1 Conclusions 
In this chapter I presented experiments designed to understand why poly I:C immunotherapy 
remained effective in the absence of specialist cross-presenting DCs by examining the ability 
of different DC subsets, the CD103+, TN, CD8α+, moDCs and CD11b+ DCs to take up and 
present soluble and cell-associated antigens in vivo and in vitro. 
Initial experiments attempted to deplete moDCs in vivo using antibodies targeting monocyte 
chemoattractant chemokines, or small molecule inhibitors towards CSF-1R. Unfortunately, 
these experiments were unsuccessful as they either failed to deplete the intended population, 
or non-specifically depleted several monocyte and DC populations. 
Further experiments investigating the DC subsets involved in antigen uptake in vivo revealed 
that multiple DC subsets were capable of acquiring both soluble and cell-associated antigen, 
with CD11b+ DCs having the largest uptake of soluble antigen. When antigen loaded DCs 
were sorted ex vivo and cultured with CD8+ purified OT-I cells to assess cross-presentation, 
CD11b+ and CD11b- DCs were equally capable of inducing proliferation, whereas moDCs 
were unable to do so.  
Taken together, these results suggest that in the absence of Clec9A+/Batf3-dependent DCs, 
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7.1 Main findings 
The overall aim of this thesis was to investigate the involvement of specialist cross-presenting 
DCs in the efficacy of cancer immunotherapy. The immunotherapies used were poly I:C or 
the combination of MSU+M.smegmatis. Treatment with poly I:C or MSU+M.smegmatis was 
successful at reducing 4T1 primary tumour size and prolonging survival, despite minimal 
changes in the immune cell infiltrate into tumours. However, both immunotherapies 
increased the number of moDCs within the tumour and dLN.  
With the goal of achieving greater anti-tumour responses, combination treatment with 
doxorubicin and immunotherapy was also investigated. Doxorubicin treatment of 4T1 
tumours in vivo was successful at slowing primary tumour growth, and the addition of poly I:C 
immunotherapy enhanced anti-tumour responses, with reduced primary tumour growth and 
prolonged survival compared to either therapy alone.  
Investigation into the role of specialist cross-presenting DCs revealed that in their absence, 
MSU+M.smegmatis immunotherapy was no longer effective at slowing tumour growth and 
prolonging survival. In contrast, poly I:C immunotherapy was still able to exhibit anti-tumour 
effects in the absence of specialist cross-presenting DCs. Further examination into the priming 
of CD8+ T cells with poly I:C revealed that the capability to proliferate and kill target 
populations was present in the absence of CD103+ DCs; however, killing was impaired. 
We discovered that multiple DC subsets were capable of the uptake of soluble and cell-
associated antigen, and through cross-presentation, were able to induce antigen-specific T cell 
proliferation ex vivo. These findings suggest that in the absence of specialist cross-presenting 
DCs, there are other DC populations that once stimulated with immunotherapy, are capable 
of inducing effector T cell functions to achieve successful anti-tumour responses (Figure 7.1). 
  









Figure 7.1: Summary of findings with poly I:C and MSU+M.smegmatis 
immunotherapies in the absence of Clec9A+/Batf3-dependent DCs. 
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7.1.1 Combination therapy with doxorubicin and poly I:C provides 
increased tumour protection  
Early work investigating the sensitivity of 4T1 cells to chemotherapeutic treatment with 
doxorubicin revealed that 4T1 cells were susceptible to chemotherapy, and responded to low 
doses of doxorubicin. Indeed, doses as low as 40 nM caused cell senescence, with blast-like 
morphology and cell death. Initial plans were made to create a doxorubicin-resistant cell line 
to investigate the sensitivity to immunotherapy. I used a method that has been described in 
other cell lines (581). However, my experiments using step-wise increases in the concentration 
of doxorubicin were not able to produce resistance, and the cells would always succumb to 
drug-induced toxicity. One study generated a doxorubicin resistant cell line from 4T1 cells 
isolated from the lung of a mouse that was treated with doxorubicin, which were no longer 
responsive to doxorubicin when injected i.v. into new hosts (580). Therefore, culturing 
doxorubicin-exposed 4T1 cells ex vivo may be a better approach at obtaining a resistant cell 
line.  
Particular markers have been associated with resistance to chemotherapy. Investigation into 
Ly6A/E, as measured by protein, revealed that a portion of the 4T1 population increased 
expression in response to doxorubicin, which was also observed at the mRNA level. Further 
investigation into the expression of mRNA encoding efflux pumps was used as another 
measure of drug resistance (513). However, no changes in relative expression were discovered, 
in concordance with observed toxicity in the population. Further studies would be required to 
investigate the development of chemotherapy resistance in 4T1 cells and the mechanisms used 
to acquire resistance. 
 
Chemotherapy is effective at reducing tumour mass, causing damage leading to cell death. 
Nevertheless, some tumour cells escape elimination and the chemotherapy-exposed cells that 
remain, are capable of releasing factors into the tumour microenvironment or the stroma, 
which can have immune-suppressive effects (496). It was found that transient exposure of 
doxorubicin on 4T1 cells in vitro caused them to release factors that worked to inhibit T cell 
proliferation. This phenomenon has also been observed in chemotherapy treated GBM cells, 
which display enhanced immune suppressive activity that is mediated in part by PGE2 (495). 
Further investigations would be required to identify the factors present in the supernatant 
from doxorubicin treated 4T1 cells.  
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There are certain conditions where cell death can induce immune tolerance (12). Due to the 
toxic effects of doxorubicin on 4T1 cells, it is likely that the supernatant from treated cultures 
will contain factors released from dead and dying cells. Studies have shown that apoptosis-
induced production of ROS can compromise molecules related to immunogenicity, like 
HMGB1 (479). Oxidation of HMGB1 prevents binding to PRRs, halting the ability to 
promote immune responses. Therefore, doxorubicin may be causing disruption to effector 
immune responses through the modification of molecules contributing to immunogenicity. 
These results suggest that doxorubicin treatment of 4T1 cells induces the release of one or 
many soluble factors that have inhibitory effects on T cell proliferation. 
 
Chemotherapy remains one of the leading treatments for cancer today, and often it is only 
when patients become resistant to traditional chemotherapeutic agents that other strategies, 
such as immunotherapy, are explored. Therefore, we wanted to investigate whether tumours 
treated with chemotherapy would be responsive to immunotherapy. We investigated the 
combination of doxorubicin with immunotherapy in a murine model, whereby tumours were 
first exposed to doxorubicin given systemically, followed by immunotherapy peritumourally. 
Doxorubicin as a single agent was successful at slowing 4T1 tumour growth in vivo. However, 
combination treatment with doxorubicin and poly I:C acted additively and prolonged survival 
better than either monotherapy. Doxorubicin in combination with MSU+M.smegmatis was not 
successful at increasing anti-tumour effects. This result highlights that poly I:C and 
MSU+M.smegmatis operate through different mechanisms, and although anti-tumour 
responses are initiated with both treatments, only poly I:C immunotherapy successfully 
combined with doxorubicin. Studies have found that the cytotoxic effects of anthracyclines 
(including doxorubicin) are mediated by type I IFNs (702), and poly I:C is a well-known type I 
IFN inducer (361,364). Therefore, an increase in type I IFNs through poly I:C may drive 
existing cytotoxic responses initiated by doxorubicin. It would be of interest to investigate 
whether pre-treatment with poly I:C immunotherapy, prior to doxorubicin, would further 
enhance anti-tumour responses. 
Nonetheless, these results imply that only certain immunotherapies may be beneficial to use in 
combination with, or following chemotherapy. Greater insight in this area would be beneficial 
for translation to the clinic, as patients receiving immunotherapy have often received prior 
chemotherapeutic treatment. 
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7.1.2 Specialist cross-presenting DCs are required for specific 
immunotherapy 
Cross-presenting DCs are important for anti-tumour immune responses, and are known as 
superior antigen-presenting DCs. Mice lacking these DCs have shown impaired CTL 
responses to tumours (76). Therefore, it was important to investigate the role of specialist 
cross-presenting DCs in poly I:C and MSU+M.smegmatis immunotherapies. Using Clec9A-
DTR mice, we found that MSU+M.smegmatis was dependent on Clec9A+ DCs for effective 
anti-tumour responses; in contrast, poly I:C immunotherapy did not require this DC subset to 
exert anti-tumour effects. Since poly I:C and MSU+M.smegmatis immunotherapies work 
through different signalling mechanisms, one explanation could be that specific receptors on 
specialist cross-presenting DCs are necessary for successful MSU+M.smegmatis 
immunotherapy. M.smegmatis can be recognised by multiple receptors, including Clec4e 
(630,631). MSU causes inflammasome activation and the release of IL-1β (352), as well as a 
danger signal binding to DAMPs on DCs (370). Poly I:C is a large inducer of type I IFNs, 
however there seems to be redundancy within the IFNα/β pathways (364), which could 
operate through different DC subsets in the absence of Clec9A+ DCs. Despite the CD8α+ and 
CD103+ DCs being classified as the specialist cross-presenting DCs, studies have shown that 
this function is not limited to those DCs. In fact, many DC populations, including CD11b+, 
moDCs and CD8- DCs, have been shown to cross-present antigen (145,151,169). Therefore, 
in the absence of Clec9A+ populations, there are multiple DC subsets that could cross-present 
tumour antigen to initiate effective anti-tumour responses. 
Immune cell infiltration in tumours 
The investigation of immune cell infiltration into tumours has been pivotal to cancer research, 
and infiltration of specific immune cell populations into tumours has been correlated with 
favorable outcomes in patients. An early study found that CD8+ T cells in colon tumours were 
associated with better survival, showing that CD8+ TIL may serve as a prognostic factor for 
patient outcome (703). Another investigation into colorectal tumours found that a Th1 
immunity profile was correlated to a beneficial effect on clinical outcomes (704) and within 
other tumour types, such as non-small-cell lung cancer and solid tumours, lymphocyte 
infiltration is also correlated with better survival (604,705). Moreover, innate populations have 
also been implicated with better survival. Iwamoto et al., found that mature, CD83+ 
expressing DCs in breast tumours were correlated with relapse free survival, in patients with 
metastases to the LN (449). However, not all immune populations are associated with 
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beneficial outcomes. Infiltration of pDCs was correlated with shorter overall survival in breast 
cancer patients, therefore suggesting this DC population could play a role in tumour 
progression (126).  
Studies undertaken in mouse models have shown similar results (193,706), however different 
tumour models will vary in their immune profile. The 4T1 model is known to be poorly 
immunogenic, and results from this thesis found that populations of TIL within 4T1 tumours 
do not change greatly with immunotherapy, or between different immunotherapies. Murine 
tumour models also differ in immune cell composition, which can impact on the efficacy of 
immunotherapies. One study found that not only was the composition of particular myeloid 
populations vastly different between murine tumour models, but also the functionality of those 
cells. For example, MDSCs and neutrophils in 4T1 tumours produce more of an anti-
inflammatory protein, haptoglobin, than those found in B16 and HER2+ tumours (639,707). 
These tumour variations exhibited are not only found in murine models, but also present in 
patient-to-patient specificities and may have a large impact on the success of therapeutic 
intervention, in particular immunotherapy. 
The contribution of DCs to innate and adaptive responses in cancer 
Poly I:C and MSU+M.smegmatis immunotherapies induced moDCs in the dLN and tumour, 
which were capable of producing pro-inflammatory mediators. Due to the importance of 
moDCs in MSU+M.smegmatis immunotherapy (142), it was thought that they may have a 
critical role in poly I:C immunotherapy. Studies have found that moDCs are important for 
the early activation of NK and CD8+ T cells (143,708), and they have been shown to cross-
present antigen to induce antigen-specific T cell proliferation (69). However, specific depletion 
of moDCs was unsuccessful and therefore, we cannot rule out the contribution of moDCs to 
poly I:C immunotherapy in the 4T1 model, particularly in the absence of CD8α+ and 
CD103+ DCs. Conversely, moDCs have also been associated with accelerated metastases and 
promotion of immune escape (317,709). It is important to note that most of the information 
for moDCs has been discovered in the context of microbial infection; therefore, there is a 
need for further studies investigating moDCs in cancer and cancer immunotherapy. 
One particular DC subset, pDCs, have been associated with poor prognosis in breast cancer 
(126). However, there is also evidence that they are involved in anti-tumour responses 
(87,710). Moreover, pDCs have high TLR9 expression; therefore, it was thought that 
MSU+M.smegmatis immunotherapy may operate through pDCs, as CpG motifs and 
components from the bacteria could bind to TLR9 and cause activation of pDCs. When 
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looking at the proportion or number of pDCs, there was no change with the administration of 
either poly I:C or MSU+M.smegmatis. Investigation into the efficacy of both poly I:C and 
MSU+M.smegmatis in pDC-depleted mice revealed that immunotherapies were still effective at 
slowing tumour growth in the 4T1 model (Sabine Kuhn, data unpublished), therefore no 
further investigations were conducted. 
The effect of immunotherapy on metastases 
It is debated whether tumour cells metastasise early or late in tumour progression, with 
confounding contributing factors like differences in tumour models and time points 
investigated. Poly I:C or MSU+M.smegmatis immunotherapies are administered 8 days 
following tumour implantation, and are successful at reducing the number of 4T1 colonies in 
the lung. In the absence of Clec9A+ DCs, MSU+M.smegmatis immunotherapy was no longer 
effective at reducing primary tumour size. However, metastatic colonies of 4T1 cells were still 
reduced in the lung compared to untreated controls.  
This could suggest that 4T1 cells are disseminating late in tumour development, which 
complements the reported correlation between the primary tumour size and metastastic 
burden (711). This finding may also suggest that specialist cross-presenting DCs are important 
for reducing tumour-mass at the primary site, but may not be the key population involved in 
the reduction of metastatic colonies in the lung. Immunotherapy may cause activation of 
immune cells with cytolytic capabilities, which can directly kill tumour cells that have broken 
away from the primary site and are about to migrate. Due to restricted access to the core of a 
primary tumour, it may be that MSU+M.smegmatis given locally around the tumour can 
preferentially impact tumour cells that are primed to metastasise.  
Another possibility is that immunotherapy administered 8 days following tumour 
implantation, is successful at modifying the environment in the lung through the induction of 
cytokines or activation of migratory populations (712). These cytokines and/or cells could 
contribute to creating a hostile environment for tumour cells and inhibit the growth of any 
early metastastic colonies. This may be occurring in Clec9A+ depleted mice treated with 
MSU+M.smegmatis, who have reduced lung colonies but no changes in primary tumour size. It 
is important to clarify that the impact of poly I:C and MSU+M.smegmatis on other metastatic 
sites was not investigated and therefore, it cannot be ruled out that specialist cross-presenting 
DCs may be involved in reducing the metastatic burden in other sites.  
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Specificities of immunotherapies to tumour models 
The magnitude of the impact poly I:C and MSU+M.smegmatis immunotherapies have on 
tumour growth rates varies between different tumour models. It is yet to be determined if poly 
I:C or MSU+M.smegmatis immunotherapies are more effective for faster growing tumours. 
One study found that faster growing tumours had an increased response rate to 5-FU 
chemotherapy (713), providing evidence that kinetics of tumour growth can impact response 
to chemotherapy. However, a correlation between tumour growth rates and response to 
immunotherapies has not yet been demonstrated. B16 melanoma is known as a fast growing 
tumour and left untreated can reach large sizes rapidly (714). In slower growing models, such 
as the 4T1 mammary cancer, the tumour growth delay between the untreated control and 
immunotherapy groups is reduced compared to that observed in B16 tumours. This suggests 
the tumour growth kinetics may contribute to the efficacy of immunotherapy and the 
differences observed between B16 melanomas in C57BL/6 mice and 4T1 mammary tumours 
in the BALB/cByJ strain. The cytokines induced by poly I:C and MSU+M.smegmatis 
immunotherapies also vary between the tumour models, with MSU+M.smegmatis increasing 
IFNγ and IL-12 in B16 melanoma (141), which was not observed in mice bearing 4T1 
tumours. The differences in immune cell infiltration within B16 and 4T1 tumours may also 
contribute to the sensitivity to immunotherapies, as B16 tumours were found to have 
increased CD3+ populations compared to 4T1 tumours (639).  
There are also differences between transplanted, spontaneous and inducible tumour models, 
with evidence suggesting that the tumour’s cell type of origin, how it transforms, and the 
location can all contribute to immunosurveillance (217). Moreover, the immunogenicity of 
murine tumour models has been shown to impact response to immunotherapy, with 
immunogenic tumours showing an increased response to combination treatment with a DC 
vaccine and a TLR agonist, compared to less immunogenic tumours (715). Therefore, the 
sensitivity to immunotherapy may vary largely between different tumour models. 
Poly I:C and MSU+M.smegmatis immunotherapies are adjuvants, but they do not include a 
model tumour-antigen and therefore, the specificity of the T cell response generated following 
immunotherapy, is not known. Multiple groups have investigated combination treatments 
with adjuvants in conjunction with known tumour-antigens. Llopiz et al., used a combination 
of poly I:C, αCD40, and OVA as a model antigen, which resulted in slowing of E.G7-OVA 
tumour growth and prolonged survival. Moreover, when this treatment was administered 
therapeutically there was complete rejection of established tumours (716). Another study used 
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a combination of poly I:C and a polypeptide from bacteria linked to a tumour antigen. This 
combination showed complete remission of a transplantable tumour (717). Previous research 
revealed that it took multiple treatments of poly I:C and MSU+M.smegmatis immunotherapies 
to achieve an effective anti-tumour immune response (578), suggesting that repeated 
stimulation was required to induce the maximal anti-tumour effect. In light of these studies, 
addition of a known tumour antigen to poly I:C or MSU+M.smegmatis immunotherapies may 
further improve efficacy of the treatments and/or achieve maximal response with reduced 
administrations. It is worth noting that this would introduce limitations to the tumour models 
that could be used, as particular strains will not respond to specific antigens. This further 
highlights the advantage of using adjuvants alone. 
 
7.1.3 Sufficient CTL responses are initiated in the absence of 
specialist cross-presenting DCs 
Investigation into the proliferation of OVA-specific T cells in BATF3 KO mice, revealed that 
poly I:C immunotherapy was able to induce expansion in the absence of Batf3-dependent 
DCs. However, there was a decrease in proliferation compared to WT mice, suggesting that 
CD103+ DCs are involved in inducing antigen-specific T cell responses. Within a tumour 
context, similar results were found with expansion of gp100-specific T cells expanding in 
response to poly I:C immunotherapy. There was a small difference in the proportion and total 
number of cells between BATF3 KO and WT mice, but this was not significant. Taken 
together, these results support the theory that different DC subsets are able to cross-prime T 
cells in the absence of CD103+ DCs. 
In the absence of Batf3-dependent DCs, CTLs were capable of killing peptide-pulsed targets, 
however there was a reduction in killing compared to WT controls. This finding agrees with 
the evidence suggesting that specialist cross-presenting DCs are required for effective CD8+ 
CTLs (76,130). However, a significant amount of killing was still detected in mice lacking 
Batf3-dependent DCs, suggesting that in the absence of CD103+ DCs, other subsets are able 
to efficiently prime CD8+ T cells after OVA+poly I:C activation. CD8α+ DCs were present in 
BATF3 KO mice and therefore could be contributing to the killing observed. Depletion of 
both CD8α+ and CD103+ DCs in Clec9A-DTR mice reduced CTL killing to undetectable 
levels, suggesting that specialist cross-presenting DCs are required for priming of effective 
CTLs. 
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It is the first time that a VITAL assay has been undertaken in Clec9A-DTR mice. This assay 
utilises OVA as the model antigen and the use of different models may provide further 
knowledge of the role of specialist cross-presenting DCs. The use of OT-I cells that have been 
genetically engineered to recognise OVA257-264, is not an accurate model reflecting T cell 
responses in patients with spontaneously arising tumours, since this artificial system is 
extremely sensitive, with the induction of strong cytolytic CD8+ T cell responses when the 
OVA257-264 peptide is recognised (718). In humans, it is substantially more complex with 
tumours generally having poor immunogenicity and the expression of multiple antigens. 
Although the use of transgenic models is helpful for investigating antigen-specific responses, 
caution is needed when interpreting data from this reductionist approach and extrapolating 
results to what may be occurring in a patient. 
Despite the reduction in specific lysis seen in mice lacking Clec9A+/Batf3-dependent DCs, 
mice bearing 4T1 or B16 tumours have effective anti-tumour responses as measured by a 
decrease in primary tumour size and prolonged survival. These results suggest that other 
mechanisms of killing could be induced with poly I:C, such as type I IFN-induced apoptosis 
(719). It still cannot be excluded that poly I:C immunotherapy works through a mechanism 
independent of DC populations as there may also be activation of other effector populations 
that can contribute to effective anti-tumour responses, such as NK cells (637). Indeed, it was 
shown that NK cells were required for effective treatment with poly I:C and 
MSU+M.smegmatis immunotherapies when treating B16 tumours (141). However, 
investigation into 4T1 tumours treated with poly I:C and MSU+M.smegmatis, did not reveal 
any changes to the NK populations found within the tumour or tumour dLN. Further 
investigation using anti-asialo GM1 antibody for NK depletion would be beneficial (720). 
There are limitations with all depletion models. Clec9A is a restricted molecule that is 
expressed on CD8α+ and CD103+ DCs, however there is low expression on pDCs (52,109). 
Therefore, DT effectively depletes CD8α+ and CD103+ DCs, but also reduces the number of 
pDCs. It has also been reported that some DTR strains can present with LN hypocellularity 
and reduced DCs, even in the absence of DT (721). Moreover, CD11c-DTR mice have been 
reported to exhibit neutrophilia and monocytosis (669,670). BATF3 KO mice also have 
limitations, with studies reporting the presence of CD8α+ DCs (75,77). Indeed, we found 
CD8α+ DCs within the dLN of BATF3 KO mice. Therefore, the limitations associated with 
these models must be taken into consideration when interpreting results. 
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Despite classification of superior cross-presenting DC subsets, there is no distinct category of a 
DC population that are the best at antigen uptake. Instead,  antigen uptake would seem to be 
context specific, with the type of antigen and the immunotherapeutic agent used contributing 
to the populations involved in antigen-uptake (145,146,151,696). Using fluorescently labelled 
OVA, it was found that CD11b+, TN, CD8α+, CD103+ and moDCs were all capable of 
antigen-uptake, with CD11b+ DCs showing the greatest uptake. When investigating cell-
associated antigen, all subsets were found to have equal uptake. Of utmost interest was 
whether uptake of antigen in vivo would lead to cross-presentation, and proliferation of 
antigen-specific T cells in vitro. Interestingly, moDCs did not induce OT-I proliferation, but 
CD11b+ and CD11b- DC subsets were equally effective at inducing proliferation, comparable 
to a positive control. 
MoDCs have been previously shown to cross-present in vitro (143,696); conversely, other 
studies have found moDCs to be less effective than cDCs (151). Further investigation is 
required to assess the capacity of moDCs to cross-present antigen in response to poly I:C. 
However, these results showed that CD11b+ and CD11b- DCs were successful at not only the 
uptake of antigen in vivo, but the cross-presentation of antigen in vitro to induce effective 
proliferation of antigen-specific T cells. Studies have shown that CD11b- DCs can present 
cell-associated antigens to T cells, with others finding that CD11b-CD8α- sorted DCs were 
more potent cross-presenters of cell-associated antigen than CD8α+ DCs in steady-state 
(722,723). Therefore, in the context of poly I:C stimulation, CD11b- DCs may have a vital 
role in initiating an effective anti-tumour response in the absence of specialist cross-presenting 
DCs. It is important to remember that soluble antigen uptake is distinct to cell-associated 
antigen and they are not equivalent (682). Moreover, presentation of a model antigen may not 
be directly comparable to the uptake of tumour material in mice bearing tumours. As 
mentioned previously, the type of tumour and the immunotherapy used will also greatly affect 
the activation of DCs, and may modify the DC’s antigen uptake, processing and presentation. 
 
7.2 Importance of findings 
Poly I:C immunotherapy and doxorubicin act additively 
Treatment of 4T1 tumours with doxorubicin and poly I:C immunotherapy boosted the 
response observed with either treatment alone, with decreased tumour size and prolonged 
survival. It is acknowledged that chemotherapy can induce immunogenic cell death, which 
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can increase anti-tumour immune responses (475,724). However, this may only apply to 
particular types of adjuvants. We found that MSU+M.smegmatis immunotherapy had no 
additional benefit with doxorubicin. However, treatment with doxorubicin prior to poly I:C 
immunotherapy, increased the sensitivity to immunotherapy, and generated an enhanced 
response that was not seen with single treatments. This finding is important as these results 
contribute to the knowledge of how chemotherapy and immunotherapy can be used together 
in effective regimes. Perhaps even more importantly, these results imply that chemotherapy 
can produce an environment that remains sensitive to immune modulators. This has clinical 
relevance, as most patients that receive current immunotherapies have gone through rigorous 
chemotherapy and radiotherapy cycles. Further investigation will be required to investigate 
the immune cell populations involved in this enhancement and determine which adjuvants 
will produce the best response. 
 
Specialist cross-presenting DCs are required for MSU+M.smegmatis 
immunotherapy, but not poly I:C immunotherapy 
Cross-presenting DCs have long been endorsed as the superior antigen-presenting cells that 
are necessary for priming of CTLs involved in anti-tumour responses (76). Therefore, it was 
important to investigate their role in poly I:C and MSU+M.smegmatis immunotherapies. This 
body of work represents the first time Clec9A-DTR mice have been used for tumour research. 
We found that depletion of Clec9A+ DCs rendered MSU+M.smegmatis immunotherapy 
ineffective; however, the efficacy of poly I:C immunotherapy remained intact. The 
implication of this finding is that other DC subsets are capable of cross-presenting tumour-
antigen to induce anti-tumour responses, which has been seen previously in other models 
(143,145). However, this is the first study to show that poly I:C immunotherapy does not 
require Clec9A+ DCs. This novel finding brings further insight into the interaction between 
DC populations and the redundancy present in the myeloid lineage. Moreover, a better 
understanding of the DC populations required for specific immunotherapy will allow for more 
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CTLs are primed with poly I:C immunotherapy in the absence of CD103+ DCs 
Previous work has found that specialist cross-presenting DCs were crucial for the initiation of 
CTLs, and that an absence of these populations allowed tumour outgrowth (76), or 
significantly impaired the ability of CTLs to mediate tumour regression (130). This study 
found that priming of CTLs with OVA+poly I:C in the absence of CD103+ DCs was present, 
but impaired. However, the proliferation and IFNγ production was functional in BATF3 KO 
mice, suggesting that CD103+ DCs were not required. Conversely, using CD11c-DTR mice, 
we found that CD11c+ expressing cells were required for poly I:C immunotherapy. This 
implies that other DC populations are capable of priming CD8+ T cells in the absence of 
CD103+ DCs, highlighting the importance of the large diversity found in the DC family. In 
this setting, a lack of one population is able to be compensated for by other DC subsets, as not 
to abolish CTL priming. Since this study focused on the model antigen OVA, it would be of 
interest to investigate CTLs using other model antigens that may elucidate which DCs co-
operate to achieve the best CTL priming. 
 
Multiple DC subsets are capable of antigen uptake 
Investigation into the literature of DC subsets involved in antigen uptake, reveals opposing 
opinions when debating preferential uptake of antigen. Some studies found that the DCs 
involved in acquiring cell-associated antigen from dying cells were exclusively CD103+ DCs 
(73,129), with others including CD8α+ DCs (687). Others argue that only CD8α+ DCs can 
cross-prime T cells (144), whereas further studies show involvement of CD8- DCs and moDCs 
(145,146). We found that multiple DC subsets were able to take up both soluble and cell-
associated antigen, which was enhanced with poly I:C immunotherapy. This finding is 
important as it suggests that in the absence of specific DC populations, other subsets may be 
capable of undertaking the necessary functions to ensure successful immunotherapy.  
 
7.3 Implications for clinical cancer immunotherapy  
The findings in this thesis have shown that different immunotherapies will vary in dependency 
on certain myeloid subsets. This is important when it comes the use of immunotherapy in a 
clinical setting, as diverse cancers and even patient-to-patient specificity will change, 
influencing the efficacy of a response to an immunotherapeutic agent. 
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The results described in this thesis, whereby MSU+M.smegmatis immunotherapy required 
specialist cross-presenting DCs and poly I:C did not, highlight the redundancy found in the 
myeloid network. It shows that some immunotherapies may require particular DC 
populations for optimal efficacy, which becomes important when designing immunotherapies 
as specific targeting of the required population would likely lead to the best outcome. Despite 
the absence of DC populations known to have high TLR3 expression (75), we found that the 
use of a TLR3 agonist provided robust anti-tumour responses, supporting the idea of targeting 
specific receptors and corresponding pathway activation. Although humans have 
corresponding DC populations to mice (8,115), there are limitations in the translation of work, 
which will be discussed below. In any case, knowledge of the mechanisms at work with 
particular immunotherapies is crucial to understanding how to improve current therapies. 
In line with the paradigm of plasticity in myeloid populations, a consideration for 
immunotherapy used in the clinic, is the impact inhibitory/depletion therapies will have on 
activated populations that are contributing to an anti-tumour response. Previous work has 
shown that therapies commonly used for targeting MDSCs can also ablate populations that 
were required for efficacy of immunotherapy (142). In light of this, caution is required when 
inhibitors are used, as restraint of one population may be at the detriment of another cell-type 
that is crucial to the desired response. Other studies have shown that re-programming of 
myeloid populations was successful and necessary for regression of tumours (607). Therefore, 
the environmental stimuli present is important for shaping preferred phenotypes and rather 
than complete ablation, methods to re-calibrate cells into effective anti-tumour populations 
may be more beneficial.  
When reflecting on the translation of the findings from this thesis, an important factor is the 
disparity between human cancer from that which can be modelled in mice. The field has 
advanced considerably in the last decade, with the addition of spontaneously arising tumours, 
designed to mimic tumour progression in humans. Transplantable tumours administered s.c. 
have been a staple in tumour research due to the speed of growth and accessibility. However, 
orthotopic implantations are seen as advantageous over s.c., as they recapitulate the tumour 
growth in the relevant environment (725). Transplantable tumours also allow for models with 
enforced antigen expression, providing a useful tool monitoring T cell responses that have 
TCRs specific for the antigen. However, this manipulation instantly generates a more artificial 
system that becomes less relevant to mimicking human tumours. Other limitations include the 
injection itself, as well as the presence of dead tumour cells within the preparation that may 
induce local inflammation (256).  
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Models that harbor both the same genetic mutation and similar responsiveness to therapy 
found in patients are the most appropriate; therefore, genetically engineered mice to harbor 
inducible or spontaneously arising tumours can be created. Early genetically engineered 
mouse models provided insight into certain immune-related genes, which were important in 
immune surveillance, as knock-outs had accelerated tumour development (726). However, a 
limitation for some cancers is the need for specialist imaging technology to monitor tumour 
responses. Despite these advances, all murine models are limited in their ability to accurately 
represent cancer in humans; however, they are necessary for pre-clinical investigation into the 
factors driving progression of disease and the effects of therapy on immune responses. 
The field of cancer immunotherapy is rapidly progressing under the success of “checkpoint-
blockade” immunotherapies; however, the number of patients that respond to treatment is still 
limiting. Therefore current work is focused on biomarkers as a way of predicting patient 
response and preventing unnecessary and expensive treatments. The growth in technology 
around detecting molecular and genetic signatures is pulling the field towards personalised 
medicine, whereby the genetic composition of individuals will be elucidated and directly 
influence the course of treatment for the individual. Another focus of the field is on neo-
antigen therapy, with patient-specific vaccines designed around tumour epitopes discovered. 
Successful treatment in a murine model with a vaccine designed around two tumour epitopes 
showed remarkable success, with >85% rejection rate. However, the identification and 
validation of tumour epitopes remains arduous, therefore improved technologies and systems 
are required before progression can be made.  
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7.4 Summary and conclusion  
Treatments with poly I:C and MSU+M.smegmatis immunotherapies are successful at slowing 
primary tumour growth and prolonging survival of 4T1 or B16 tumour-bearing mice; 
however, the mechanisms used to induce anti-tumour responses differ. MSU+M.smegmatis was 
found to require specialist cross-presenting DCs for efficacy, whereas depletion of CD8α+ and 
CD103+ DCs had no impact on poly I:C immunotherapy. This result suggested an effective 
anti-tumour response was not impaired in the absence of specialist cross-presenting DCs.  
To investigate further, T cell responses in mice lacking Batf3-dependent DCs were examined. 
Proliferation of antigen-specific T cells to cognate antigen was observed in mice stimulated 
with poly I:C immunotherapy, and CD8+ T cells were capable of producing IFNγ. CTLs 
were able to kill target populations, although at a reduced capacity, suggesting that CD103+ 
DCs play a role in the priming of effector T cells.  
Further investigation into the DC subsets involved in the anti-tumour response in BATF3 KO 
mice revealed that multiple subsets were capable of soluble antigen-uptake, with half of the 
CD11b+ DCs acquiring OVA. However, when antigen-loaded DCs were sorted ex vivo and 
cultured with responder CD8+ OT-I cells, both the CD11b+ and CD11b- DC subsets were 
capable of inducing proliferation. 
Collectively these results show that poly I:C and MSU+M.smegmatis immunotherapies are 
both successful in stimulating anti-tumour immune responses, yet differ on their dependency 
on specialist cross-presenting DCs. Effective CTL responses are still induced with poly I:C 
immunotherapy in BATF3 KO mice, suggesting that other DC populations are able to cross-
present and stimulate anti-tumour immune responses. Further investigation into the key 
mediators involved in anti-tumour responses will aid in the development of treatments that 
efficiently stimulate the immune system to treat cancer. 
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7.5 Future directions  
It is still unclear whether cross-presenting DCs are a specialised population or cross-
presentation is a function that can be increased or decreased according to the environment 
and stimuli present (148). Further investigation is required to define the role of cross-
presenting DCs in anti-tumour responses, and to clarify the populations involved in anti-
tumour responses in poly I:C treated BATF3 KO mice. Several suggestions for experiments to 
explore these questions are briefly summarised below. 
 
Which DC subsets take up tumour-associated antigen in Clec9A-DTR mice? 
In the absence of Clec9A+ DCs, it would be of interest to elucidate which DC subsets are 
capable of antigen uptake. DCs could then be sorted ex vivo and plated with responder cells to 
assess cross-presentation. Studies would need to be undertaken in Clec9A-DTR x C57BL/6 
offspring, as BALB/cByJ mice do not respond to OVA. It would also be of interest to 
compare these results to those from BATF3 KO mice. Ultimately, studies undertaken in a 
tumour context would be most informative, with DCs taking up tumour material rather than 
soluble antigen. However, this remains technically difficult given that uptake of a small piece 
of a fluorescently-labelled tumour cell increases the difficulty of detection when compared to 
the uptake of a whole labelled-protein. Furthermore, cross-presentation assays are required to 
demonstrate that the DC has acquired antigen that is capable of stimulating T cell responses. 
Development of advanced models and technology will aid in the ability to detect uptake of 
tumour-associated antigen by DCs in vivo. 
 
Are poly I:C and MSU+M.smegmatis immunotherapies effective in cDC depleted 
mice? 
A new strain has become available, the Zbtb-DTR mouse. The Zbtb46 gene is expressed on 
cDCs and certain activated monocytes, but is not expressed on pDCs, which are sensitive to 
DT in the Clec9A-DTR mice (727-729). Due to the confounding populations concerned in 
the CD11c-DTR model, such as the decrease in NK cells, the Zbtb-DTR mice would be 
useful to confirm findings from experiments undertaken with CD11c-DTR mice, and further 
clarify exactly which DC subsets are involved in poly I:C and MSU+M.smegmatis 
immunotherapies. 
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How does poly I:C induce effector T cells in the absence of Batf3-dependent DCs? 
Despite the absence of Clec9A+/Batf3-dependent DCs, poly I:C is able to induce sufficient 
CTL responses. This finding suggests that either poly I:C immunotherapy activates different 
DC subsets to drive T cell priming, or; poly I:C immunotherapy operates through different 
effector populations. It is known that CD8+ T cells are required for poly I:C immunotherapy; 
however, other effector populations may be involved in the response activated. NK cells were 
shown to be involved in both poly I:C and MSU+M.smegmatis immunotherapies in B16 
melanoma (141), however further work is required to fully investigate NK cells in the 4T1 
model. 
 
The findings in this thesis highlight that CD103+ DCs play an important role in anti-tumour 
responses activated by certain stimuli; yet, in different methods of activation, other DCs can 
replace the requirement for CD103+ DCs. Further studies using Clec9A-DTR mice with 
different adjuvants or vaccines may help reveal the impact that Clec9A+ DCs have on anti-
tumour responses.  
When investigating immunotherapies for patients, it is unlikely that one single treatment will 
be effective in all patients, much less different types of cancer. As combination regimes grow 
with the design of new immunotherapies, it will be crucial to have well supported research in 
pre-clinical models. The observation that different immunotherapies require distinct DC 
subsets, emphasises the need for a deeper understanding of the requirements for successful 
immunotherapies. Use of this knowledge will assist in the advancement of developing effective 
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A  BD cytometer specifications 
LSRII Specifications 
Table A: LSR II Lasers 
Number Wavelength Power and Type 
1 355 nm 20mW solid state (UV) 
2 488 nm 100mW solid state (blue) 
3 532 nm 150mW Pulsed diode (green)  
4 405 nm 50mW CUBE diode laser (violet) 
5 640 nm 40mW CUBE diode laser (red) 
 
Table B: LSR II Detectors 
Name Laser Wavelength 
range 
Dyes 
UV379/28 1 365-393 nm BUV 395 
UV450/50 1 425-475 nm DAPI, Live/Dead Fixable Blue 
UV740/35 1 723-757 nm Hoechst Red, Qdot 800 
B488/10 2 478-498 nm SSC 
B515/20 2 505-525 nm AlexaF488, GFP, Alexa Fluor 500, CFSE, 
FITC 
B705/70 2 670-740 nm PerCP, PE-Cy5.5 
G575/26 3 562-580 nm PE 
G610/20 3 600-620 nm PI, PE-Texas Red 
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G780/60 3 750-810 nm PE-Cy7,  
V450/50 4 425-475 nm Pacific Blue, Live/Dead Fixable Violet  
V525/50 4 500-550 nm AmCyan 
V560/40 4 540-580 nm BV560  
V605/40 4 585-625 nm BV605 
V660/20 4 650-670 nm BV650 
V720/40 4 700-740 nm BV 711, Qdot 705 
V780/60 4 750-810 nm BV 786 
R670/14 5 663-677 nm APC, AlexaF 647 
R710/50 5 685-735 nm Alexa Fluor 700 
R780/60 5 755-805 nm APC-Cy7 
 
  Appendix 282 
LSR Fortessa Specifications 
Table C: LSR Fortessa Lasers 
Number Wavelength Power and Type 
1 355 nm 20mW solid state (UV) 
2 488 nm 50mW solid state (blue) 
3 455 nm 75mW solid state (blue-violet) 
4 532 nm 150mW Pulsed diode (green)  
5 405 nm 50mW CUBE diode laser (violet) 
6 640 nm 40mW CUBE diode laser (red) 
 
Table D: LSR Fortessa Detectors 
Name Laser Wavelength 
range 
Dyes 
UV379/28 1 365-393 nm BUV 395 
UV450/50 1 425-475 nm DAPI, Live/Dead Fixable Blue 
UV740/35 1 723-757 nm BUV737 
UV820/60 1 790-850 nm Hoechst Red, Qdot 800 
B488/10 2 478-498 nm SSC 
B515/20 2 505-525 nm AlexaF488, GFP, Alexa Fluor 500, CFSE, FITC 
B685/35 2 667-702 nm PerCP, PE-Cy5.5 
BV504/12* 3 498-510 nm AmCyan, Live/Dead Aqua 
G575/25 4 562-580 nm PE 
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G610/20 4 600-620 nm PI, PE-Texas Red 
G670/30 4 640-680 nm PE-Cy5, PE-Alexa Fluor 647 
G695/40 4 675-715 nm PerCP-Cy5.5, PE-Alexa Fluor700, PE-Cy5.5 
G780/60 4 750-810 nm PE-Cy7,  
V450/50 5 425-475 nm Pacific Blue, Live/Dead Fixable Violet  
V525/50 5 500-550 nm AmCyan 
V610/20 5 585-625 nm BV605 
V660/20 5 650-670 nm BV650 
V710/20 5 670-740 nm Qdot 705 
V780/60 5 750-810 nm BV 786 
R670/14 6 663-677 nm APC, AlexaF 647 
R720/40 6 685-735 nm Alexa Fluor 700 
R780/60 6 750-810 nm APC-Cy7 
 






  Appendix 284 
BD Influx Specifications 
Table E: BD Influx Lasers 
Pinhole 
Number 
Wavelength Power and Type 
1 488 nm 200mW Solid State Laser (Blue) 
2 445 nm 100mW Solid State Laser (Blue Violet) 
3 405 nm 100mW Solid State Laser (Violet) 
4 - - 
5 355 nm 100mW Solid State Laser (UV) 
6 640 nm 120mW Solid State Laser (Red) 
7 552 nm 200mW Solid State Laser (Green) 
 
Table F: BD Influx Detectors 
Name Laser Wavelength 
range 
Dyes 
520/35 1 502-537 nm AlexaF488, GFP, Alexa Fluor 500, CFSE, FITC 
692/40 1 672-712 nm PerCP, PE-Cy5.5 
504/12 2 498-510 nm AmCyan 
425/26 3 412-438 nm BV421, V450, Pacific Blue, Live/Dead Fixable 
Violet 
520/35 3 503-537 nm BV510 
610/20 3 600-630 nm BV605, Qdot 605 
Appendix 285 
660/20 3 650-670 nm BV650, Qdot 655 
710/50 3 685-735 nm BV 711, Qdot 705 
780/60 3 750-810 nm BV 786, Qdot 800 
379/34 5 362-396 nm BUV 395 
460/50 5 435-485 nm DAPI, Live/Dead Fixable Blue 
670/30 5 655-685 nm BUV 687 
730/45 5 708-752 mm BUV 737 
670/30 6 655-685 nm APC, AlexaF 647 
720/40 6 700-740 nm Alexa Fluor 700 
780/60 6 750-610 nm APC-Cy7 
575/26 7 562-588 nm PE, DsRed 
610/20 7 600-620 nm PI, PE-Texas Red 
670/30 7 655-685 nm PE-Cy5 
710/50 7 685-735 nm PE-Cy5.5 
780/60 7 750-810 nm PE-Cy7  
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B Lung metastasis 
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Figure B: Poly I:C and MSU+M.smegmatis immunotherapies reduce the 4T1 
metastatic load in the lung. A) Clec9A-DTR mice bearing orthotopic 4T1 tumours were 
administered 20 ng/g of DT by intraperitoneal injection on days 8, 10, 14, 18 and 20. Organs 
were harvested on day 21 to confirm DC depletion and lungs were processed to analyse 
metastatic 4T1 colonies. Lung colonies were analysed as described in 2.2.5.7. Briefly, single 
cells suspensions of lungs were plated with media containing 6-thioguanine. The surviving 
4T1 colonies were fixed, stained and counted. Tumour weight as mean ± SEM. B) Raw 4T1 
colony counts in the lung with total numbers expressed as the geometric mean. C) The 
number of colonies per gram of lung tissue was calculated, log transformed and then 
normalised to the PBS control. Data are expressed as mean ± SD. Statistical evaluation was 
by Kruskal-Wallis with Dunn’s post test. *p<0.05. 
 
C  Assessment of CD11c+ depletion in CD11c-DTR mice 
 
 
Figure C: CD11c+ cells are successfully depleted in CD11c-DTR mice. A) 
C57BL/6 or CD11c-DTR BM chimeras were injected with B16 tumors, treated every second 
day for four times with poly I:C or PBS, and at the same time depleted of CD11c+ cells by DT 
treatment 16-18 hours before treatment. Additional mice were set up to sacrifice and check 
for depletion on day 14 in the dLN and B) spleen. Data are pooled from two experiments with 
four to five mice per group. Representative gating is shown for the dLN and spleen.  
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Figure D: CD11b+ and TN DCs are not depleted in Clec9A-DTR x C57BL/6 mice 
depleted of CD8α+ and CD103+ DCs. A) Clec9A-DTR x C57BL/6 mice were treated 
with DT 3 times before spleen and dLN were taken for analysis of depletion. B) Gating 
strategy for CD8α+, CD103+, CD11b+ and TN DCs is shown. Depletion of CD8α+ and 
CD103+ DCs was shown in Figure 5.7. Proportions and total numbers of CD11b+ and TN 
DCs are expressed as mean ± SEM.  
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E Proportion of B16.OVA+ DCs 
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Figure E: Multiple DCs uptake cell-associated antigen. A) C57BL/6 mice were 
administered irradiated CTO-labeled B16.OVA subcutaneously either with or without poly 
I:C. One group was treated 2 days prior to harvest, the other one day prior. dLNs were 
harvested and analysed for B16.OVA uptake by flow cytometry. B) Cells were previously 
gated for singlets and live. Representative gating of FACs plots on DC populations. C) 
Proportion of OVA+ DC are expressed as mean ± SEM. Absolute numbers of DCs are shown 
in Figure 6.5. Data are pooled from two experiments and statistical evaluation was by 
Kruskal-Wallis with Dunn’s post-test. ****p<0.0001.  
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